<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4885858</PMID><DateCompleted><Year>1969</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0008-7335</ISSN><JournalIssue CitedMedium="Print"><Volume>107</Volume><Issue>50</Issue><PubDate><Year>1968</Year><Month>Dec</Month><Day>06</Day></PubDate></JournalIssue><Title>Casopis lekaru ceskych</Title><ISOAbbreviation>Cas Lek Cesk</ISOAbbreviation></Journal><ArticleTitle>[Relationship between ion metabolism and affective disorders].</ArticleTitle><Pagination><MedlinePgn>1531-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bojanovský</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rysánek</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>cze</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Vztah metabolismu iontů k afektivním poruchám.</VernacularTitle></Article><MedlineJournalInfo><Country>Czech Republic</Country><MedlineTA>Cas Lek Cesk</MedlineTA><NlmUniqueID>0004743</NlmUniqueID><ISSNLinking>0008-7335</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NEZ333N27</RegistryNumber><NameOfSubstance UI="D012964">Sodium</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWP5GA015D</RegistryNumber><NameOfSubstance UI="D011188">Potassium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001826" MajorTopicYN="N">Body Fluids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011188" MajorTopicYN="N">Potassium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012964" MajorTopicYN="N">Sodium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014882" MajorTopicYN="N">Water-Electrolyte Balance</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>58</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1968</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1968</Year><Month>12</Month><Day>6</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1968</Year><Month>12</Month><Day>6</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4885858</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18350681</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Moans, stones, groans, bones and psychiatric overtones: lithium-induced hyperparathyroidism.</ArticleTitle><Pagination><MedlinePgn>171-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lienert</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rege</LastName><ForeName>Sanil</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006961" MajorTopicYN="N">Hyperparathyroidism</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18350681</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3552219</PMID><DateCompleted><Year>1987</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0362-5664</ISSN><JournalIssue CitedMedium="Print"><Volume>9 Suppl 4</Volume><PubDate><Year>1986</Year></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Antimanic effects of the calcium-antagonist D600. A double-blind placebo-controlled study.</ArticleTitle><Pagination><MedlinePgn>553-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aldenhoff</LastName><ForeName>J B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Schlegel</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Heuser</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Wetzel</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>39WPC8JHR8</RegistryNumber><NameOfSubstance UI="D005711">Gallopamil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005711" MajorTopicYN="N">Gallopamil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3552219</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27369680</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-2163</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Turk psikiyatri dergisi = Turkish journal of psychiatry</Title><ISOAbbreviation>Turk Psikiyatri Derg</ISOAbbreviation></Journal><ArticleTitle>[The Relationship of Verbal Working Memory and Theory of Mind in First Degree Relatives of Patients With Schizophrenia and Bipolar Disorder].</ArticleTitle><Pagination><MedlinePgn>8-14</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We aimed to compare Theory of Mind (ToM) functions and investigate the relationship between ToM functions and verbal working memory (VWM) in first degree relatives of bipolar disorder and schizophrenia patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The sample consisted of first degree relatives of patients with bipolar disorder (n=22), schizophrenia (n=28), and age, gender, education and total IQ matched healthy volunteers (n=27) without a family history of schizophrenia or bipolar disorder. We administered Auditory Consonants Test (ACT) to evaluate VWM, first and second order false belief tests (ToM-1, ToM-2), Faux Pas Test (FPT), Hinting Test (HT) to evaluate different domains of ToM functions.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Both relative groups performed significantly lower in all components of ToM and VWM tests compared to the control group. When VWM scores were employed as covariate in the analyses, the FPT difference between the groups remained significant, HT difference regressed to a marginal level, and the difference between ToM-1 and ToM-2 disappeared.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">To our knowledge, this is the first study indicating the presence of ToM impairment among first degree relatives of bipolar disorder patients similar to relatives of schizophrenia patients. VWM performance seems to affect first and second order ToM functions in relatives of patients with schizophrenia and bipolar disorder. On the other hand, FPT and HT domains seem to be independent of VWM performances in these groups. FPT and HT impairments may be familial vulnerability markers that are independent from neurocognitive impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yücel</LastName><ForeName>Mehmet Onur</ForeName><Initials>MO</Initials></Author><Author ValidYN="Y"><LastName>Devrimci Özgüven</LastName><ForeName>Halise</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sakarya</LastName><ForeName>Ayşegül</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Baskak</LastName><ForeName>Bora</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Özel Kızıl</LastName><ForeName>Erguvan Tuğba</ForeName><Initials>ET</Initials></Author><Author ValidYN="Y"><LastName>Sakarya</LastName><ForeName>Direnç</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Haran</LastName><ForeName>Seda</ForeName><Initials>S</Initials></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Şizofreni ve Psikotik Özellikli Bipolar Bozukluk Hastalarının Birinci Derece Akrabalarında Zihin Kuramı ve Sözel Çalışma Belleğinin İlişkisi.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Psikiyatri Derg</MedlineTA><NlmUniqueID>9425936</NlmUniqueID><ISSNLinking>1300-2163</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="N">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016743" MajorTopicYN="N">Mental Competency</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013647" MajorTopicYN="N">Task Performance and Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27369680</ArticleId><ArticleId IdType="pii">1013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3983290</PMID><DateCompleted><Year>1985</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2739</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>1985</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychiatrie, Neurologie, und medizinische Psychologie</Title><ISOAbbreviation>Psychiatr Neurol Med Psychol (Leipz)</ISOAbbreviation></Journal><ArticleTitle>[Cognitive disorders in endogenous psychoses].</ArticleTitle><Pagination><MedlinePgn>22-9</MedlinePgn></Pagination><Abstract><AbstractText>Cognitive disorders of schizophrenics as well as subjects with affective psychosis were studied with the aid of 10 tests. Differences between schizophrenics and patients with affective psychosis could hardly be detected. Subgroup differences within the two broad diagnostic categories are pointing to the importance of the severity of illness. However, some differences between two small samples (N = 9) carefully matched with regard to several relevant aspects - especially concerning the severity of disorder - show that the diagnostic category is not wholly unimportant. Judged on the basis of these differences, there are probably no deficits of a fundamentally different nature; the assumption of divergent cognitive styles or defence mechanisms considering comparable basic deficits seems more plausible.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Plaum</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Duhm</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><VernacularTitle>Kognitive Störungen bei endogenen Psychosen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Neurol Med Psychol (Leipz)</MedlineTA><NlmUniqueID>0376467</NlmUniqueID><ISSNLinking>0033-2739</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3983290</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19192979</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-4877</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Current medical research and opinion</Title><ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation></Journal><ArticleTitle>Cost analysis in a Medicaid program for patients with bipolar disorder who initiated atypical antipsychotic monotherapy.</ArticleTitle><Pagination><MedlinePgn>351-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1185/03007990802634077 </ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Use of atypical antipsychotics in treatment of patients with bipolar disorder is increasingly common, yet few studies have systematically investigated or compared medical costs associated with use of specific atypical antipsychotics.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the direct healthcare costs associated with olanzapine, risperidone, or quetiapine monotherapy among Medicaid patients diagnosed with bipolar disorder (ICD-9: 296.4x-296.8x).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">North Carolina Medicaid patients with bipolar disorder were followed for 12 months after initiation of atypical antipsychotic monotherapy (index date). They had no bipolar-related medical visit, hospitalization, or use of atypical antipsychotics 90-days prior to the treatment initiation. Costs of index drug, all bipolar-related medical care, and all health-related costs were examined. A two-stage sample selection model was employed to account for potential confounders and sample selection bias. Medication adherence measures using cumulative medication acquisition and cumulative medication gap were calculated as separate outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Inclusion criteria were met by 838 continuously eligible patients (393 olanzapine, 262 risperidone, 183 quetiapine). Drug-taking adherence was similar across the drug cohorts. After adjusting for potential confounders, patients taking olanzapine incurred $863 (p &lt; 0.001) and $449 higher (p &lt; 0.01) index drug costs than patients taking risperidone and quetiapine, respectively. Bipolar-related medical costs for patients taking olanzapine were higher ($616; p = 0.06) than for patients taking risperidone at 10% significance level, while such costs for patients taking olanzapine and quetiapine were similar. Total health-related costs did not differ across patient cohorts, including or excluding the index drug costs.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The final study sample is a highly selected one based on the study design. This sample may not represent the entire bipolar population. The criteria used to guard against omitting bipolar disorder patients misdiagnosed with major depression need further validation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">No evidence was identified that there is any difference for total health-related costs in using olanzapine, risperidone, or quetiapine monotherapy to treat bipolar disorder, from a Medicaid payer's perspective. The clinical difference between these atypical antipsychotic drugs for the treatment of bipolar disorder could be of more interest than the economic difference.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Merck &amp; Co, Inc, Whitehouse Station, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Dale B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Alex Z</ForeName><Initials>AZ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Gordon G</ForeName><Initials>GG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Med Res Opin</MedlineTA><NlmUniqueID>0351014</NlmUniqueID><ISSNLinking>0300-7995</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009657" MajorTopicYN="N" Type="Geographic">North Carolina</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19192979</ArticleId><ArticleId IdType="doi">10.1185/03007990802634077</ArticleId><ArticleId IdType="pii">10.1185/03007990802634077</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15978780</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>2-3</Issue><PubDate><Year>2005</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Deficits in sustained attention in schizophrenia but not in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>225-33</MedlinePgn></Pagination><Abstract><AbstractText>The aim of the present study was to investigate sustained attention in remitted patients with bipolar disorder and in patients with schizophrenia, as compared to each other and to healthy controls; a secondary aim was to investigate the correlations of different symptom dimensions with performance on sustained attention in the two patient groups. Participants were 29 (18 men) outpatients with schizophrenia (SZ), 19 (8 men) patients with bipolar disorder I (BP) in remission, and 30 (15 men) healthy controls (HC); all three groups were matched on age, sex ratio, and level of education. Symptom severity (positive symptoms, negative symptoms, and general psychopathology) of patients with SZ were assessed with the Greek version of the Positive and Negative Syndrome Scale (PANSS); residual affective symptoms of patients with BP were assessed with the Young Mania Rating Scale (YMRS) and the Montgomery-Asberg Depression Rating Scale (MADRS). Sustained attention was measured by means of the Penn Continuous Performance Test (PCPT). The three groups differed significantly on the PCPT scores. Patients with SZ performed more poorly than both the BP and HC groups, whereas patients with BP did not differ significantly from HC. Performance on the PCPT did not correlate significantly with scores on the YMRS and MADRS in patients with BP. Also, scores on the PCPT did not correlate significantly with scores on any of the three subscales of the PANSS. Outpatients with schizophrenia presented deficits in sustained attention, whereas patients with bipolar disorder I in remission did not manifest such impairment. These results imply that impaired sustained attention might be a more enduring deficit in schizophrenia than it appears to be in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bozikas</LastName><ForeName>Vasilis P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>2nd Department of Psychiatry, Aristotle University of Thessaloniki, Greece. vpbozikas@oneway.gr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreou</LastName><ForeName>Christina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Giannakou</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tonia</LastName><ForeName>Thomy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Anezoulaki</LastName><ForeName>Dimitra</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Karavatos</LastName><ForeName>Athanasios</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fokas</LastName><ForeName>Kostas</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kosmidis</LastName><ForeName>Mary H</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="Y">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>03</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>05</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>05</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15978780</ArticleId><ArticleId IdType="pii">S0920-9964(05)00205-7</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2005.05.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25678174</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>175</Volume><PubDate><Year>2015</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Course and outcome following a first episode of mania: four-year prospective data from the Systematic Treatment Optimization Program (STOP-EM).</ArticleTitle><Pagination><MedlinePgn>411-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.01.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)00036-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">First episode mania (FEM) cohorts provide an opportunity to identify windows for intervention to potentially alter the course of bipolar disorder (BD). Despite several efforts to prospectively characterize first episode patients, follow-up of such cohorts has seldom exceeded 1 year. We present 4-year outcomes from the STOP-EM FEM cohort.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Of 101 identified FEM patients, 81 had longitudinal follow-up. Clinical evaluations including substance misuse, sociodemographics and family history were characterized using semi-structured instruments. Clinical reassessments occurred every 6 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Within one year, all patients had remitted and 95% recovered. Recurrence following remission occurred in 58% of patients by 1 year and 74% by 4 years (60% depressive, 28% manic and 12% hypomanic). Recurrence within one year was associated with a higher rate of recurrence thereafter. Older age was associated with a shorter time to remission. Substance misuse was associated with delayed recovery and earlier recurrence.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This prospective multiwave longitudinal design employed may be limited by the assessment schedule and associated recall bias. The influences of attrition of this sample should be considered when attempting to generalize our findings.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Best practices in FEM result in remission and recovery. While recurrence is common, minimizing recurrence within the first year through risk factor modification may alter the course of the BD.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gignac</LastName><ForeName>Andréanne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mood Disorders Centre of Excellence, University of British Columbia, Vancouver, BC, Canada; Institut universitaire en santé mentale de Québec, Department of Psychiatry, Université Laval, Quebec City, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGirr</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Raymond W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Mood Disorders Centre of Excellence, University of British Columbia, Vancouver, BC, Canada; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>Lakshmi N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Mood Disorders Centre of Excellence, University of British Columbia, Vancouver, BC, Canada; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. Electronic address: yatham@mail.ubc.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">First episode mania</Keyword><Keyword MajorTopicYN="N">Prospective cohort</Keyword><Keyword MajorTopicYN="N">Recovery</Keyword><Keyword MajorTopicYN="N">Recurrence</Keyword><Keyword MajorTopicYN="N">Remission</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25678174</ArticleId><ArticleId IdType="pii">S0165-0327(15)00036-1</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.01.032</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10868328</PMID><DateCompleted><Year>2000</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1095-0680</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The journal of ECT</Title><ISOAbbreviation>J ECT</ISOAbbreviation></Journal><ArticleTitle>ECT in mixed affective states: a case series.</ArticleTitle><Pagination><MedlinePgn>183-8</MedlinePgn></Pagination><Abstract><AbstractText>There is limited information regarding the effectiveness of electroconvulsive therapy (ECT) as a treatment for patients in a mixed affective state. The authors report their experience using this treatment in medication-resistant patients meeting Research Diagnostic Criteria (RDC) for both mania and major depression. Clinical and response characteristics of these patients are described. Forty-one consecutively admitted patients meeting the RDC for mania received pharmacotherapy. Eight patients failing to respond to pharmacotherapy were referred for ECT, and seven consented. All met RDC for both mania and major depressive disorder. All patients receiving ECT remitted. The patient who did not accept ECT did not improve and ultimately needed transfer to a state hospital for longer term care. Mixed manic-depressive states are responsive to ECT, even in medication-refractory patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>N P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>UT-Harris County Psychiatric Center, Department of Psychiatry and Behavioral Sciences, University of Texas-Houston Health Sciences Center (UT-HHSC) 77021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dilsaver</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Shoaib</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Swann</LastName><ForeName>A C</ForeName><Initials>AC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J ECT</MedlineTA><NlmUniqueID>9808943</NlmUniqueID><ISSNLinking>1095-0680</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="Y">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>10</Month><Day>21</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10868328</ArticleId><ArticleId IdType="doi">10.1097/00124509-200006000-00010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30427819</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-1145</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of psychiatric practice</Title><ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation></Journal><ArticleTitle>Diagnosis and Use of Psychotherapy Among Children and Adolescents Prescribed Antipsychotics.</ArticleTitle><Pagination><MedlinePgn>323-330</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PRA.0000000000000336</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the diagnoses, demographics, and prevalence of psychotherapy use among children and adolescents prescribed antipsychotics by psychiatric providers in a community setting.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Medical records from 1127 children aged 0 to 17 years who were prescribed antipsychotics in 2014-2015 at Pine Rest Christian Mental Health Services (PRCMHS) outpatient network were analyzed. Antipsychotics, diagnosis codes, demographics, and number of psychotherapy sessions during this time frame were analyzed using χ and logistic regression analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During this year, 50.8% of the patients attended psychotherapy, and 35.6% attended 5 or more sessions of psychotherapy. The most prevalent primary diagnosis was bipolar disorder (37.1%), followed by attention-deficit/hyperactivity disorder (19.7%). Females being treated with antipsychotics were significantly more likely to attend psychotherapy than their male peers (55.7% vs. 47.9%, P=0.01). In the fully adjusted models, patients with diagnoses of bipolar disorder or disorders first diagnosed in infancy, childhood, or adolescence were less than half as likely to attend psychotherapy as patients with depressive disorders, with adjusted odds ratios of 0.41 and 0.42, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Approximately half of the child and adolescent patients prescribed antipsychotics in this community sample did not attend psychotherapy, and 39% of the patients did not have a diagnosis of bipolar disorder, psychotic disorder, or autistic disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vanbronkhorst</LastName><ForeName>Sara B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>VANBRONKHORST, EDWARDS, and BLANKENSHIP: Pine Rest Christian Mental Health Services, Grand Rapids, MI ROBERTS: Michigan State University College of Human Medicine, Grand Rapids, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Daniel E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Evonne M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Blankenship</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychiatr Pract</MedlineTA><NlmUniqueID>100901141</NlmUniqueID><ISSNLinking>1527-4160</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008824" MajorTopicYN="N" Type="Geographic">Michigan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30427819</ArticleId><ArticleId IdType="doi">10.1097/PRA.0000000000000336</ArticleId><ArticleId IdType="pii">00131746-201809000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11032979</PMID><DateCompleted><Year>2000</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>7</Issue><PubDate><Year>2000</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery.</ArticleTitle><Pagination><MedlinePgn>674-84</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive deficits associated with mood disorders, especially bipolar disorder, have been the focus of limited systematic investigation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We tested 35 bipolar (21 in depressed state and 14 in mixed or manic state) and 58 nonbipolar depressed consecutively admitted young adult inpatients and 51 matched healthy individuals on the Cambridge Neuropsychological Test Automated Battery, a computerized neurocognitive battery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The mixed/manic bipolar patients demonstrated robust deficits in episodic and working memory, spatial attention, and problem solving. In contrast, depressed bipolar and nonbipolar patients demonstrated impairments only in episodic memory.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neuropsychologic findings with the Cambridge Neuropsychological Test Automated Battery indicate widely distributed deficits in cognitive domains subserved by temporal, parietal, and frontostriatal systems in bipolar patients during mixed/manic states of illness. Significant deficits in bipolar and nonbipolar depressed patients were restricted to episodic memory, suggesting a more selective dysfunction in mesial temporal lobe function during episodes of depression. These findings highlight the different cognitive profiles of mania and depression, demonstrate similar patterns of neuropsychologic deficits in bipolar and nonbipolar depression, and point to a need for further research investigating the characteristics, causes, course, and treatment of severe cognitive deficits associated with mixed/manic phases of bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Neurobehavioral Studies Program and the Mental Health Intervention Research Center, Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kmiec</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>MH01433</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH42969</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH45156</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009949" MajorTopicYN="N">Orientation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011340" MajorTopicYN="N">Problem Solving</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>10</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>10</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11032979</ArticleId><ArticleId IdType="pii">S0006-3223(00)00910-0</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(00)00910-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22136096</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8992</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of child and adolescent psychopharmacology</Title><ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>545-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/cap.2010.0140</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy. The current study examines co-morbid DBD and aggression prospectively as predictors of pharmacotherapy outcome, as well as potential moderators of response to a specific medication (risperidone vs. divalproex), among children with PBD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data are from a prospective 6-week double-blind, placebo-controlled, randomized outpatient medication treatment trial of risperidone versus divalproex for manic episodes in 65 children 8-18 with PBD. Outcome measures were administered at pretest, post-test, and weekly during the 6 weeks of treatment. Mixed-effects regression models were used to examine pharmacotherapy response.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results indicated that youth with co-morbid DBD experienced greater improvement in manic symptoms in response to risperidone versus divalproex, whereas youth with non-co-morbid DBD experienced similar trajectories of symptom improvement in both medication groups. In addition, the non-DBD group experienced greater improvement in global functioning over time as compared with youth with co-morbid-DBD, and this gap increased over the course of treatment. Results also indicated that high-aggression youth experienced worse global functioning by end treatment versus low-aggression youth.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, a co-morbid diagnosis of DBD and/or high levels of aggressive symptoms in youth with PBD may be important clinical predictors of variation in treatment response to pharmacotherapy. These findings may help researchers and clinicians develop tailored treatment approaches that optimize symptom and functional outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>West</LastName><ForeName>Amy E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Illinois, Chicago, Illinois 60608, USA. awest@psych.uic.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Sally M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Celio</LastName><ForeName>Christine I</ForeName><Initials>CI</Initials></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pavuluri</LastName><ForeName>Mani N</ForeName><Initials>MN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1 K23 RR018638-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NIHMO1-RR-13987</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA><NlmUniqueID>9105358</NlmUniqueID><ISSNLinking>1044-5463</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019958" MajorTopicYN="N">Attention Deficit and Disruptive Behavior Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22136096</ArticleId><ArticleId IdType="doi">10.1089/cap.2010.0140</ArticleId><ArticleId IdType="pmc">PMC3243464</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 1986 Jan;143(1):35-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3942284</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Child Adolesc Psychol. 2002 Dec;31(4):567-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12402575</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6715741</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jul;166(7):795-804</Citation><ArticleIdList><ArticleId IdType="pubmed">19448190</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ment Health Adm. 1997 Summer;24(3):278-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9230570</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 Sep;44(9):821-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3632256</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Nov;88(3):279-85</Citation><ArticleIdList><ArticleId IdType="pubmed">16169087</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2008 Feb;4(1):55-68</Citation><ArticleIdList><ArticleId IdType="pubmed">18728804</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2004 Fall;14(3):395-404</Citation><ArticleIdList><ArticleId IdType="pubmed">15650495</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2006 Jul;12(4):214-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16883146</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1982 Dec;38(4):963-74</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jan;162(1):58-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15625202</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Dec;166(12):1392-401</Citation><ArticleIdList><ArticleId IdType="pubmed">19884222</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2006 Dec;16(6):665-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17201610</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Sep;12(6):593-605</Citation><ArticleIdList><ArticleId IdType="pubmed">20868458</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 May;157(5):818-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10784478</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2003 Jun;26(2):435-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12778842</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1983 Nov;40(11):1228-31</Citation><ArticleIdList><ArticleId IdType="pubmed">6639293</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Nov;51(2):145-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10743847</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Child Fam Psychol Rev. 2001 Mar;4(1):63-84</Citation><ArticleIdList><ArticleId IdType="pubmed">11388564</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Nov;51(2):153-64</Citation><ArticleIdList><ArticleId IdType="pubmed">10743848</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Oct;65(10):1125-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18838629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29024194</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>12</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Disrupted cortico-limbic connectivity during reward processing in remitted bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>661-675</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12560</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Bipolar disorder (BD) is associated with elevated reward sensitivity and persistent positive affect, yet the neural mechanisms underlying these patterns are not well understood. In the present study, we examined putative disruptions in communication within a well-known cortico-limbic reward circuit during reward processing as a potential contributing mechanism to these symptoms.</AbstractText><AbstractText Label="METHODS">The present investigation employed a within- and between-subjects design utilizing a monetary and social incentive delay task among adults with bipolar disorder type I (BD; N = 24) and a healthy non-psychiatric control group (HC; N = 25) during functional magnetic resonance imaging (fMRI). Participants in the BD group were remitted at the time of testing.</AbstractText><AbstractText Label="RESULTS">Functional connectivity analyses revealed increased connectivity between the ventral striatum (VS) seed region and orbitofrontal cortex (OFC) as well as the amygdala during processing of reward receipt in the BD group. After omission of expected rewards, the BD group showed decreased functional connectivity between the VS and a medial frontopolar cortex (mFPC) region associated with consideration of behavioral alternatives. Follow-up analyses within the BD group showed that increased VS-OFC connectivity after reward receipt, and decreased VS-mFPC connected after reward omission, were associated with higher levels of subthreshold mania symptoms.</AbstractText><AbstractText Label="CONCLUSIONS">Results point toward potential mechanisms implicated in elevated reward sensitivity in BD. Enhanced VS-OFC connectivity after reward receipt may be involved in elevated valuation of rewards whereas blunted VS-mFPC connectivity after reward omission may reflect a failure to consider behavioral alternatives to reward pursuit.</AbstractText><CopyrightInformation>© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dutra</LastName><ForeName>Sunny J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0003-2956-5913</Identifier><AffiliationInfo><Affiliation>Boston University School of Medicine, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kober</LastName><ForeName>Hedy</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruber</LastName><ForeName>June</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 DA000167</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024139</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID> CIHR-111257 </GrantID><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="Y">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063132" MajorTopicYN="N">Connectome</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008032" MajorTopicYN="Y">Limbic System</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="N">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">monetary</Keyword><Keyword MajorTopicYN="Y">reward</Keyword><Keyword MajorTopicYN="Y">social</Keyword><Keyword MajorTopicYN="Y">ventral striatum</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29024194</ArticleId><ArticleId IdType="doi">10.1111/bdi.12560</ArticleId><ArticleId IdType="pmc">PMC5739987</ArticleId><ArticleId IdType="mid">NIHMS900995</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 1997 Mar 14;275(5306):1593-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9054347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Apr 25;146(3):407-13</Citation><ArticleIdList><ArticleId IdType="pubmed">23021378</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2003;17(7):491-511</Citation><ArticleIdList><ArticleId IdType="pubmed">12751919</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):310-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18271911</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2004 Oct;23(2):752-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15488425</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1997 Apr;48(4):491-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9090732</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2012 Jan;16(1):61-71</Citation><ArticleIdList><ArticleId IdType="pubmed">22197477</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2010 Jan;35(1):4-26</Citation><ArticleIdList><ArticleId IdType="pubmed">19812543</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopathol Behav Assess. 1999 Dec 1;21(4):275-292</Citation><ArticleIdList><ArticleId IdType="pubmed">21765591</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2015 Nov;124(4):890-904</Citation><ArticleIdList><ArticleId IdType="pubmed">26390194</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Aug 22;301(5636):1104-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12934011</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2012;8:243-67</Citation><ArticleIdList><ArticleId IdType="pubmed">22077912</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 1998 Jul;80(1):1-27</Citation><ArticleIdList><ArticleId IdType="pubmed">9658025</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2008 Aug 28;59(4):648-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18760700</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Sci. 2010 Jul;21(7):1021-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20519486</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2014 Jan 1;84:1042-52</Citation><ArticleIdList><ArticleId IdType="pubmed">24055504</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 May;14(3):249-60</Citation><ArticleIdList><ArticleId IdType="pubmed">22548898</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2005 Feb;25(2):241-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15642648</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jun;166(6):702-10</Citation><ArticleIdList><ArticleId IdType="pubmed">19411368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Dec;10(8):916-27</Citation><ArticleIdList><ArticleId IdType="pubmed">19594507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000;61 Supp 13:38-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11153811</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 Nov;109(4):721-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11195996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Apr 2;28(14):3697-706</Citation><ArticleIdList><ArticleId IdType="pubmed">18385328</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Feb 15;73(4):360-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22981656</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jul 15;60(2):93-105</Citation><ArticleIdList><ArticleId IdType="pubmed">16406007</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Jan 2;59(1):431-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21810475</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Feb 1;59(3):2142-54</Citation><ArticleIdList><ArticleId IdType="pubmed">22019881</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 May;170(5):533-41</Citation><ArticleIdList><ArticleId IdType="pubmed">23558337</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2009 Jun 11;62(5):733-43</Citation><ArticleIdList><ArticleId IdType="pubmed">19524531</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Mar 1;67(5):414-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19931855</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Aug 9;26(32):8368-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16899732</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol (New York). 2009 Jun 1;16(2):206-226</Citation><ArticleIdList><ArticleId IdType="pubmed">20161008</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2007 Dec;12(12):887-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18163034</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2007 Apr;191(3):823-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17265148</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2012 Dec;13(8):605-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21812622</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2000 Jul;12(1):20-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10875899</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 May;57(5):660-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16675760</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Feb 1;59(3):2636-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21924359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2010 Jul;31(7):958-69</Citation><ArticleIdList><ArticleId IdType="pubmed">19950195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Aug;11(5):453-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19624385</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2004 Apr;72(5):341-72</Citation><ArticleIdList><ArticleId IdType="pubmed">15157726</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Connect. 2017 Apr;7(3):152-171</Citation><ArticleIdList><ArticleId IdType="pubmed">28398812</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1975 Nov;12(3):189-98</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2012 Apr;51(4):356-67</Citation><ArticleIdList><ArticleId IdType="pubmed">22449642</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2009 Jan;12(1):32-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19029888</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2012 Feb;22(2):100-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21820878</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1995 Mar;20(3):288-304</Citation><ArticleIdList><ArticleId IdType="pubmed">7550362</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1997 Oct;6(3):218-29</Citation><ArticleIdList><ArticleId IdType="pubmed">9344826</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Dir Psychol Sci. 2010 Jun 1;19(3):189-194</Citation><ArticleIdList><ArticleId IdType="pubmed">20606725</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Psychother. 2011 Sep-Oct;18(5):356-65</Citation><ArticleIdList><ArticleId IdType="pubmed">21953907</ArticleId></ArticleIdList></Reference><Reference><Citation>Dialogues Clin Neurosci. 2013 Sep;15(3):247-62</Citation><ArticleIdList><ArticleId IdType="pubmed">24174898</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Jun 23;70(6):1054-69</Citation><ArticleIdList><ArticleId IdType="pubmed">21689594</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Neurobiol. 2011 Jun;21(3):381-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21498067</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Jun 1;50(5):781-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16731515</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Jun 29;475(7356):377-80</Citation><ArticleIdList><ArticleId IdType="pubmed">21716290</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 1979 Mar;86(2):420-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18839484</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2012 May;121(2):339-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22004113</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopathol Behav Assess. 2001 Sep 1;23(3):133-143</Citation><ArticleIdList><ArticleId IdType="pubmed">21765592</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1996 May;26(3):477-86</Citation><ArticleIdList><ArticleId IdType="pubmed">8733206</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rev. 2006 Apr;113(2):300-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16637763</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Apr 1;63(7):686-92</Citation><ArticleIdList><ArticleId IdType="pubmed">17916330</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Aug;33(9):2217-27</Citation><ArticleIdList><ArticleId IdType="pubmed">17987058</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2007 Oct 26;318(5850):594-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17962551</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2012 Mar;169(3):316-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22267184</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2002 Jul;3(7):563-73</Citation><ArticleIdList><ArticleId IdType="pubmed">12094212</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2010 May 12;21(7):502-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20357688</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Netw. 2000 Oct-Nov;13(8-9):861-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11156197</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2006 May;29(5):272-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16545468</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Jan 15;162(1):27-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18063349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Aug;11(5):530-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19624392</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 1968 Jul;9(3):272-9</Citation><ArticleIdList><ArticleId IdType="pubmed">5666976</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 1999 Dec;31(1):6-41</Citation><ArticleIdList><ArticleId IdType="pubmed">10611493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7772648</PMID><DateCompleted><Year>1995</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>6</Issue><PubDate><Year>1995</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Antisaccades and smooth pursuit eye movements in schizophrenia.</ArticleTitle><Pagination><MedlinePgn>394-401</MedlinePgn></Pagination><Abstract><AbstractText>Saccadic and smooth pursuit eye movements were recorded in schizophrenic patients, nonschizophrenic psychiatric patients, and normal controls. Both schizophrenic subjects and psychiatric controls demonstrated greater increases in error rates and greater delays in generating antisaccades than did normal controls. Schizophrenic patients with impaired smooth pursuit tracking showed greater increases in error rates in the antisaccade task than did schizophrenic patients with normal pursuit. Among psychiatric controls, increased errors on the antisaccade task were unrelated to pursuit performance. The small size of this group, however, reduces the power to detect a relation between smooth pursuit tracking and performance on the antisaccade task. Although most patients were receiving one or more medications, some of which can affect eye movements, medication state in this study did not account for differences we report in dependent variables.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sereno</LastName><ForeName>A B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Harvard University, Department of Psychology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holzman</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>MH31154</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH31340</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH44866</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011698" MajorTopicYN="N">Pursuit, Smooth</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012438" MajorTopicYN="N">Saccades</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>3</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>3</Month><Day>15</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7772648</ArticleId><ArticleId IdType="pii">0006-3223(94)00127-O</ArticleId><ArticleId IdType="doi">10.1016/0006-3223(94)00127-O</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15558889</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1323-1316</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>White matter hyperintensity detected by magnetic resonance imaging and lithium response in bipolar disorder: a preliminary observation.</ArticleTitle><Pagination><MedlinePgn>117-20</MedlinePgn></Pagination><Abstract><AbstractText>The possible relationship between deep white matter hyperintensity (WMHI) lesions detected by magnetic resonance imaging and response to lithium was examined in 16 patients with bipolar disorder who had been under maintenance treatment with lithium for more than 1 year. Bipolar patients who had higher scores of WMHI responded significantly better to lithium (r = 0.57, P &lt; 0.05) than did those who had lower scores. This preliminary result suggests that the presence of WMHI may be associated with a better response to lithium.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Faculty of Medicine, University of Tokyo, Tokyo, Japan. tadafumi-tky@umin.ac.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kamiya</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>N</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>G4962QA067</RegistryNumber><NameOfSubstance UI="D018021">Lithium Chloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018021" MajorTopicYN="N">Lithium Chloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15558889</ArticleId><ArticleId IdType="doi">10.1046/j.1440-1819.2000.00646.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10232294</PMID><DateCompleted><Year>1999</Year><Month>05</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>5</Issue><PubDate><Year>1999</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.</ArticleTitle><Pagination><MedlinePgn>407-12</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Omega3 fatty acids may inhibit neuronal signal transduction pathways in a manner similar to that of lithium carbonate and valproate, 2 effective treatments for bipolar disorder. The present study was performed to examine whether omega3 fatty acids also exhibit mood-stabilizing properties in bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 4-month, double-blind, placebo-controlled study, comparing omega3 fatty acids (9.6 g/d) vs placebo (olive oil), in addition to usual treatment, in 30 patients with bipolar disorder.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A Kaplan-Meier survival analysis of the cohort found that the omega3 fatty acid patient group had a significantly longer period of remission than the placebo group (P = .002; Mantel-Cox). In addition, for nearly every other outcome measure, the omega3 fatty acid group performed better than the placebo group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Omega3 fatty acids were well tolerated and improved the short-term course of illness in this preliminary study of patients with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stoll</LastName><ForeName>A L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Department of Psychiatry, Harvard Medical School, Boston, Mass, USA. alstoll@mclean.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Severus</LastName><ForeName>W E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>M P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Rueter</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zboyan</LastName><ForeName>H A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cress</LastName><ForeName>K K</ForeName><Initials>KK</Initials></Author><Author ValidYN="Y"><LastName>Marangell</LastName><ForeName>L B</ForeName><Initials>LB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015525">Fatty Acids, Omega-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Gen Psychiatry. 1999 May;56(5):413-4; discussion 415-6</RefSource><PMID Version="1">10232295</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Gen Psychiatry. 2000 Jul;57(7):715</RefSource><PMID Version="1">10891044</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Gen Psychiatry. 2000 Jul;57(7):716-7</RefSource><PMID Version="1">10891047</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Arch Gen Psychiatry. 2001 May;58(5):512-3</RefSource><PMID Version="1">11343534</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015525" MajorTopicYN="N">Fatty Acids, Omega-3</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>5</Month><Day>8</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>5</Month><Day>8</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10232294</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.56.5.407</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17588605</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2008</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Relationship between age at onset and magnetic resonance image-defined hyperintensities in mood disorders.</ArticleTitle><Pagination><MedlinePgn>443-50</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine in patients with mood disorders the relationship of age at onset with the location and degree of MRI-defined brain hyperintensities.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Fifty-two patients diagnosed as having mood disorders and 14 controls participated in the study. Brain MR images were analyzed according to semiquantitative ratings for the anatomical distribution and severity of T2-weighted hyperintensities. We compared these hyperintensities among the three age- and sex-matched groups of late-onset mood disorder patients (LOM), early-onset mood disorder patients (EOM), and controls. The time since the onset of disorder was significantly longer in the EOM than in the LOM group. We also conducted linear multiple regression analysis using the severity of hyperintensities as dependent variable to determine whether the clinical features correlate with vascular pathology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As for deep white matter hyperintensity (DWMH), LOM exhibited higher ratings than EOM; as for brain areas, significant between-group differences were detected in the bilateral frontal areas and in the left parieto-occipital area. No significant difference was observed between EOM and controls. As for periventricular hyperintensity, there was no difference among the three groups. We obtained a significant regression model to predict DWMH ratings; age, number of ECTs, and LOM were selected as significant variables.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present study suggests that the time since the onset of disorder does not affect the development of white matter lesions, but that white matter lesions are associated with late-onset mood disorders. The frontal areas and the left parieto-occipital area would be important for the development of late-onset mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Human Behavior, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oshima</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ida</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Kumano</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yuuki</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Amanuma</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Endo</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mikuni</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004585" MajorTopicYN="N">Electrooculography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>05</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>05</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17588605</ArticleId><ArticleId IdType="pii">S0022-3956(07)00089-1</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2007.05.003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21276242</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2011</Year><Month>Jan</Month><Day>28</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Pattern of neural responses to verbal fluency shows diagnostic specificity for schizophrenia and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-244X-11-18</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Impairments in executive function and language processing are characteristic of both schizophrenia and bipolar disorder. Their functional neuroanatomy demonstrate features that are shared as well as specific to each disorder. Determining the distinct pattern of neural responses in schizophrenia and bipolar disorder may provide biomarkers for their diagnoses.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">104 participants underwent functional magnetic resonance imaging (fMRI) scans while performing a phonological verbal fluency task. Subjects were 32 patients with schizophrenia in remission, 32 patients with bipolar disorder in an euthymic state, and 40 healthy volunteers. Neural responses to verbal fluency were examined in each group, and the diagnostic potential of the pattern of the neural responses was assessed with machine learning analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the verbal fluency task, both patient groups showed increased activation in the anterior cingulate, left dorsolateral prefrontal cortex and right putamen as compared to healthy controls, as well as reduced deactivation of precuneus and posterior cingulate. The magnitude of activation was greatest in patients with schizophrenia, followed by patients with bipolar disorder and then healthy individuals. Additional recruitment in the right inferior frontal and right dorsolateral prefrontal cortices was observed in schizophrenia relative to both bipolar disorder and healthy subjects. The pattern of neural responses correctly identified individual patients with schizophrenia with an accuracy of 92%, and those with bipolar disorder with an accuracy of 79% in which mis-classification was typically of bipolar subjects as healthy controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In summary, both schizophrenia and bipolar disorder are associated with altered function in prefrontal, striatal and default mode networks, but the magnitude of this dysfunction is particularly marked in schizophrenia. The pattern of response to verbal fluency is highly diagnostic for schizophrenia and distinct from bipolar disorder. Pattern classification of functional MRI measurements of language processing is a potential diagnostic marker of schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costafreda</LastName><ForeName>Sergi G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, King's College London, De Crespigny Park, London UK. sergi.1.costafreda@kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Cynthia H Y</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Picchioni</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Toulopoulou</LastName><ForeName>Timothea</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Colm</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kravariti</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Walshe</LastName><ForeName>Muriel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Prata</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Robin M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>McGuire</LastName><ForeName>Philip K</ForeName><Initials>PK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0300977</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0802594</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G90/96</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013064" MajorTopicYN="N">Speech Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>09</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>01</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21276242</ArticleId><ArticleId IdType="pii">1471-244X-11-18</ArticleId><ArticleId IdType="doi">10.1186/1471-244X-11-18</ArticleId><ArticleId IdType="pmc">PMC3042380</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hum Brain Mapp. 2008 Nov;29(11):1265-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17894392</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Jul 27;4(7):e6353</Citation><ArticleIdList><ArticleId IdType="pubmed">19633718</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2001 Apr;16(3):167-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11353595</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2008 Jan;88(1):37-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18195082</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Mar;91(1-3):82-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17307337</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Dec;64(12):1348-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18056542</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Comput. 2010 Nov;22(11):2729-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20804386</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2006 Mar;19(2):145-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16612194</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2000 Mar;31(2-3):364-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10719164</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1997 Nov 15;42(10):948-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9359982</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 1999 Jun;41(6):1274-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10371463</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Oct;61(10):974-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15466670</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Aug 1;27(31):8161-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17670959</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):709-19</Citation><ArticleIdList><ArticleId IdType="pubmed">12668360</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Jan 15;49(2):1875-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19770054</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Dec 15;72(1):41-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15531406</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1997 May;170:426-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9307691</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2003 Sep 1;19(13):1636-43</Citation><ArticleIdList><ArticleId IdType="pubmed">12967959</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Jun;9(4):358-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17547582</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Jan 15;49(2):1153-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19833216</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Mar;164(3):450-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17329470</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2008 Aug;38(8):1185-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18507885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Jan;10(1):105-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15340357</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2007 Jan 19;315(5810):393-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17234951</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Apr 1;63(7):656-62</Citation><ArticleIdList><ArticleId IdType="pubmed">17949689</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2006 Jul;9(7):971-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16767087</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Nov 1;64(9):774-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18486104</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15700-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16227444</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2008 Apr;131(Pt 4):971-86</Citation><ArticleIdList><ArticleId IdType="pubmed">18158315</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2011 Jan;16(1):67-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19949389</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 May;186:364-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15863738</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2001 Oct;2(10):685-94</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Dec 15;80(2-3):137-49</Citation><ArticleIdList><ArticleId IdType="pubmed">16183257</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Soc Clin Psychol. 1967 Dec;6(4):278-96</Citation><ArticleIdList><ArticleId IdType="pubmed">6080235</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Mar;165(3):378-84</Citation><ArticleIdList><ArticleId IdType="pubmed">18198268</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 1998 May;4(3):265-78</Citation><ArticleIdList><ArticleId IdType="pubmed">9623001</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2009 Mar;33(3):279-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18824195</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2009 Nov;30(11):3795-811</Citation><ArticleIdList><ArticleId IdType="pubmed">19434601</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Mar;162(3):485-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15741465</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6173-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18427123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2009 Oct;30(10):3287-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19479729</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1998 Aug;121 ( Pt 8):1437-49</Citation><ArticleIdList><ArticleId IdType="pubmed">9712006</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2005 May 30;139(1):19-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15950442</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Dec;160(12):2209-15</Citation><ArticleIdList><ArticleId IdType="pubmed">14638592</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1994 Dec 15;350(3):337-56</Citation><ArticleIdList><ArticleId IdType="pubmed">7533796</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Nov;62(11):1218-27</Citation><ArticleIdList><ArticleId IdType="pubmed">16275809</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Apr;164(4):638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17403978</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1279-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19164577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2009 Dec;30(12):3958-69</Citation><ArticleIdList><ArticleId IdType="pubmed">19449330</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2010 Mar;34(3):468-86</Citation><ArticleIdList><ArticleId IdType="pubmed">19772872</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Affect Behav Neurosci. 2007 Dec;7(4):367-79</Citation><ArticleIdList><ArticleId IdType="pubmed">18189010</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2010 Sep;40(9):1409-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20085668</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2005 May;25(1):60-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15846819</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 May 15;56(2):809-13</Citation><ArticleIdList><ArticleId IdType="pubmed">20483379</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Oct;17(2):871-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12377161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Sep;10(9):811-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15970930</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2009 May 15;46(1):115-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19457393</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7183760</PMID><DateCompleted><Year>1983</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>1</Issue><PubDate><MedlineDate>1982-1983</MedlineDate></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Age at onset in bipolar-related major affective illness: clinical and genetic implications.</ArticleTitle><Pagination><MedlinePgn>5-18</MedlinePgn></Pagination><Abstract><AbstractText>Age-of-onset data were collected on 142 bipolar probands (61 males, 81 females) and 110 siblings. After correcting for demographic factors the age at illness onset did not distinguish bipolar from unipolar siblings or siblings from probands. This indicates that in a subset of pedigree data, bipolar and unipolar affective disorders may be different phenotypic manifestations of the same underlying disorder. A total of 43% of affected individuals gave evidence of illness before age 30 and 11% were ill as adolescents. Also 2% were affected prior to age 15. The data indicate that affective illness is not uncommon in adolescence and may occur as a childhood disorder. Estimation of the age-of-onset probability distribution was obtained by incorporating demographic factors (survivorship data) into the observed ages at onset of affected individuals. A square-root normal curve fits the age-of-onset probability density function. The implications for morbid risk prediction and genetic analysis of affective disorders were discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baron</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Risch</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mendlewicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KO1MH00176</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7183760</ArticleId><ArticleId IdType="doi">10.1016/0022-3956(82)90030-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19268175</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2009</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>35 Suppl 2</Volume><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Social environment and social rhythms].</ArticleTitle><Pagination><MedlinePgn>S72-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0013-7006(09)75538-1</ELocationID><Abstract><AbstractText>The social environment lies at the aetiopathogenic heart of many diseases including bipolar disorders. It has been established that disturbances of social rhythms as a result of more or less severe events predispose to relapse of a mood disorder. Treatments are offered to regulate social rhythms. These may be incorporated into psychoeducational programmes or form a specific programme themselves (IPSRT), incorporating interpersonal therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gay</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinique du Château, 11 bis rue de la Porte Jaune, 92380 Garches. Christian.gay@clinique-garches.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Environnement social et rythmes sociaux.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021081" MajorTopicYN="N">Chronobiology Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019454" MajorTopicYN="N">Chronotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="Y">Social Environment</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>8</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19268175</ArticleId><ArticleId IdType="pii">S0013-7006(09)75538-1</ArticleId><ArticleId IdType="doi">10.1016/S0013-7006(09)75538-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11684138</PMID><DateCompleted><Year>2002</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>6</Issue><PubDate><MedlineDate>2001 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>MRI study of posterior fossa structures and brain ventricles in bipolar patients.</ArticleTitle><Pagination><MedlinePgn>313-22</MedlinePgn></Pagination><Abstract><AbstractText>Previous brain imaging studies have suggested anatomical abnormalities in posterior fossa structures and brain ventricles in bipolar patients. Such abnormalities could possibly be implicated in the pathophysiology of bipolar disorder. Twenty-two DSM-IV bipolar outpatients (mean age+/-S.D.=36+/-10 years) and 22 healthy controls (mean age+/-S.D.=38+/-10 years) underwent an 1.5T MRI (3D-gradient echo-imaging SPGR), performed in the coronal plane (TR=25 ms, TE=5 ms, slice thickness=1.5 mm). The brain structures of interest were traced blindly with a semi-automated software. No significant differences were found between bipolar patients and healthy controls for any posterior fossa measures, or for measures of third or lateral ventricles (MANOVA, age covariate, P&gt;0.05). Age was directly correlated with 3rd ventricle volumes in bipolar patients (Pearson correlation coefficient=0.458, P=0.032), but not in healthy controls (Pearson correlation coefficient=0.313, P=0.155). There was a significant direct correlation between the number of prior illness episodes and right lateral ventricle volumes (Partial correlation coefficient=0.658, P=0.011). Familial patients had smaller left and right cerebellar hemispheres and total vermis volumes, and larger left lateral ventricle volumes compared with non-familial ones (MANOVA, age covariate, P&lt;0.05). In this preliminary study, we were not able to replicate previous findings of abnormalities in cerebellum or brain ventricles in bipolar individuals. However, there were suggestions that abnormalities in cerebellum, vermis, and lateral ventricle sizes may be present in familial cases of the disorder, which should be further examined in future studies with larger patient samples.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brambilla</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harenski</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nicoletti</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mallinger</LastName><ForeName>A G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Keshavan</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 01736</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 29618</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 30915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001933" MajorTopicYN="N">Brain Stem</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="Y">abnormalities</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="Y">abnormalities</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003388" MajorTopicYN="N">Cranial Fossa, Posterior</DescriptorName><QualifierName UI="Q000002" MajorTopicYN="Y">abnormalities</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>10</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>4</Month><Day>24</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>10</Month><Day>31</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11684138</ArticleId><ArticleId IdType="pii">S002239560100036X</ArticleId><ArticleId IdType="doi">10.1016/s0022-3956(01)00036-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11907593</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0327-6139</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>43</Issue><PubDate><MedlineDate>2001 Mar-May</MedlineDate></PubDate></JournalIssue><Title>Vertex (Buenos Aires, Argentina)</Title><ISOAbbreviation>Vertex</ISOAbbreviation></Journal><ArticleTitle>[Some concepts about the treatment of the depressive episode in bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>51-6</MedlinePgn></Pagination><Abstract><AbstractText>A frequent clinical mistake is to diagnose a Depressive Episode of the Bipolar Disorder as a Unipolar Depression. This, generally, has iatrogenic consequences for the patient. In this article the approaches are revised for a correct diagnosis and also an algorithm for an appropriate treatment is suggested.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>García Bonetto</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hospital Neuropsiquiátrico Provincial, Córdoba, Clínica "Saint Michel". gbonetto@hotmail.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Algunos conceptos en torno al tratamiento del episodio depresivo en el trastorno bipolar.</VernacularTitle></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Vertex</MedlineTA><NlmUniqueID>9440528</NlmUniqueID><ISSNLinking>0327-6139</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11907593</ArticleId><ArticleId IdType="pii">040579197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6222095</PMID><DateCompleted><Year>1983</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>1983</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Methylene blue. A possible treatment for manic depressive psychosis.</ArticleTitle><Pagination><MedlinePgn>155-61</MedlinePgn></Pagination><Abstract><AbstractText>Methylene blue was given to patients who had failed to respond to standard therapies. Of the 19 manic depressives who received oral methylene blue, 14 were judged to show definite improvement, 3 patients in whom the diagnosis was uncertain showed no beneficial response.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Narsapur</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Naylor</LastName><ForeName>G J</ForeName><Initials>GJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>T42P99266K</RegistryNumber><NameOfSubstance UI="D008751">Methylene Blue</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008751" MajorTopicYN="N">Methylene Blue</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6222095</ArticleId><ArticleId IdType="pii">0165-0327(83)90008-3</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(83)90008-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10624554</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>12</Issue><PubDate><Year>1999</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mania associated with St. John's wort.</ArticleTitle><Pagination><MedlinePgn>1707-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">St. John's wort, the popular herbal remedy touted as an antidepressant, is generally thought to be benign, with few reported side effects. Given its possible efficacy as an antidepressant, evaluation of its propensity to cause affective switching should be evaluated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This report presents two cases of mania temporally associated with the use of St. John's wort (hypericum).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As with other antidepressant agents, St. John's wort may precipitate hypomania, mania, or an increased cycling of mood states, particularly in patients with occult bipolar disorder.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Because the majority of people who take this popular over-the-counter preparation do so without formal psychiatric evaluations, risk of hypericum-induced mania may be significant. Physicians should screen patients for a history of hypomania or mania before recommending use of St. John's wort for depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burt</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020902" MajorTopicYN="N">Hypericum</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010946" MajorTopicYN="Y">Plants, Medicinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>1</Month><Day>7</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>7</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10624554</ArticleId><ArticleId IdType="pii">S0006-3223(99)00233-4</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(99)00233-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16730331</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>8</Issue><PubDate><Year>2006</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Impairment of endothelial function in unipolar and bipolar depression.</ArticleTitle><Pagination><MedlinePgn>889-91</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous studies have suggested an association between abnormal endothelial function and depression. We therefore tested this hypothesis in patients with depression in the course of mood disorders and assessed the effect of antidepressant treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Psychometric evaluation and hemodynamic and endothelial function studies using pulse wave analysis were performed on a group of 31 patients with unipolar or bipolar depression. The control group consisted of 18 healthy subjects, age- and gender-matched.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Arterial endothelial function was impaired in patients compared with that in control subjects, both during a depressive episode and when in remission after pharmacological treatment. The diagnosis, intensity of depression, and type of antidepressant drugs did not influence the results.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The impairment of endothelial function might constitute a trait marker of the biological make-up of patients with mood disorders and might contribute to the increased frequency of cardiovascular conditions observed in these patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Janusz K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland. rybakows@wlkp.top.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wykretowicz</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Heymann-Szlachcinska</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wysocki</LastName><ForeName>Henryk</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000318">Adrenergic beta-Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>QF8SVZ843E</RegistryNumber><NameOfSubstance UI="D000420">Albuterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000318" MajorTopicYN="N">Adrenergic beta-Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000420" MajorTopicYN="N">Albuterol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014664" MajorTopicYN="N">Vasodilation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16730331</ArticleId><ArticleId IdType="pii">S0006-3223(06)00401-X</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2006.03.025</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1773247</PMID><DateCompleted><Year>1992</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>159</Volume><PubDate><Year>1991</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Rapid-cycling manic-depressive illness following subarachnoid haemorrhage.</ArticleTitle><Pagination><MedlinePgn>279-80</MedlinePgn></Pagination><Abstract><AbstractText>The case of a young man who developed a remarkably regular and rapid cyclical affective illness following a subarachnoid haemorrhage is reported. A CT scan showed damage restricted to the brain-stem. The illness proved resistant to a variety of agents; carbamazepine and lithium combined proved effective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blackwell</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>St Augustine's Hospital, Chartham, Canterbury, Kent.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Psychiatry. 1992 Feb;160:283</RefSource><PMID Version="1">1540777</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013345" MajorTopicYN="N">Subarachnoid Hemorrhage</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1773247</ArticleId><ArticleId IdType="pii">S0007125000142126</ArticleId><ArticleId IdType="doi">10.1192/bjp.159.2.279</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26301477</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>187</Volume><PubDate><Year>2015</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Optimising screening for cognitive dysfunction in bipolar disorder: Validation and evaluation of objective and subjective tools.</ArticleTitle><Pagination><MedlinePgn>10-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.07.039</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)30359-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Cognitive impairment is common in bipolar disorder and contributes to socio-occupational difficulties. The objective was to validate and evaluate instruments to screen for and monitor cognitive impairments, and improve the understanding of the association between cognitive measures and socio-occupational capacity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with bipolar disorder in partial or full remission (n=84) and healthy controls (n=68) were assessed with the Screen for Cognitive Impairment in Psychiatry (SCIP), Cognitive Complaints in Bipolar Disorder Rating Scale (COBRA), and established neuropsychological tests and subjective rating scales. Socio-occupational function and affective symptoms were evaluated with the Functional Assessment Short Test, and the Hamilton Depression Rating Scale 17-items and Young Mania Rating Scale, respectively. Concurrent validity of the SCIP and COBRA were assessed by correlation with established objective and subjective cognitive measures, and decision validity was determined with Receiver-Operating-Characteristic analyses. Correlations and linear regression analyses were conducted to determine the associations between objective and subjective cognitive impairment, and socio-occupational difficulties.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The SCIP and COBRA correlated strongly with established objective and subjective cognitive measures, respectively. The SCIP yielded higher sensitivity and specificity for detection of cognitive dysfunction than the COBRA or a combined SCIP-COBRA measure. Correlations between objective and subjective cognitive impairment were weak but both were associated with socio-occupational difficulties.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Influence of ageing was not investigated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The SCIP and COBRA are valid for detection of objective and subjective cognitive impairment in bipolar disorder. Screening for cognitive dysfunction should be conducted with an objective measure like the SCIP.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Johan Høy</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet Dep. 6233, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Støttrup</LastName><ForeName>Mette Marie</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet Dep. 6233, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nayberg</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet Dep. 6233, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knorr</LastName><ForeName>Ulla</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet Dep. 6233, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullum</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet Dep. 2031, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purdon</LastName><ForeName>Scot E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Alberta Hospital Edmonton Neuropsychology, and the University of Alberta Faculty of Medicine &amp; Dentistry, Box 307 (17480 Fort Road), Edmonton, Alta., Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>Lars V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet Dep. 6233, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miskowiak</LastName><ForeName>Kamilla W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet Dep. 6233, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. Electronic address: Kamilla@miskowiak.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Cognitive complaints</Keyword><Keyword MajorTopicYN="N">Cognitive impairment</Keyword><Keyword MajorTopicYN="N">Screening</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>06</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>07</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>07</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26301477</ArticleId><ArticleId IdType="pii">S0165-0327(15)30359-1</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.07.039</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24103187</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>119-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12118</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Ketamine, an N-methyl d-aspartate (NMDA) antagonist, has rapid antidepressant effects in depressed subjects with bipolar disorder (BD). Evidence supports a role for the glutamatergic system in the pathophysiology of BD. This double-blind, randomized, cross-over study sought to determine cerebral metabolic correlates of antidepressant response to ketamine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-one subjects with BD currently in a depressed state underwent [(18) F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging after receiving a placebo infusion as well as after receiving a ketamine infusion. Metabolism was compared between ketamine and placebo infusions, and correlated with clinical response. Regional metabolic rate of glucose (rMRGlu) in regions of interest (ROIs) and Montgomery-Åsberg Depression Rating Scale (MADRS) scores were the main outcome measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study found that change in metabolism between sessions was significantly correlated with percentage change in MADRS scores in the right ventral striatum; subjects who showed the greatest improvement had the largest metabolic increase after ketamine infusion compared to placebo. In a voxel-wise analysis, subjects with BD had significantly lower glucose metabolism in the left hippocampus following the ketamine infusion than following the placebo infusion. In addition, metabolism in the subgenual anterior cingulate cortex (ACC) following the placebo infusion was positively correlated with percentage improvement in MADRS score following the ketamine infusion.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Taken together, the results suggest that higher activity in the subgenual ACC may predict antidepressant response to ketamine. Ketamine administration altered glucose metabolism in areas known to be involved in mood disorders; these alterations may partially underlie ketamine's mechanism of action.</AbstractText><CopyrightInformation>Published 2013. This article is a U.S. Government work and is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nugent</LastName><ForeName>Allison C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Experimental Therapeutics and Pathophysiology Branch, NIMH, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diazgranados</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Lobna</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Luckenbaugh</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Brutsche</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Herscovitch</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Drevets</LastName><ForeName>Wayne C</ForeName><Initials>WC</Initials></Author><Author ValidYN="Y"><LastName>Zarate</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA MH002857-08</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA MH002927-03</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="N">Ketamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">N-methyl d-aspartate (NMDA) antagonist</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">imaging</Keyword><Keyword MajorTopicYN="N">ketamine</Keyword><Keyword MajorTopicYN="N">positron emission tomography (PET)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>07</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24103187</ArticleId><ArticleId IdType="doi">10.1111/bdi.12118</ArticleId><ArticleId IdType="pmc">PMC3949142</ArticleId><ArticleId IdType="mid">NIHMS515258</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurosci Biobehav Rev. 2009 May;33(5):699-771</Citation><ArticleIdList><ArticleId IdType="pubmed">19428491</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2009 May;34(3):175-80</Citation><ArticleIdList><ArticleId IdType="pubmed">19448846</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Aug;156(8):1149-58</Citation><ArticleIdList><ArticleId IdType="pubmed">10450253</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2003 Apr 1;23(7):2744-50</Citation><ArticleIdList><ArticleId IdType="pubmed">12684460</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1988 Nov 8;277(2):195-213</Citation><ArticleIdList><ArticleId IdType="pubmed">2466057</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2002 Mar;26(3):368-75</Citation><ArticleIdList><ArticleId IdType="pubmed">11850151</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Nov;45(11):1426-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21722919</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2005 Dec 26;493(4):479-509</Citation><ArticleIdList><ArticleId IdType="pubmed">16304624</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Sep;63(9):978-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16953000</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2003 Feb;8(2):241-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12610658</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Jul;61(7):649-57</Citation><ArticleIdList><ArticleId IdType="pubmed">15237077</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2009 Dec;17(12):1022-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20104059</ArticleId></ArticleIdList></Reference><Reference><Citation>Synapse. 2000 Aug;37(2):95-103</Citation><ArticleIdList><ArticleId IdType="pubmed">10881030</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2010 Winter;22(1):75-84</Citation><ArticleIdList><ArticleId IdType="pubmed">20160213</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2008 Aug;106(4):1758-65</Citation><ArticleIdList><ArticleId IdType="pubmed">18540994</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 Jun;34(7):1810-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19194376</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1996 Dec;1(6):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9154245</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2009 Feb 16;78(2-3):69-74</Citation><ArticleIdList><ArticleId IdType="pubmed">18950692</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 May 30;163(1):76-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18406580</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2010 Feb;35(3):834-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19956089</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Jan;136(1-2):63-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21925739</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Feb;65(2):154-64</Citation><ArticleIdList><ArticleId IdType="pubmed">18250253</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2002 Dec;164(4):401-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12457270</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 1982 Jun;23(6):538-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7077405</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2010 Aug;67(8):793-802</Citation><ArticleIdList><ArticleId IdType="pubmed">20679587</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2007 Jan 5;1127(1):108-18</Citation><ArticleIdList><ArticleId IdType="pubmed">17113057</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2010 Jun;35(7):1415-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20393460</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2003 Dec 30;62(3):231-40</Citation><ArticleIdList><ArticleId IdType="pubmed">14698356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2000 Mar;10(3):206-19</Citation><ArticleIdList><ArticleId IdType="pubmed">10731217</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2010 Mar-Apr;51(2):187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20152301</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Jun;84(2-3):214-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16549338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Jan;120(1-3):120-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19539998</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2000 Jan-Feb;34(1):35-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10696831</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2008 Aug;13(8):663-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18704022</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2008 Jun;52(7):1322-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18336953</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2012 Mar;66(2):138-45</Citation><ArticleIdList><ArticleId IdType="pubmed">22353326</ArticleId></ArticleIdList></Reference><Reference><Citation>Synapse. 2002 Jan;43(1):19-29</Citation><ArticleIdList><ArticleId IdType="pubmed">11746730</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 Jun 1;71(11):939-46</Citation><ArticleIdList><ArticleId IdType="pubmed">22297150</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2008 Dec;43(4):764-74</Citation><ArticleIdList><ArticleId IdType="pubmed">18718871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2003 Jan;18(1):30-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12454910</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 Apr 24;386(6627):824-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9126739</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32019354</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1665</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists</Title><ISOAbbreviation>Australas Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Non-consensual recommendations for managing bipolar II disorder.</ArticleTitle><Pagination><MedlinePgn>335-338</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1039856220901473</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The objective of this study is to report on the degree of consensus in experts' recommendations for managing bipolar II disorder.</AbstractText><AbstractText Label="METHODS">Eighteen international clinician researchers with expertise in managing bipolar disorders were provided with 14 questions addressing nuances in managing those with a bipolar II disorder.</AbstractText><AbstractText Label="RESULTS">To all questions, the independently derived recommended strategies demonstrated distinct divergence.</AbstractText><AbstractText Label="CONCLUSION">The lack of consensus in management recommendations is likely to reflect the disorder being relatively recently formalised, the lack of condition-specific randomised controlled trial data and the nature of psychiatric practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3424-5519</Identifier><AffiliationInfo><Affiliation>School of Psychiatry, University of NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Australas Psychiatry</MedlineTA><NlmUniqueID>9613603</NlmUniqueID><ISSNLinking>1039-8562</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="Y">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar II disorder</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">management guidelines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32019354</ArticleId><ArticleId IdType="doi">10.1177/1039856220901473</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3372890</PMID><DateCompleted><Year>1988</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0309-2402</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>1988</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of advanced nursing</Title><ISOAbbreviation>J Adv Nurs</ISOAbbreviation></Journal><ArticleTitle>Manic depressive psychosis: an alternative therapeutic model of nursing.</ArticleTitle><Pagination><MedlinePgn>93-8</MedlinePgn></Pagination><Abstract><AbstractText>Traditionally, the approach to affective disorders has focused upon the biophysical aetiology of the disorder. Given that a significant proportion of the so called 'recovered' manic depressive population experience a relapse, the adequacy of traditional treatment methods is questionable. The nursing literature represents the view that manic depressive patients have little, if any, control over their condition and the nursing management, therefore, is predominantly custodial, supportive and directive in character. Recent research suggests that life events, in particular the patient's perception and interpretation of such events, are potentially significant in the development of manic depressive symptomatology. This paper reports some aspects of an on-going nursing research project which is evaluating the efficacy of a multi-model nursing management package. The therapeutic model of nursing under study is briefly discussed and results of locus of control measurements are presented, which compare a random sample of recovered manic depressive women with existing norms. A description is also given of an attribution schedule developed by the authors for the research project. This schedule attempts to specifically assess the patient's attitudes towards her control of her illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hume</LastName><ForeName>A J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Royal Dundee Liff Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Swan</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Adv Nurs</MedlineTA><NlmUniqueID>7609811</NlmUniqueID><ISSNLinking>0309-2402</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="N">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="N">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="Y">nursing</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007389" MajorTopicYN="N">Internal-External Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011568" MajorTopicYN="N">Psychiatric Nursing</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3372890</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2648.1988.tb01395.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1337539</PMID><DateCompleted><Year>1993</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0720-4299</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>12</Issue><PubDate><Year>1992</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Fortschritte der Neurologie-Psychiatrie</Title><ISOAbbreviation>Fortschr Neurol Psychiatr</ISOAbbreviation></Journal><ArticleTitle>[Importance of calcium ions and calcium antagonists in affective psychoses].</ArticleTitle><Pagination><MedlinePgn>471-6</MedlinePgn></Pagination><Abstract><AbstractText>Apart from the eminent changes in the neurotransmitter systems of the central nervous system, a disturbance of the calcium ion concentration may be of significance in the pathophysiology of affective psychoses. The present paper deals with the contribution of calcium ions in the generation of affective psychoses and discusses the calcium antagonism as a new strategy in the treatment of the disease. The following topics will be described: 1. Disturbances of calcium metabolism in affective psychoses, 2. a comparison of lithium and carbamazepine effects, 3. clinical studies with organic calcium channel blockers in affective psychoses and 4. the role of calcium ions in affective psychoses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walden</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Psychiatrische Klinik, Albert-Ludwigs-Universität Freiburg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Olbrich</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Bedeutung von Kalziumionen und Kalziumantagonisten bei affektiven Psychosen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Fortschr Neurol Psychiatr</MedlineTA><NlmUniqueID>8103137</NlmUniqueID><ISSNLinking>0720-4299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015220">Calcium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015220" MajorTopicYN="N">Calcium Channels</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1337539</ArticleId><ArticleId IdType="doi">10.1055/s-2007-1000670</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19497250</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature.</ArticleTitle><Pagination><MedlinePgn>1078-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.08r04505</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review extant literature implicating inflammation in the pathophysiology of bipolar disorder. Furthermore, we review evidence regarding the anti-inflammatory actions of mood-stabilizing medication, the putative reciprocal association of inflammation with behavioral parameters and medical burden in bipolar disorder, and the potential role of anti-inflammatory agents in the treatment of bipolar disorder.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">MEDLINE and PubMed searches were conducted of English-language articles published from 1950 to April 2008 using the search terms bipolar disorder, manic, or mania, cross-referenced with inflammation, inflammatory, interleukin, cytokine, C-reactive protein, or tumor necrosis factor. The search, which was conducted most recently on August 20, 2008, was supplemented by manually reviewing reference lists from the identified publications.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Articles selected for review were based on adequacy of sample size, the use of standardized experimental procedures, validated assessment measures, and overall manuscript quality.</AbstractText><AbstractText Label="DATA EXTRACTION" NlmCategory="METHODS">Studies were reviewed for statistical comparisons of cytokines among persons with and without bipolar disorder, during symptomatic and non-symptomatic intervals and before and after pharmacologic treatment. Significant and nonsignificant findings were tabulated.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Available evidence indicates that bipolar disorder and inflammation are linked through shared genetic polymorphisms and gene expression as well as altered cytokine levels during symptomatic (i.e., mania and depression) and asymptomatic intervals. However, results are inconsistent. Several conventional mood stabilizers have anti-inflammatory properties. The cyclooxygenase-2-selective anti-inflammatory celecoxib may offer antidepressant effects. Inflammation is closely linked with behavioral parameters such as exercise, sleep, alcohol abuse, and smoking, as well as with medical comorbidities including coronary artery disease, obesity and insulin resistance, osteoporosis, and pain. Methodological limitations precluding definitive conclusions are heterogeneity in sample composition, cytokine assessment procedures, and treatment regimens. The inclusion of multiple ethnic groups introduces another source of variability but also increases the generalizability of study findings.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Inflammation appears relevant to bipolar disorder across several important domains. Further research is warranted to parse the reciprocal associations between inflammation and symptoms, comorbidities, and treatments in bipolar disorder. Studies of this topic among youth are needed and may best serve this purpose.</AbstractText><CopyrightInformation>© Copyright 2009 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin I</ForeName><Initials>BI</Initials><AffiliationInfo><Affiliation>Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, 3811 O'Hara Street, Pittsburgh, PA 16213, USA. goldsteinbi@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kemp</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Soczynska</LastName><ForeName>Joanna K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 RR024990</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>JCX84Q7J1L</RegistryNumber><NameOfSubstance UI="D000068579">Celecoxib</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010054" MajorTopicYN="N">Brief Psychiatric Rating Scale</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068579" MajorTopicYN="N">Celecoxib</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>156</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>08</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19497250</ArticleId><ArticleId IdType="doi">10.4088/JCP.08r04505</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12975680</PMID><DateCompleted><Year>2003</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1516-4446</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2003</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)</Title><ISOAbbreviation>Braz J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>[Genes related to phospholipid metabolism as risk factors related to bipolar affective disorder].</ArticleTitle><Pagination><MedlinePgn>51-5</MedlinePgn></Pagination><Abstract><AbstractText>The studies of genetic epidemiology provides consistent evidence of genetic factors having a major role on the risk for the bipolar affective disorder, although, vulnerability genes have not yet been identified in unequivocal form. The authors show that phospholipids play an important role in the cellular signalling processes, besides this, some studies with mood-stabilisers neurochemistry suggest that these drugs act in the phospholipase regulated signalling views. They conclude that analysis of gene variants that code enzymes of the phospholipids metabolism as potential susceptibility genes can extend the knowledge concerning the risk factors and the physiopatological mechanisms underling this mood disturbance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meira-Lima</LastName><ForeName>Ivanor V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Laboratório de Neurociências. Instituto de Psiquiatria Faculdade de Medicina da Universidade de São Paulo. São Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallada</LastName><ForeName>Homero</ForeName><Initials>H</Initials></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Genes relacionados ao metabolismo dos fosfolípides como fatores de risco para o transtorno afetivo bipolar.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Braz J Psychiatry</MedlineTA><NlmUniqueID>100895975</NlmUniqueID><ISSNLinking>1516-4446</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>40</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12975680</ArticleId><ArticleId IdType="pii">S1516-44462003000100010</ArticleId><ArticleId IdType="doi">10.1590/s1516-44462003000100010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30802696</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>249</Volume><PubDate><Year>2019</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A pilot study of brexpiprazole for bipolar depression.</ArticleTitle><Pagination><MedlinePgn>315-318</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(18)32885-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2019.02.056</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Past studies suggest that brexpiprazole is an effective adjunctive treatment for major depressive disorder and schizophrenia; however, no studies have examined brexpiprazole for bipolar depression. In this study, we examined the effects of brexpiprazole on mood, cognition, and quality of life in outpatients with bipolar depression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-one adults with bipolar disorder (most recent episode depressed) and scoring at least a 25 on the Montgomery-Åsberg Depression Rating Scale (MADRS) were recruited. Brexpiprazole was titrated up to 4 mg/day over the 8-week period. Depressive symptoms were measured using MADRS and Inventory of Depressive Symptomatology Self-report (IDS-SR<sub>30</sub>). Manic symptoms were measured using Young Mania Rating Scale, quality of life with the Quality of Life in Bipolar Disorder (QOLBD), and cognition with Rey Auditory Verbal Learning Test, Stroop Color Word Test, and Trail Making Test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">MADRS and IDS-SR<sub>30</sub> scores decreased from baseline at weeks 4 and 8. YMRS and cognitive scores did not change significantly. QOLBD scores increased from baseline to week 8.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">A limitation to this study is the open-label design.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">To our knowledge, this is the first study to examine the effects of brexpiprazole on bipolar depression. We found a significant reduction in depressive symptoms and an increase in quality of life.</AbstractText><CopyrightInformation>Copyright © 2019. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>E Sherwood</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8849, United States. Electronic address: sherwood.brown@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khaleghi</LastName><ForeName>Neusha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8849, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Enkevort</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8849, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivleva</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8849, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Alyson</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8849, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Traci</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8849, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Brittany L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8849, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escalante</LastName><ForeName>Chastity</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8849, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013876">Thiophenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>2J3YBM1K8C</RegistryNumber><NameOfSubstance UI="C000591922">brexpiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013876" MajorTopicYN="N">Thiophenes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Brexpiprazole</Keyword><Keyword MajorTopicYN="Y">Cognition</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30802696</ArticleId><ArticleId IdType="pii">S0165-0327(18)32885-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2019.02.056</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20458195</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-736X</ISSN><JournalIssue CitedMedium="Internet"><Volume>198</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Detecting differences in diagnostic assessment of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>339-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NMD.0b013e3181da4f67</ELocationID><Abstract><AbstractText>During the past 25 years, semistructured diagnostic interviews have been the standard for diagnostic evaluations in research relying on reliable and valid psychiatric assessment and diagnosis. However, the use of semistructured interviews still requires interpretation of the diagnostic criteria and does not preclude the application of different diagnostic thresholds. The goal of this report from the Rhode Island Methods to Improve Diagnostic Assessment and Services project is to illustrate how a self-report scale can be used to detect systematic differences in the application of diagnostic criteria for bipolar disorder and to demonstrate the wide variation in how broadly different groups tend to diagnose bipolar disorder. We compared the frequency of bipolar diagnoses in 4 studies that examined the performance of mood disorders questionnaire (MDQ) with the Structured Clinical Interview for DSM-IV (SCID). We also compared the prevalence rate of MDQ cases and the ratio of SCID diagnoses with MDQ cases. The frequency of bipolar disorder in the 4 studies ranged from 10.9% to 76.2%-a 7-fold difference in prevalence rates. The frequency of MDQ-positive cases ranged from 17.8% to 31.2%, less than a 2-fold difference in prevalence rates. Thus, there was much less variability in MDQ rates than diagnosis rates. Moreover, the rank order of the prevalence of MDQ cases differed from the rank order of the prevalence of SCID diagnoses. The SCID/MDQ ratio significantly differed between the studies. These findings demonstrate how systematic differences in diagnostic practice might be detected using a self-administered scale such as the MDQ. The results also underscore that wide variation exists in the bias toward diagnosing bipolar disorder, even after controlling for differences in prevalence among samples.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Human Behavior, Brown School of Medicine, Providence, RI 02905, USA. mzimmerman@lifespan.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruggero</LastName><ForeName>Camilo J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Galione</LastName><ForeName>Janine N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>McGlinchey</LastName><ForeName>Joseph B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Dalrymple</LastName><ForeName>Kristy</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Chelminski</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH085730</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012237" MajorTopicYN="N" Type="Geographic">Rhode Island</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20458195</ArticleId><ArticleId IdType="doi">10.1097/NMD.0b013e3181da4f67</ArticleId><ArticleId IdType="pii">00005053-201005000-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18188683</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-005X</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Culture, medicine and psychiatry</Title><ISOAbbreviation>Cult Med Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cultural formulation with attention to language and cultural dynamics in a mexican psychiatric patient treated in San Diego, California.</ArticleTitle><Pagination><MedlinePgn>102-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11013-007-9072-0</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bucardo</LastName><ForeName>Jesús A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive (MS 0680), San Diego, CA 92093, USA. jbucardo@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH49671</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH080002-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH080002</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH43693</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH59101</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Cult Med Psychiatry</MedlineTA><NlmUniqueID>7707467</NlmUniqueID><ISSNLinking>0165-005X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000069" MajorTopicYN="N">Acculturation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="Y">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003466" MajorTopicYN="Y">Cultural Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017058" MajorTopicYN="N">Mexican Americans</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019303" MajorTopicYN="Y">Multilingualism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18188683</ArticleId><ArticleId IdType="doi">10.1007/s11013-007-9072-0</ArticleId><ArticleId IdType="pmc">PMC2552996</ArticleId><ArticleId IdType="mid">NIHMS58954</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Annu Rev Psychol. 2000;51:571-98</Citation><ArticleIdList><ArticleId IdType="pubmed">10751981</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 2004 Feb;19(2):167-74</Citation><ArticleIdList><ArticleId IdType="pubmed">15009796</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 1988;26(12):1233-43</Citation><ArticleIdList><ArticleId IdType="pubmed">3206245</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1995 Sep;18(3):449-65</Citation><ArticleIdList><ArticleId IdType="pubmed">8545261</ArticleId></ArticleIdList></Reference><Reference><Citation>J Subst Abuse Treat. 1996 Mar-Apr;13(2):119-26</Citation><ArticleIdList><ArticleId IdType="pubmed">8880669</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2005 Oct;31(4):922-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16037481</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Oct;66(10):1304-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16259545</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20231325</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2010</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>167</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Gender and depressive symptoms in 711 patients with bipolar disorder evaluated prospectively in the Stanley Foundation bipolar treatment outcome network.</ArticleTitle><Pagination><MedlinePgn>708-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2009.09010105</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors assessed gender differences in the proportion of clinical visits spent depressed, manic, or euthymic in patients with bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Data were analyzed from 711 patients with bipolar I or II disorder who were followed prospectively over 7 years (13,191 visits). The main outcome measures were the presence of symptoms of depression or of hypomania or mania, measured by the Inventory of Depressive Symptomatology and the Young Mania Rating Scale. Data were analyzed using three separate repeated-measures regressions with a logistic link function to model the probability that an individual was depressed, manic, or euthymic. The models controlled for bipolar I or bipolar II diagnosis, rapid cycling, age, time in the study, comorbid anxiety disorders, and comorbid substance use disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In approximately half of visits, patients had depressive, manic, or hypomanic symptoms. The likelihood of having depressive symptoms was significantly greater for women than for men. This was accounted for by higher rates in women of rapid cycling and anxiety disorders, each of which was associated with increased rates of depression. All patient groups showed an increase in number of euthymic visits and a decrease in number of visits with depressive and manic symptoms with increased time in study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bipolar patients spend a substantial proportion of their time ill. Significant gender differences exist, with women spending a greater proportion of their visits in the depressive pole. This finding appears to be related to the corresponding differences in rates of rapid cycling and anxiety disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>Lori L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, Jane and Terry Semel Institute of Neuroscience and Human Behavior, UCLA, USA. laltshuler@mednet.ucla.edu &lt;laltshuler@mednet.ucla.edu&gt;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Hellemann</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Sugar</LastName><ForeName>Catherine A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Leverich</LastName><ForeName>Gabriele S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Keck</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Zermeno</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Suppes</LastName><ForeName>Trisha</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20231325</ArticleId><ArticleId IdType="pii">appi.ajp.2009.09010105</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2009.09010105</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1827477</PMID><DateCompleted><Year>1991</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>1991</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Multi-center study of seasonal affective disorders in Japan. A preliminary report.</ArticleTitle><Pagination><MedlinePgn>57-65</MedlinePgn></Pagination><Abstract><AbstractText>A multi-center study on seasonal affective disorder (SAD) was conducted from the autumn of 1988 to the spring of 1989 with the cooperation of 16 facilities in Japan. Forty-six SAD patients were identified among 1104 respondents to our advertisements in mass media, or patients seen at the outpatient clinics. Essentially similar findings to other previous reports were obtained in terms of onset age of the first episode, duration of episode, high proportion of depression in first-degree relatives and atypical vegetative symptoms. However, a nearly equal sex ratio, together with a high proportion of unipolar depression, is characteristic of the present study. Increased appetite and carbohydrate craving were predominant only in female patients, whereas hypersomnia was prominent in both sexes. Effective response to light therapy was found in 17 SAD patients. However, a controlled study on a large number of patients is required to allow final conclusions on the efficacy of light therapy in Japanese SAD patients.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Mental Disorders Research, National Institute of Neurosciences, NCNP, Kodaira, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asano</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kohsaka</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Okawa</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Higuchi</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ishizuka</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kawaguchi</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="N">Phototherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1827477</ArticleId><ArticleId IdType="pii">0165-0327(91)90019-O</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(91)90019-o</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32739706</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>276</Volume><PubDate><Year>2020</Year><Month>11</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Trends in prescriptions of lithium and other medications for patients with bipolar disorder in office-based practices in the United States: 1996-2015.</ArticleTitle><Pagination><MedlinePgn>883-889</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(20)32508-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2020.07.063</ELocationID><Abstract><AbstractText Label="BACKGROUND">Studies have shown that rates of lithium use for bipolar disorder in the United States declined through the 1990s as other mood stabilizing anticonvulsants and second-generation antipsychotics (SGAs) became more popular. We examined trends of medications for bipolar disorder from 1996 to 2015.</AbstractText><AbstractText Label="METHODS">Twenty years of data from the National Ambulatory Medical Care Survey (NAMCS) were used. Weighted percentages of reported use of lithium, anticonvulsants, SGAs and antidepressants were calculated over two-year intervals. Logistic regression was used to examine factors related to polytherapy.</AbstractText><AbstractText Label="RESULTS">Reported use of lithium declined from 38.1% (95%CI: 29.8% - 46.3%) in 1996-97 to 14.3% (95%CI: 10.6% - 18.1%) in 2006-07 and has remained stable since. During this time, reports of SGAs more than doubled. SGAs and/or anticonvulsants were reported in 75.4% (95%CI: 69.5% - 81.3%) of visits with bipolar diagnoses in 2014-15. Polytherapy increased by approximately 3% every two years and in 2014-15 occurred in over 30% of visits. Antidepressants were reported in 40-50% of visits, but their reported use without other mood stabilizers decreased from 18.2% (95%CI: 11.7% - 24.8%) in 1998-99 to 7.5% (95%CI: 4.2% - 10.9%) in 2014-15.</AbstractText><AbstractText Label="LIMITATIONS">The sample had limited power to study the effect of individual medications or the potential for differing effects in certain sub-groups of patients.</AbstractText><AbstractText Label="CONCLUSIONS">This study further documents the declining use of lithium for bipolar disorder, and corresponding increase in use of anticonvulsants and SGAs, despite the fact that lithium is typically recommended as a first line therapy for bipolar disorder.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yian</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mojtabai</LastName><ForeName>Ramin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goes</LastName><ForeName>Fernando S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zandi</LastName><ForeName>Peter P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, United States. Electronic address: pzandi1@jhu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055656" MajorTopicYN="N">Prescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Anticonvulsants</Keyword><Keyword MajorTopicYN="Y">Antidepressants</Keyword><Keyword MajorTopicYN="Y">Antipsychotic agents</Keyword><Keyword MajorTopicYN="Y">Drug therapy, combination</Keyword><Keyword MajorTopicYN="Y">Lithium</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>01</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32739706</ArticleId><ArticleId IdType="pii">S0165-0327(20)32508-8</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2020.07.063</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23314407</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>260</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Bipolar affective disorder preceding frontotemporal dementia in a patient with C9ORF72 mutation: is there a genetic link between these two disorders?</ArticleTitle><Pagination><MedlinePgn>1155-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-013-6833-2</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Floris</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Borghero</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cannas</LastName><ForeName>Antonino</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Stefano</LastName><ForeName>Francesca Di</ForeName><Initials>FD</Initials></Author><Author ValidYN="Y"><LastName>Murru</LastName><ForeName>Maria R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Corongiu</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cuccu</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tranquilli</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Marrosu</LastName><ForeName>Maria G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Chiò</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Marrosu</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>3B744AG22N</RegistryNumber><NameOfSubstance UI="D019690">Technetium Tc 99m Exametazime</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2014 Sep;16(6):667-8</RefSource><PMID Version="1">24798095</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019690" MajorTopicYN="N">Technetium Tc 99m Exametazime</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23314407</ArticleId><ArticleId IdType="doi">10.1007/s00415-013-6833-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Psychiatry. 2009 Apr;194(4):298-305</Citation><ArticleIdList><ArticleId IdType="pubmed">19336778</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2012 Mar;135(Pt 3):736-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22366791</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Case Rep. 2011 Feb 02;2011:</Citation><ArticleIdList><ArticleId IdType="pubmed">22714610</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):257-68</Citation><ArticleIdList><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2012 Mar;135(Pt 3):794-806</Citation><ArticleIdList><ArticleId IdType="pubmed">22366795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2011;27(4):791-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21891869</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1998 Dec;51(6):1546-54</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 20;72(2):245-56</Citation><ArticleIdList><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2000 Oct;2(5):440-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11122994</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychogeriatrics. 2011 Mar;11(1):60-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21447111</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Feb;72(2):126-33</Citation><ArticleIdList><ArticleId IdType="pubmed">21382304</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">47592</PMID><DateCompleted><Year>1975</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>7912</Issue><PubDate><Year>1975</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Letter: Lithium and pyruvate kinase.</ArticleTitle><Pagination><MedlinePgn>932</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pscheidt</LastName><ForeName>G R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Meltzer</LastName><ForeName>H Y</ForeName><Initials>HY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.40</RegistryNumber><NameOfSubstance UI="D011770">Pyruvate Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011770" MajorTopicYN="N">Pyruvate Kinase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1975</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1975</Year><Month>4</Month><Day>19</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1975</Year><Month>4</Month><Day>19</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">47592</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(75)91748-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2750387</PMID><DateCompleted><Year>1989</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0044-4588</ISSN><JournalIssue CitedMedium="Print"><Volume>89</Volume><Issue>4</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)</Title><ISOAbbreviation>Zh Nevropatol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[Clinico-diagnostic criteria of protracted anxiety-related depression in manic-depressive psychosis and attacks of schizophrenia].</ArticleTitle><Pagination><MedlinePgn>73-6</MedlinePgn></Pagination><Abstract><AbstractText>The study of premorbid period and factors capable of provocking the disease enabled the author to give the comparative clinical and psychopathological characterization of formation and course of prolonged anxious depressions in the framework of circular psychosis vs. schizophrenia. The predictors of these diseases prolongation are described. The present work allowed us to perform a differentiated approach to treatment of prolonged anxious depressions in patients with different disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dmitriev</LastName><ForeName>A S</ForeName><Initials>AS</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Kliniko-diagnosticheskie kriterii zatiazhnykh trevozhnykh depresiĭ pri maniaka'lno-depressivnom psikhoze i pristupoobrazno protekaiushcheĭ shizofrenii.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevropatol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>8710066</NlmUniqueID><ISSNLinking>0044-4588</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2750387</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1655851</PMID><DateCompleted><Year>1991</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>1991</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Platelet tritiated imipramine binding in patients suffering from mania.</ArticleTitle><Pagination><MedlinePgn>105-10</MedlinePgn></Pagination><Abstract><AbstractText>Platelet imipramine binding was measured in 16 patients suffering from DSM-IIIR mania and compared with binding values reported in depressed and healthy control subjects recruited in a parallel study (Ellis et al., 1990). Binding levels in the manic group did not differ from control values, but were higher than in the depressed group. Within the manic group, binding did not differ with severity of illness or the presence of depressive symptoms but there was a trend to lower values (comparable to those in the depressed group) with increasing duration of illness. This raises the possibility that changes in imipramine binding in depression and mania may be similar, consistent with the permissive hypothesis of serotonin function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>P M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Wellington School of Medicine, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellsop</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Beeston</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cooke</LastName><ForeName>R R</ForeName><Initials>RR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011955">Receptors, Drug</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017981">Receptors, Neurotransmitter</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C027775">imipramine receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>OGG85SX4E4</RegistryNumber><NameOfSubstance UI="D007099">Imipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="Y">Carrier Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007099" MajorTopicYN="N">Imipramine</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011955" MajorTopicYN="Y">Receptors, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017981" MajorTopicYN="N">Receptors, Neurotransmitter</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1655851</ArticleId><ArticleId IdType="pii">0165-0327(91)90043-R</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(91)90043-r</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26819404</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1665</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists</Title><ISOAbbreviation>Australas Psychiatry</ISOAbbreviation></Journal><ArticleTitle>First episode mania following cessation of varenicline (Champix).</ArticleTitle><Pagination><MedlinePgn>292-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1039856215626642</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To describe a case of first episode mania and in which varenicline (Champix) or its withdrawal appears to have been the precipitating factor.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The clinical presentation and progress are detailed and the relevant literature in relation to varenicline is provided.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The case report adds to the literature indicating that varenicline may induce a range of mood states, albeit with reported incidents of mania being rare.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In reviewing causes of mood states, including mania, seeking information on any exposure to varenicline would appear to be relevant.</AbstractText><CopyrightInformation>© The Royal Australian and New Zealand College of Psychiatrists 2016.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Associate Conjoint Lecturer, School of Psychiatry, University of New South Wales, Sydney, NSW, and; Chief Registrar, Psychiatry, St Vincent's Public Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Nav</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Resident, Prince of Wales Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Scientia Professor, School of Psychiatry, University of New South Wales, Sydney, NSW, and; Professorial Fellow, Black Dog Institute, POW Hospital, Randwick, NSW, and; Consultant Psychiatrist, Prince of Wales Hospital, Sydney, NSW, Australia G.Parker@unsw.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Australas Psychiatry</MedlineTA><NlmUniqueID>9613603</NlmUniqueID><ISSNLinking>1039-8562</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018722">Nicotinic Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>W6HS99O8ZO</RegistryNumber><NameOfSubstance UI="D000068580">Varenicline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018722" MajorTopicYN="N">Nicotinic Agonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068580" MajorTopicYN="N">Varenicline</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028761" MajorTopicYN="N">Withholding Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">mania</Keyword><Keyword MajorTopicYN="N">psychosis</Keyword><Keyword MajorTopicYN="N">varenicline</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26819404</ArticleId><ArticleId IdType="pii">1039856215626642</ArticleId><ArticleId IdType="doi">10.1177/1039856215626642</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21352183</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2011</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1751-7893</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Early intervention in psychiatry</Title><ISOAbbreviation>Early Interv Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Early psychosis intervention service for children and youth: a retrospective chart review of the first four years.</ArticleTitle><Pagination><MedlinePgn>99-107</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1751-7893.2009.00115.x</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">There are at present no published reports of outpatient Early Psychosis Intervention (EPI) service designed for children aged 16 years and under. The objectives of this study are to describe aspects of an outpatient paediatric EPI programme from the time period after the initial pilot and during its first 4 years of service with dedicated staffing.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This study employed a retrospective chart review model in which variables were operationalized and then extracted from existing patient medical records spanning a 4-year time period. Data were then analysed for frequency, mean and range values.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Demographic characteristics and service profiles for 56 patients were collected. The majority were male (64.3%) and the mean age was 14.8 years (range: 9-17 years). The average number of days from referral to first in-person contact was 7.3 days. The most common discharge diagnosis was Bipolar Disorder (38.7%) followed by Psychosis Not Otherwise Specified (25.8%) in those with psychosis, whereas an anxiety disorder was the most common diagnosis in those who were not psychotic. The majority of discharged patients were able to be followed up by community-based services. Readmission and hospitalization rates for this EPI service were low.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings of this study suggest that an EPI model of care extended to a younger age group can be implemented to provide early intervention to youth with a range of psychiatric disorders that present with psychotic symptoms.</AbstractText><CopyrightInformation>© 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Asia Pty Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Mary K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Keyes</LastName><ForeName>Randy</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ashmore</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Early Interv Psychiatry</MedlineTA><NlmUniqueID>101320027</NlmUniqueID><ISSNLinking>1751-7885</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21352183</ArticleId><ArticleId IdType="doi">10.1111/j.1751-7893.2009.00115.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17644186</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2012</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>153</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Quinone oxidoreductase (NQO1) gene polymorphism may not confer a susceptibility to mood disorders.</ArticleTitle><Pagination><MedlinePgn>83-6</MedlinePgn></Pagination><Abstract><AbstractText>Quinone oxidoreductase (NQO1) plays a key role in the cellular antioxidant defense by detoxifying quinine derivatives. Case-control association study of the possible relationship between the NQO1 gene polymorphism and mood disorders (patients with major depressive disorder, n=61; patients with bipolar I disorder, n=80; control, n=106) was carried out using PCR-based techniques. These preliminary results showed that the NQO1 gene polymorphism was not related to a susceptibility to mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pae</LastName><ForeName>Chi-Un</ForeName><Initials>CU</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, 505 Banpo-Dong, Seocho-Gu, Seoul 137-701, South Korea. pae@catholic.ac.kr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Soo-Jung</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Patkar</LastName><ForeName>Ashwin A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jung-Jin</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chul</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Paik</LastName><ForeName>In-Ho</ForeName><Initials>IH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.6.5.2</RegistryNumber><NameOfSubstance UI="D016660">NAD(P)H Dehydrogenase (Quinone)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.5.2</RegistryNumber><NameOfSubstance UI="C447479">NQO1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007723" MajorTopicYN="N" Type="Geographic">Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016660" MajorTopicYN="N">NAD(P)H Dehydrogenase (Quinone)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17644186</ArticleId><ArticleId IdType="pii">S0165-1781(06)00022-9</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2006.01.011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11142544</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-006X</ISSN><JournalIssue CitedMedium="Print"><Volume>68</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of consulting and clinical psychology</Title><ISOAbbreviation>J Consult Clin Psychol</ISOAbbreviation></Journal><ArticleTitle>The relation of religious belief and practices, depression, and hopelessness in persons with clinical depression.</ArticleTitle><Pagination><MedlinePgn>1102-6</MedlinePgn></Pagination><Abstract><AbstractText>Religious belief and practices have been associated with lower levels of depression in persons dealing with stressful situations. In this study, researchers examined this relationship in 271 persons diagnosed with clinical depression. It was hypothesized that religious belief and practices would be associated with lower depression and that this relationship would be mediated by hopelessness. Religious belief, but not religious behavior, was a significant predictor of lower levels of hopelessness and depression beyond demographic variables. Through the relation of religious belief to lower levels of hopelessness, religious belief was indirectly related to less depression. There was also a small direct positive association of belief with depression, pointing to the complexity of the role belief plays for religious persons. Further study is needed for a better understanding of different ways religion affects depressed persons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>P E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Department of Pastoral Counseling, Loyola College in Maryland, USA. pemurphy@msn.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciarrocchi</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Piedmont</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Cheston</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Peyrot</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fitchett</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Consult Clin Psychol</MedlineTA><NlmUniqueID>0136553</NlmUniqueID><ISSNLinking>0022-006X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012069" MajorTopicYN="Y">Religion and Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>1</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>1</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11142544</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17854907</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>107</Volume><Issue>1-3</Issue><PubDate><Year>2008</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>How best to identify a bipolar-related subtype among major depressive patients without spontaneous hypomania: superiority of age at onset criterion over recurrence and polarity?</ArticleTitle><Pagination><MedlinePgn>77-88</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">History of high depressive recurrence (without history of mania/hypomania) has been proposed as a mood subtype close to bipolar disorders. Herein we test whether this is the best approach to this question.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We systematically evaluated consecutive 224 Major Depressive (MDD) and 336 Bipolar II Disorders (BP-II) outpatients in a private practice, by the SCID for DSM-IV (modified for better probing hypomania by Akiskal and Benazzi [Akiskal, H.S., Benazzi, F., 2005. Optimizing the detection of bipolar II disorder in outpatient private practice: toward a systematization of clinical diagnostic wisdom. J. Clin. Psychiatry 66, 914-921]). We conducted univariate and multivariate analyses on such putative bipolar validators as early age at onset of first major depressive episode (before 21 years), high recurrence, family history for bipolar disorders, and depressive mixed states (mixed depression, i.e. depression plus concurrent hypomanic symptoms), in order to identify an MDD subgroup close to BP-II.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All bipolar validators were independent predictors of BP-II. Early onset was the only variable which identified an MDD subgroup significantly associated with all bipolar validators. This MDD subgroup was similar to BP-II on age at onset and bipolar family history, and had a high frequency of mixed depression. A dose-response relationship was found between number of bipolar validators present in MDD, and bipolar family history loading among MDD relatives.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Study limited to outpatients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">From among the bipolar validators, early age at onset of first major depression (&lt;21 years) was superior to high recurrence (&gt;4 depressive episodes) in identifying an MDD subgroup close to BP-II, which might be subsumed under the broad bipolar spectrum. Implications of unipolar-bipolar boundaries and genetic investigations are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hecker Psychiatry Research Center, Department of Psychiatry, National Health Service, Forli, Italy. FrancoBenazzi@FBenazzi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011331" MajorTopicYN="N">Private Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>05</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17854907</ArticleId><ArticleId IdType="pii">S0165-0327(07)00293-5</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2007.07.032</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32265532</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>04</Month><Day>07</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A multivariable Mendelian randomization to appraise the pleiotropy between intelligence, education, and bipolar disorder in relation to schizophrenia.</ArticleTitle><Pagination><MedlinePgn>6018</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-63104-6</ELocationID><Abstract><AbstractText>Education and intelligence are highly correlated and inversely associated with schizophrenia. Counterintuitively, education genetically associates with an increased risk for the disease. To investigate why, this study applies a multivariable Mendelian randomization of intelligence and education. For those without college degrees, older age of finishing school associates with a decreased likelihood of schizophrenia-independent of intelligence-and, hence, may be entangled with the health inequalities reflecting differences in education. A different picture is observed for schooling years inclusive of college: more years of schooling increases the likelihood of schizophrenia, whereas higher intelligence distinctly and independently decreases it. This implies the pleiotropy between years of schooling and schizophrenia is horizontal and likely confounded by a third trait influencing education. A multivariable Mendelian randomization of schooling years and bipolar disorder reveals that the increased risk of schizophrenia conferred by more schooling years is an artefact of bipolar disorder - not education.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Charleen D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>City of Hope, Beckman Research Institute, 1500 E. Duarte Road, Duarte, CA 91010, USA. chaadams@coh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="Y">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058685" MajorTopicYN="N">Genetic Pleiotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="Y">Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057182" MajorTopicYN="N">Mendelian Randomization Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>02</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32265532</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-63104-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-63104-6</ArticleId><ArticleId IdType="pmc">PMC7138794</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kendler, K. S., Ohlsson, H., Sundquist, J. &amp; Sundquist, K. IQ and schizophrenia in a Swedish national sample: their causal relationship and the interaction of IQ with genetic risk. Am J Pyschiatry 172, 259–265 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2014.14040516</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale, C. R., Batty, G. D., Tynelius, P., Deary, I. J. &amp; Rasmussen, F. Intelligence in early adulthood and subsequent hospitalization for mental disorders. Epidemiology 21, 70–77 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181c17da8</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal, V. et al. Genome-wide association study results for educational attainment aid in identifying genetic heterogeneity of schizophrenia. Nat Commun 9, (2018).</Citation></Reference><Reference><Citation>Clark, D. &amp; Royer, H. The effect of education on adult mortality and health: evidence from Britain. Am Econ Rev 103, 2087–2120 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1257/aer.103.6.2087</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies, N. M. et al. Multivariable two-sample Mendelian randomization estimates of the effects of intelligence and education on health. Elife 8, 1–22 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.43990</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary, I. J., Strand, S., Smith, P. &amp; Fernandes, C. Intelligence and educational achievement. Intelligence 35, 13–21 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intell.2006.02.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill, W. D. et al. A combined analysis of genetically correlated traits identifies 187 loci and a role for neurogenesis and myelination in intelligence. Mol Psychiatry 24, 169–181 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-017-0001-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, E. L. et al. Education, intelligence and Alzheimer’s disease: evidence from a multivariable two-sample Mendelian randomization study. bioRxiv 401042 https://doi.org/10.1101/401042 (2018).</Citation></Reference><Reference><Citation>Okbay, A. et al. Genome-wide association study identifies 74 loci associated with educational attainment. Nature 533, 539–542 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17671</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess, S. &amp; Thompson, S. G. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 32, 377–389 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0255-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller, W., Slichter, D., Bowden, J. &amp; Davey Smith, G. Detecting and correcting for bias in Mendelian randomization analyses using Gene-by-Environment interactions. Int J Epidemiol https://doi.org/10.1093/ije/dyy204 (2018).</Citation></Reference><Reference><Citation>MacCabe, J. H. et al. Excellent school performance at age 16 and risk of adult bipolar disorder: National cohort study. Br J Psychiatry 196, 109–115 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.108.060368</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreeker, A. et al. High educational performance is a distinctive feature of bipolar disorder; a study on cognition in bipolar disorder, schizophrenia patients, relatives and controls. Psychol Med 46, 807–818 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0033291715002299</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey Smith, G. &amp; Ebrahim, S. ‘Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32, 1–22 (2003).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyg070</ArticleId></ArticleIdList></Reference><Reference><Citation>Schooling, C. M., Freeman, G. &amp; Cowling, B. J. Mendelian randomization and estimation of treatment efficacy for chronic diseases. Am J Epidemiol 177, 1128–1133 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kws344</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani, G., Bowden, J. &amp; Smith, G. D. Evaluating the potential role of pleiotropy in Mendelian randomization studies. Hum Mol Genet 27, 195–208 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy163</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, 1–29 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.34408</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess, S., Butterworth, A. &amp; Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 37, 658–665 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.21758</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden, J., Smith, G. D. &amp; Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 44, 512–525 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv080</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, T. Efficient calculation for multi-SNP genetic risk scores. In American Society of Human Genetics Annual Meeting. 10.1038/ng.784 (2012).</Citation></Reference><Reference><Citation>Davey Smith, G. &amp; Hemani, G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 23, R89–98 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderson, E., Davey Smith, G., Windmeijer, F. &amp; Bowden, J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol 48, 713–727 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy262</ArticleId></ArticleIdList></Reference><Reference><Citation>Didelez, V. &amp; Sheehan, N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res. 16, 309–330 (2007).</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280206077743</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins, R. What makes UK Biobank special? Lancet 379, 1173–1174 (2012).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)60404-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow, C. et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. Plos Med 12, 1–10 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale Lab. Rapid GWAS of thousands of phenotypes for 337,000 samples in the UK Biobank. (2017).</Citation></Reference><Reference><Citation>Burgess, S. &amp; Thompson, S. G. Avoiding bias from weak instruments in mendelian randomization studies. Int J Epidemiol 40, 755–764 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyr036</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce, B. L. &amp; Burgess, S. Efficient design for mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 178, 1177–1184 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwt084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J. J. et al. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. Nat Genet 50, 1112–1121 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0147-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess, S., Davies, N. M. &amp; Thompson, S. G. Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol 40, 597–608 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gepi.21998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sklar, P. et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 43, 977–985 (2011).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.943</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripke, S. et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–7 (2014).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13595</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: a language and environment for statistical computing, Vienna, Austria (2013). URL http://www.R-project.org/ .</Citation></Reference><Reference><Citation>Richmond, R. C. &amp; Davey Smith, G. Commentary: orienting causal relationships between two phenotypes using bidirectional Mendelian randomization. Int J Epidemiol 48, 907–911 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz149</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden, J. et al. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. Int J Epidemiol 1–15 https://doi.org/10.1093/ije/dyy101 (2018).</Citation></Reference><Reference><Citation>Del Greco M, F., Minelli, C., Sheehan, N. A. &amp; Thompson, J. R. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat. Med. 34, 2926–2940 (2015).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.6522</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawlor, D. A., Tilling, K. &amp; Davey Smith, G. Triangulation in aetiological epidemiology. Int J Epidemiol 45, 1866–1886 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw127</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller, W., Davies, N. M. &amp; Palmer, T. M. Software application profile: mrrobust — a tool for performing two-sample summary Mendelian randomization analyses. Int J Epidemiol 48, 684–690 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarmolinsky, J. et al. Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: a Mendelian randomization analysis. PLOS Med 16, e1002893 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang, L., Lawlor, D. A., Freathy, R. M., Evans, D. M. &amp; Warrington, N. M. Using a two-sample Mendelian randomization design to investigate a possible causal effect of maternal lipid concentrations on offspring birth weight. Int J Epidemiol 005, 1–11 (2019).</Citation></Reference><Reference><Citation>Bowden, J., Greco, D., Minelli, C., Davey Smith, G. &amp; Thompson, J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 36, 1783–1802 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7221</ArticleId></ArticleIdList></Reference><Reference><Citation>McShane, B. B., Gal, D., Gelman, A., Robert, C. &amp; Tackett, J. L. Abandon statistical significance. Am. Stat. 73, 235–245 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00031305.2018.1527253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sniekers, S. et al. Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence. Nat Genet 49, 1107–1112 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3869</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20148868</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The relationship between religious involvement and clinical status of patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>68-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2009.00772.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Religion and spirituality are important coping strategies in depression but have been rarely studied within the context of bipolar disorder. The present study assessed the association between different forms of religious involvement and the clinical status of individuals treated for bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional observation study of follow-up data from a large cohort study of patients receiving care for bipolar disorder (n = 334) at an urban Veterans Affairs mental health clinic was conducted. Bivariate and multivariate analyses were performed to assess the association between public (frequency of church attendance), private (frequency of prayer/meditation), as well as subjective forms (influence of beliefs on life) of religious involvement and mixed, manic, depressed, and euthymic states when demographic, anxiety, alcohol abuse, and health indicators were controlled.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Multivariate analyses found significant associations between higher rates of prayer/meditation and participants in a mixed state [odds ratio (OR) = 1.29; 95% confidence interval (CI) = 1.10-1.52, chi square = 9.42, df = 14, p &lt; 0.05], as well as lower rates of prayer/meditation and participants who were euthymic (OR = 0.84; 95% CI = 0.72-0.99, chi square = 4.60, df = 14, p &lt; 0.05). Depression and mania were not associated with religious involvement.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared to patients with bipolar disorder in depressed, manic, or euthymic states, patients in mixed states have more active private religious lives. Providers should assess the religious activities of individuals with bipolar disorder in mixed states and how they may complement/deter ongoing treatment. Future longitudinal studies linking bipolar states, religious activities, and treatment-seeking behaviors are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Advanced Center for Intervention and Services, Research for Late-life Mood and Anxiety Disorders, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA. cruzm@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pincus</LastName><ForeName>Harold Alan</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Welsh</LastName><ForeName>Deborah E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Greenwald</LastName><ForeName>Devra</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lasky</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kilbourne</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 RR024153</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH071520</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 HS016097</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 MH071944</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5U18 HS016097</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH071520-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Bipolar Disord. 2010 Aug;12(5):582; author reply 583-4</RefSource><PMID Version="1">20712761</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006787" MajorTopicYN="N">Hospitals, Veterans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012067" MajorTopicYN="Y">Religion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012068" MajorTopicYN="N">Religion and Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20148868</ArticleId><ArticleId IdType="pii">BDI772</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2009.00772.x</ArticleId><ArticleId IdType="pmc">PMC2853940</ArticleId><ArticleId IdType="mid">NIHMS164798</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 1997 Jun;154(6):885-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9167530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):158-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17391358</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 May;153(5):674-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8615413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ment Health Serv Res. 2002 Dec;4(4):225-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12558008</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Dec;47(12):1106-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2244795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Nov;65(11):1499-504</Citation><ArticleIdList><ArticleId IdType="pubmed">15554762</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 2003 Jul;18(7):549-57</Citation><ArticleIdList><ArticleId IdType="pubmed">12848838</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2007 Apr;15(4):282-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17384313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Oct;5(5):366-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14525558</ArticleId></ArticleIdList></Reference><Reference><Citation>J Fam Pract. 2001 Apr;50(4):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">11300982</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Apr;155(4):536-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9546001</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Dec;149(12):1633-44</Citation><ArticleIdList><ArticleId IdType="pubmed">1359799</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Educ Behav. 1998 Dec;25(6):700-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9813743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Jun;7(3):281-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15898966</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Aug;65(3):231-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11511403</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2006 May-Jun;47(3):161-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16635643</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2006 Dec;194(12):975-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17164640</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontologist. 2008 Oct;48(5):692-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18981285</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1986 Jun 13;255(22):3138-42</Citation><ArticleIdList><ArticleId IdType="pubmed">3702024</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):443-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17680914</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Oct;6(5):368-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15383128</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Aug;75(3):247-57</Citation><ArticleIdList><ArticleId IdType="pubmed">12880937</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2007 Jun;63(6):529-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17457851</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2001 May-Jun;42(3):190-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11349236</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2008 May;59(5):483-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18451002</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2009 Jun;17(6):503-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19461258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Sep;10(6):718-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18837866</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Dec;2(4):340-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11252648</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2007 Apr;15(4):273-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17384312</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Dec 14;272(22):1749-56</Citation><ArticleIdList><ArticleId IdType="pubmed">7966923</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1991 Sep;48(9):807-12</Citation><ArticleIdList><ArticleId IdType="pubmed">1929771</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20958841</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-0391</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>6</Issue><PubDate><MedlineDate>2010 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>The American journal on addictions</Title><ISOAbbreviation>Am J Addict</ISOAbbreviation></Journal><ArticleTitle>Reasons for substance use among adolescents with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>474-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1521-0391.2010.00077.x</ELocationID><Abstract><AbstractText>We examined whether children and adolescents with bipolar disorder (BPD) "self-medicate" with cigarettes, alcohol, or other substances of abuse. One hundred and five adolescents with BPD and 98 controls were comprehensively assessed with a structured psychiatric diagnostic interview for psychopathology and the Drug Use Screening Inventory (DUSI) for self-medication. Thirteen control (mean ± standard deviation [SD]= 15.31 ± 1.18 years) and 27 BPD (15.30 ± 2.09 years) subjects endorsed use of one of the listed drugs in the DUSI Section A within the past year and were included in all analyses. BPD adolescents were more likely than nonmood disordered, substance-using controls to report starting to use their preferred drug for mood-altering effects. There were no differences between groups in motivation for use with respect to starting substances to sleep better or get high, or in continuing substances to change mood, sleep better, or get high. These data may contribute to increased prevention of substance use disorders and to the treatment of adolescent BPD. Further studies clarifying the characteristics of self-medication are necessary.</AbstractText><CopyrightInformation>© American Academy of Addiction Psychiatry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lorberg</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pediatric Psychopharmacology Unit of the Psychiatry Department, Massachusetts General Hospital, Boson, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilens</LastName><ForeName>Timothy E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Martelon</LastName><ForeName>Marykate</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Parcell</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DA012945</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Addict</MedlineTA><NlmUniqueID>9208821</NlmUniqueID><ISSNLinking>1055-0496</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000294" MajorTopicYN="N">Adolescent Behavior</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012651" MajorTopicYN="N">Self Medication</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20958841</ArticleId><ArticleId IdType="doi">10.1111/j.1521-0391.2010.00077.x</ArticleId><ArticleId IdType="pmc">PMC2959189</ArticleId><ArticleId IdType="mid">NIHMS228810</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17015816</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1995 Nov 1;142(9):904-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7572970</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Apr;79(1-3):279-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15023508</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Addict Behav. 2005 Mar;19(1):28-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15783275</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 May;61(5):459-67</Citation><ArticleIdList><ArticleId IdType="pubmed">15123490</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Nov;51(2):145-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10743847</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Mar;48(2-3):199-205</Citation><ArticleIdList><ArticleId IdType="pubmed">9543210</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Oct;36(10):1378-87; discussion 1387-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9334551</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1998 Feb;37(2):171-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9473913</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1997 Jul;44(2-3):177-88</Citation><ArticleIdList><ArticleId IdType="pubmed">9241578</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2000 Jan;39(1):49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">10638067</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jul;34(7):867-76</Citation><ArticleIdList><ArticleId IdType="pubmed">7649957</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Jul 15;62(2):129-34</Citation><ArticleIdList><ArticleId IdType="pubmed">17481590</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Drug Alcohol Abuse. 1997 May;23(2):207-19</Citation><ArticleIdList><ArticleId IdType="pubmed">9143634</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2008 Jun 1;95(3):188-98</Citation><ArticleIdList><ArticleId IdType="pubmed">18343050</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):483-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16403174</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Mar;160(3):430-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12611821</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1998 Apr 18;316(7139):1236-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9553006</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1999 Jun;38(6):680-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10361785</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1974 Jan;131(1):83-6</Citation><ArticleIdList><ArticleId IdType="pubmed">4808436</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Aug;62(8):851-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16061762</ArticleId></ArticleIdList></Reference><Reference><Citation>Depression. 1996;4(2):77-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9160645</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):709-14</Citation><ArticleIdList><ArticleId IdType="pubmed">7608043</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Addict. 2007;16 Suppl 1:14-21; quiz 22-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17453603</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):715-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7608044</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Mar 15;39(6):458-60</Citation><ArticleIdList><ArticleId IdType="pubmed">8679794</ArticleId></ArticleIdList></Reference><Reference><Citation>Addiction. 2003 Nov;98(11):1493-504</Citation><ArticleIdList><ArticleId IdType="pubmed">14616175</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 1997 Jan-Feb;4(5):231-44</Citation><ArticleIdList><ArticleId IdType="pubmed">9385000</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17015815</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Drug Alcohol Abuse. 1992;18(2):121-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1562010</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1985 Nov;142(11):1259-64</Citation><ArticleIdList><ArticleId IdType="pubmed">3904487</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology. 1990 Jan;1(1):43-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2081237</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jun;115(3):367-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19004504</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jan;36(1):30-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9000778</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 May;9(3):213-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17430295</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Addict. 2008 Sep-Oct;17(5):364-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18770078</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3247404</PMID><DateCompleted><Year>1989</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2658</ISSN><JournalIssue CitedMedium="Print"><Volume>90</Volume><Issue>9</Issue><PubDate><Year>1988</Year></PubDate></JournalIssue><Title>Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica</Title><ISOAbbreviation>Seishin Shinkeigaku Zasshi</ISOAbbreviation></Journal><ArticleTitle>[The course and social adjustment in the bipolar type of affective disorders after long-term lithium therapy].</ArticleTitle><Pagination><MedlinePgn>699-716</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Etoh</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Saitoh</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Seishin Shinkeigaku Zasshi</MedlineTA><NlmUniqueID>9801787</NlmUniqueID><ISSNLinking>0033-2658</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003376" MajorTopicYN="N">Counseling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="Y">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3247404</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12776654</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2674</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>2</Issue><PubDate><MedlineDate>2003 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>[Personality traits in patients with unipolar and bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>225-33</MedlinePgn></Pagination><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To compare the personality traits as described by H. Eysenck in persons with unipolar and bipolar disorder and healthy persons.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">60 patients with a diagnosis of uni- and bipolar disorder were studied with the Eysenck Personality Questionnaire (EPQ-R).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">It was noted that there are significant differences amongst the groups in their neuroticism and extraversion but no differences were noted in the domain of psychoticism. Patients diagnosed as having unipolar disorder have a significantly higher level of neuroticism and a lower level of extraversion than those having bipolar disorder. These domains also differentiate the affective disorder patients from healthy individuals.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The knowledge about the individual characteristic personality traits of patients with affective uni- and bipolar disorder can be important for the diagnostic and therapeutic processes in these disorders, therefore further study on these characteristics is necessary.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sariusz-Skapska</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Kliniki Psychiatrii Dorosłych CM UJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czabała</LastName><ForeName>Czesław</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dudek</LastName><ForeName>Dominika</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zieba</LastName><ForeName>Andrzej</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rduch</LastName><ForeName>Szymon</ForeName><Initials>S</Initials></Author></AuthorList><Language>pol</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Cechy osobowości osób chorujacych na zaburzenia jedno- i dwubiegunowe.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005120" MajorTopicYN="N">Extraversion, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009497" MajorTopicYN="N">Neurotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>6</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12776654</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8101125</PMID><DateCompleted><Year>1993</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>162</Volume><PubDate><Year>1993</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mania and Down's syndrome.</ArticleTitle><Pagination><MedlinePgn>739-43</MedlinePgn></Pagination><Abstract><AbstractText>Until recently, it was considered that Down's syndrome precluded a diagnosis of mania, or gave rise to an atypical presentation. There have been seven case reports of mania in people with Down's syndrome and all these cases are reviewed. The clinical features of mania are noted to be similar to those previously described in individuals with learning disabilities due to other causes. However, all reported cases are male and none has a family history of affective disorder. In two of the seven men reported, the illness followed a rapid cycling pattern. Hypothyroidism and monoamine biochemistry in people with Down's syndrome are discussed in the context of these atypical features.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>S A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Frith Hospital, Leicester.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collacott</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Psychiatry. 1994 Mar;164(3):422</RefSource><PMID Version="1">7911058</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Br J Psychiatry. 1993 Sep;163:417</RefSource><PMID Version="1">8401980</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8101125</ArticleId><ArticleId IdType="pii">S0007125000180845</ArticleId><ArticleId IdType="doi">10.1192/bjp.162.6.739</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1561887</PMID><DateCompleted><Year>1992</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>85</Volume><Issue>3</Issue><PubDate><Year>1992</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>A cluster-analytically derived subtyping of chronic affective disorders.</ArticleTitle><Pagination><MedlinePgn>177-82</MedlinePgn></Pagination><Abstract><AbstractText>This article aims to propose a mathematically legitimate and externally validated subclassification of chronic affective disorders. Three subtypes emerged from the cluster analysis of the symptom data of 40 patients with chronic affective disorder that had been present without remission for more than 2 years; the subtypes were then validated by psychosocial variables. The first cluster, a predominantly male group with young onset, is characterized by past history of psychotic features and is named psychotic subtype. The second cluster, a predominantly female group with late onset, is tentatively called late-onset female subtype. The third cluster has the youngest onset and the longest duration, and is characterized by early object loss and high neuroticism score: depressive personality subtype.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Furukawa</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Toyohashi City Hospital, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sumita</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="Y">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009769" MajorTopicYN="N">Object Attachment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010553" MajorTopicYN="N">Personality Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1561887</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1992.tb08591.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7108498</PMID><DateCompleted><Year>1982</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>170</Volume><Issue>10</Issue><PubDate><Year>1982</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Mania ratings at discharge from hospital: a follow-up.</ArticleTitle><Pagination><MedlinePgn>638-9</MedlinePgn></Pagination><Abstract><AbstractText>Seventeen patients hospitalized for acute mania were followed up 1 month after discharge. Ratings of psychopathology at discharge using a new Mania Rating Scale differentiated the 12 patients who maintained outpatient status for 1 month from the five who did not. Total scores greater than 14.0 predicted being rehospitalized or jailed. Significantly higher item ratings for speech (rate and amount), language-thought disorder, irritability, and disruptive-aggressive behavior were noted in the poorer compared to the better outcome group.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Nysewander</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Schreiber</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010351" MajorTopicYN="Y">Patient Discharge</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7108498</ArticleId><ArticleId IdType="doi">10.1097/00005053-198210000-00009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20636635</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2010</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Cortical and subcortical white matter abnormalities in adults with remitted first-episode mania revealed by Tract-Based Spatial Statistics.</ArticleTitle><Pagination><MedlinePgn>383-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2010.00829.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Abnormalities of brain white matter have been noted in structural magnetic resonance imaging and diffusion tensor imaging (DTI) studies of bipolar disorder, but there are fewer investigations specifically examining white matter integrity early in the course of illness. In this study, we employed DTI to elucidate white matter changes in adult patients with remitted first-episode mania and hypothesized that first-episode mania was associated with decreased fractional anisotropy in cortical (frontal) and subcortical (thalamus, striatum) white matter as well as white matter tracts (cingulum, corpus callosum).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Diffusion tensor images were acquired from 16 patients with remitted first-episode mania and 16 healthy controls matched for age, gender, handedness, and years of education. Fractional anisotropy and radial and axial diffusivities were analyzed using Tract-Based Spatial Statistics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients had lower fractional anisotropy and higher radial diffusivity in the left anterior frontal white matter, right posterior thalamic radiation, left cingulum, and bilateral sagittal striatum. In addition, increased radial diffusivity was found in the left corpus callosum.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings highlighted that white matter abnormalities were present by the time of remission of first-episode mania. The widespread occurrence of these white matter abnormalities both in first-episode mania and chronic bipolar disorder suggested that disruption of white matter cortical-subcortical networks as well as projection, associative, and commissural tracts is a hallmark of the illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Wai-Yen</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Research Division, Institute of Mental Health, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guo-Liang</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>Ming-Ying</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Woon</LastName><ForeName>Puay-San</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Keefe</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sitoh</LastName><ForeName>Yih-Yian</ForeName><Initials>YY</Initials></Author><Author ValidYN="Y"><LastName>Nowinski</LastName><ForeName>Wieslaw Lucjan</ForeName><Initials>WL</Initials></Author><Author ValidYN="Y"><LastName>Sim</LastName><ForeName>Kang</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016880" MajorTopicYN="N">Anisotropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20636635</ArticleId><ArticleId IdType="pii">BDI829</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2010.00829.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29626765</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1568-7856</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><PubDate><Year>2018</Year><Month>05</Month></PubDate></JournalIssue><Title>DNA repair</Title><ISOAbbreviation>DNA Repair (Amst)</ISOAbbreviation></Journal><ArticleTitle>Oxidatively-induced DNA damage and base excision repair in euthymic patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>64-72</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1568-7864(18)30041-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dnarep.2018.03.006</ELocationID><Abstract><AbstractText>Oxidatively-induced DNA damage has previously been associated with bipolar disorder. More recently, impairments in DNA repair mechanisms have also been reported. We aimed to investigate oxidatively-induced DNA lesions and expression of DNA glycosylases involved in base excision repair in euthymic patients with bipolar disorder compared to healthy individuals. DNA base lesions including both base and nucleoside modifications were measured using gas chromatography-tandem mass spectrometry and liquid chromatography-tandem mass spectrometry with isotope-dilution in DNA samples isolated from leukocytes of euthymic patients with bipolar disorder (n = 32) and healthy individuals (n = 51). The expression of DNA repair enzymes OGG1 and NEIL1 were measured using quantitative real-time polymerase chain reaction. The levels of malondialdehyde were measured using high performance liquid chromatography. Seven DNA base lesions in DNA of leukocytes of patients and healthy individuals were identified and quantified. Three of them had significantly elevated levels in bipolar patients when compared to healthy individuals. No elevation of lipid peroxidation marker malondialdehyde was observed. The level of OGG1 expression was significantly reduced in bipolar patients compared to healthy individuals, whereas the two groups exhibited similar levels of NEIL1 expression. Our results suggest that oxidatively-induced DNA damage occurs and base excision repair capacity may be decreased in bipolar patients when compared to healthy individuals. Measurement of oxidatively-induced DNA base lesions and the expression of DNA repair enzymes may be of great importance for large scale basic research and clinical studies of bipolar disorder.</AbstractText><CopyrightInformation>Copyright © 2018 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ceylan</LastName><ForeName>Deniz</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vocational School of Health Services, Izmir University of Economics, Izmir, Turkey; Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey. Electronic address: denizceylandr@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuna</LastName><ForeName>Gamze</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirkali</LastName><ForeName>Güldal</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Thoracic and Gastrointestinal Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD, 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tunca</LastName><ForeName>Zeliha</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Can</LastName><ForeName>Güneş</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mardin State Hospital, Mardin, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arat</LastName><ForeName>Hidayet Ece</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Department of Psychology, Istanbul Gelişim University, Istanbul, Turkey, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kant</LastName><ForeName>Melis</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dizdaroglu</LastName><ForeName>Miral</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biomolecular Measurement Division, National Institute of Standards and Technology, Gaithersburg, MD, 20899, USA. Electronic address: miral.dizdar@nist.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Özerdem</LastName><ForeName>Ayşegül</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Health Sciences Institute, Dokuz Eylul University, Izmir, Turkey; Department of Psychiatry, School of Medicine, Dokuz Eylul University, Izmir, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>9999-NIST</GrantID><Acronym>ImNIST</Acronym><Agency>Intramural NIST DOC</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>DNA Repair (Amst)</MedlineTA><NlmUniqueID>101139138</NlmUniqueID><ISSNLinking>1568-7856</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.2.-</RegistryNumber><NameOfSubstance UI="D045647">DNA Glycosylases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.2.-</RegistryNumber><NameOfSubstance UI="C473634">NEIL1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.2.-</RegistryNumber><NameOfSubstance UI="C479058">oxoguanine glycosylase 1, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="Y">DNA Damage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045647" MajorTopicYN="N">DNA Glycosylases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004260" MajorTopicYN="Y">DNA Repair</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Base excision repair</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">DNA damage</Keyword><Keyword MajorTopicYN="Y">DNA repair</Keyword><Keyword MajorTopicYN="Y">Formamidopyrimidines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>02</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29626765</ArticleId><ArticleId IdType="pii">S1568-7864(18)30041-7</ArticleId><ArticleId IdType="doi">10.1016/j.dnarep.2018.03.006</ArticleId><ArticleId IdType="pmc">PMC7243967</ArticleId><ArticleId IdType="mid">NIHMS1588382</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Indian J Psychiatry. 2010 Jul;52(3):220-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21180406</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1990 Jul 31;29(30):7024-32</Citation><ArticleIdList><ArticleId IdType="pubmed">2223758</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2010 Sep;35(5):296-302</Citation><ArticleIdList><ArticleId IdType="pubmed">20569644</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2014 Aug 15;218(1-2):61-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24794031</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Soc Trans. 2004 Feb;32(Pt 1):46-50</Citation><ArticleIdList><ArticleId IdType="pubmed">14748710</ArticleId></ArticleIdList></Reference><Reference><Citation>J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Apr;27(2):120-39</Citation><ArticleIdList><ArticleId IdType="pubmed">19412858</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2006 Sep;31(5):326-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16951735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 May;17(3):257-68</Citation><ArticleIdList><ArticleId IdType="pubmed">25118140</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2014 Oct;13(3):211-23</Citation><ArticleIdList><ArticleId IdType="pubmed">25273285</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2012 Dec 31;327(1-2):26-47</Citation><ArticleIdList><ArticleId IdType="pubmed">22293091</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1677-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18657586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):657-62</Citation><ArticleIdList><ArticleId IdType="pubmed">19689508</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2015 Mar 17;54(10):1859-62</Citation><ArticleIdList><ArticleId IdType="pubmed">25741586</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2015 Aug 04;5:e614</Citation><ArticleIdList><ArticleId IdType="pubmed">26241352</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2007 Sep 30;153(1):27-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17582509</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2012 Dec 31;327(1-2):73-89</Citation><ArticleIdList><ArticleId IdType="pubmed">22252118</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuk Res. 2007 Mar;31(3):387-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16949154</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Jul 29;351(5):476-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15282355</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2013 Aug;16(7):1505-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23449001</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Sep;70(9):931-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23863861</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosom Med. 2009 Oct;71(8):894-900</Citation><ArticleIdList><ArticleId IdType="pubmed">19661187</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 2006 Feb 18;34(4):1102-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16488882</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):56-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22230647</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Res Toxicol. 2006 Apr;19(4):491-505</Citation><ArticleIdList><ArticleId IdType="pubmed">16608160</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotox Res. 2016 Aug;30(2):251-67</Citation><ArticleIdList><ArticleId IdType="pubmed">27126805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rep. 2013;65(6):1558-71</Citation><ArticleIdList><ArticleId IdType="pubmed">24553004</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Feb 1;172:367-74</Citation><ArticleIdList><ArticleId IdType="pubmed">25451439</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 May 25;293(20):2528-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15914754</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Dec;111(2-3):135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">18539338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2008 Nov;33(6):516-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18982174</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucleic Acids Res. 1988 Feb 11;16(3):1215</Citation><ArticleIdList><ArticleId IdType="pubmed">3344216</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Res. 2015 May;49(5):525-48</Citation><ArticleIdList><ArticleId IdType="pubmed">25812590</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Dec 1;58(11):879-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16005436</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1662-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15548477</ArticleId></ArticleIdList></Reference><Reference><Citation>Environ Toxicol. 2017 Sep;32(9):2144-2153</Citation><ArticleIdList><ArticleId IdType="pubmed">28568507</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2016 Aug 09;6(8):e867</Citation><ArticleIdList><ArticleId IdType="pubmed">27505230</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2004 May;184:386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15123501</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2015 Jun;65:63-70</Citation><ArticleIdList><ArticleId IdType="pubmed">25959616</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Angew Chem Int Ed Engl. 2002 Mar 1;41(5):771-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12491331</ArticleId></ArticleIdList></Reference><Reference><Citation>Biotechnol Lett. 2006 Oct;28(19):1601-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16900335</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Biotechnol. 2007 Aug;25(8):939-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17632524</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):342-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18271914</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutat Res. 2017 Jan - Mar;771:99-127</Citation><ArticleIdList><ArticleId IdType="pubmed">28342455</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2018 Mar;261:589-596</Citation><ArticleIdList><ArticleId IdType="pubmed">29407727</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry (Edgmont). 2007 Jul;4(7):28-37</Citation><ArticleIdList><ArticleId IdType="pubmed">20526405</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Clin Lab Invest. 2016;76(2):151-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26767849</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2006 Aug;57(8):1140-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16870965</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 Sep;12(8):1089-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19272208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 May;67(5):783-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16841628</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Sci Monit. 2015 Feb 06;21:412-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25656523</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcinogenesis. 2009 Jan;30(1):2-10</Citation><ArticleIdList><ArticleId IdType="pubmed">18978338</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2007 Feb 23;144(4):1447-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17184924</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull World Health Organ. 1997;75(4):377-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9342897</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Res Toxicol. 2000 Jul;13(7):575-84</Citation><ArticleIdList><ArticleId IdType="pubmed">10898589</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Jul 29;8(7):e69894</Citation><ArticleIdList><ArticleId IdType="pubmed">23922845</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2014 Sep;205(3):183-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24970771</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Chem. 2001 Sep;47(9):1725-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11514418</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods. 2001 Dec;25(4):402-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2009 Jan 1;1790(1):16-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18983898</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Sep;152(9):1386-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7653701</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutat Res Rev Mutat Res. 2015 Jan-Mar;763:212-45</Citation><ArticleIdList><ArticleId IdType="pubmed">25795122</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 1;173:22-6</Citation><ArticleIdList><ArticleId IdType="pubmed">25462391</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Mar;17(2):212-23</Citation><ArticleIdList><ArticleId IdType="pubmed">25130321</ArticleId></ArticleIdList></Reference><Reference><Citation>Free Radic Biol Med. 2002 Jun 1;32(11):1102-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12031895</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Chem Soc. 2002 Jun 26;124(25):7278-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12071730</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 May;108(1-2):43-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17904227</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2014 May;42:157-69</Citation><ArticleIdList><ArticleId IdType="pubmed">24548785</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Jul;93(1-3):33-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17442540</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 May 7-13;327(6117):77-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3574469</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2012 Jul;63(7):714-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22752037</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2013 Mar;39(2):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">22045828</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20536186</PMID><DateCompleted><Year>2010</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1520-6882</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>13</Issue><PubDate><Year>2010</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Analytical chemistry</Title><ISOAbbreviation>Anal Chem</ISOAbbreviation></Journal><ArticleTitle>Metallomics studies of human blood serum from treated bipolar disorder patients.</ArticleTitle><Pagination><MedlinePgn>5859-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/ac101063t</ELocationID><Abstract><AbstractText>In the present work, metallomics studies using biomolecular (matrix-assisted laser desorption ionization time-of-flight tandem mass spectrometry, MALDI-TOF MS/MS) and elemental mass spectrometry (laser ablation inductively coupled plasma mass spectrometry, LA-ICPMS) of human blood serum samples from bipolar disorder (BD) patients compared to controls were performed. The serum samples from three different groups: control (n = 25), BD patients treated with Li (n = 15), and BD patients not treated with Li (n = 10), were pooled according to their groups and separated by two-dimensional polyacrylamide gel electrophoresis (2-D PAGE). Then, in order to determine the metals bound to the protein spots and search for differences among the studied groups, the 2-D gels were analyzed by LA-ICPMS in three distinct modes: bioimaging of metals in gel sections, line scan through the protein spots, and microlocal analysis of selected protein spots. MALDI-TOF MS/MS characterized 32 serum proteins, and they were associated with the metals previously detected. When comparing control and treated BD patient groups, a differentiation in terms of metals bound to proteins was possible to observe. The main metals bound to proteins found in all groups were Na, Mg, Zn, Ca, and Fe. Mn was only detected in the control group; Co was only observed in the control and BD patients treated with Li group. K and Ti were only found in the BD patient groups, and P was only observed in control and BD patients not treated with Li drugs. This exploratory work shows that the association of LA-ICPMS with MALDI-TOF MS/MS is a powerful strategy in metallomics studies applied to determine differences in metal-containing proteins, being able to play an important role on the discovery of potential markers for BD and its treatment with Li in serum samples.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sussulini</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Group of Spectrometry, Sample Preparation and Mechanization (GEPAM), University of Campinas (Unicamp), P.O. Box 6154, 13083-970 Campinas, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kratzin</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jahn</LastName><ForeName>Olaf</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Banzato</LastName><ForeName>Claudio E Muller</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Arruda</LastName><ForeName>Marco A Zezzi</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Johanna Sabine</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anal Chem</MedlineTA><NlmUniqueID>0370536</NlmUniqueID><ISSNLinking>0003-2700</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008667">Metalloproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008670">Metals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015180" MajorTopicYN="N">Electrophoresis, Gel, Two-Dimensional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008667" MajorTopicYN="N">Metalloproteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008670" MajorTopicYN="N">Metals</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019032" MajorTopicYN="N">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20536186</ArticleId><ArticleId IdType="doi">10.1021/ac101063t</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20728005</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2010</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8384</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>5</Issue><PubDate><MedlineDate>2010 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Severity of affective temperament and maladaptive self-schemas differentiate borderline patients, bipolar patients, and controls.</ArticleTitle><Pagination><MedlinePgn>486-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.comppsych.2010.02.006</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">There is an unsettled debate on whether borderline personality disorder and bipolar disorder should be considered related or distinct. This study aimed to further the understanding of the similarities and differences between the 2 disorders by comparing borderline patients, bipolar patients, and controls in terms of various affective temperaments and maladaptive self-schemas.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The sample consisted of 85 participants (31 borderline patients, 25 bipolar patients and 29 student controls) who completed 2 questionnaires: The Temperament Evaluation of the Memphis, Pisa, Paris, and San Diego Autoquestionnaire and the Young Schema Questionnaire. All of the patients were in remission from affective episodes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to the bipolar patients and the controls, the borderline patients were characterized by significantly higher mean scores on most of the maladaptive self-schemas and affective temperaments. The bipolar patients differed significantly from controls by higher mean scores on the cyclothymic temperament and insufficient self-control.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study suggests that affective temperaments and maladaptive self-schemas are more severe in borderline patients than in bipolar patients. These findings point to phenomenological differences between the 2 disorders and therefore question their degree of kinship.</AbstractText><CopyrightInformation>Copyright 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Astrid Kristine Kahr</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Psychology, Aarhus University, Aarhus 8000, Denmark. kahr@psy.au.dk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jørgensen</LastName><ForeName>Carsten René</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Straarup</LastName><ForeName>Krista Nielsen</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>Licht</LastName><ForeName>Rasmus Wentzer</ForeName><Initials>RW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007389" MajorTopicYN="N">Internal-External Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="Y">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>01</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20728005</ArticleId><ArticleId IdType="pii">S0010-440X(10)00009-X</ArticleId><ArticleId IdType="doi">10.1016/j.comppsych.2010.02.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19393382</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Apr</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[How to differentiate schizophrenia from bipolar disorder using cognitive assessment?].</ArticleTitle><Pagination><MedlinePgn>139-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.encep.2008.03.011</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia raise the question of a continuum between the two entities. Griesinger (1817-1868) proposed a unitary concept of psychosis: "Einheitspsychose", adaptations of which have survived until the present day. Although Kraepelin's traditional dichotomy is still a common base for clinicians every day: diagnosis, prognosis and treatment of psychotic disorders, recent epidemiological and neurobiological data are congruent with a dimensional aspect of psychosis. Epidemiological data are consistent with the existence of an individual and a familial overlap between bipolar disorder and schizophrenia. Schizophrenia is probably the most debilitating psychological disorder. It was primarily considered as a behavioural disorder, characterized by socially inappropriate and bizarre behaviour, but much attention has been focussed nowadays on the cognitive component and the cognitive pathology underlying schizophrenia. On the other hand, bipolar, or manic depressive disorder has been primarily considered as a mood or affective disorder, characterized by excessive swings of emotion and motivation. Manic depression is more about recurrent dimensions. However, symptoms associated with the diagnosis of schizophrenia can be associated with psychotic mood disorders: hallucinations and delusions (50%), disorganised speech and behaviour (all patients with moderate to severe mania or mixed episode), negative symptoms (all patients with moderate to severe depression). The social and job dysfunction may be due to disturbances in the volitional system in patients with schizophrenia or severe bipolar disorder. LITERATURES FINDINGS: A considerable body of literature exists concerning the relationship between cognitive impairment in schizophrenia, but there is less data about cognition in bipolar disorder. However, there are some notable similarities between data observed in schizophrenia and bipolar disorder. Many domains of cognition are disrupted in schizophrenia with varying degrees of deficit. Concerning mood disorders, cognitive dysfunction could be considered as a state marker. Globally some studies indicate that, compared with schizophrenia, those with bipolar disorder display a similar but less severe neuropsychological pattern of impairment. However, it is only recently that cognitive dysfunction has been recognized as a primary and enduring core deficit in schizophrenia and further studies in bipolar disorder are needed.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">In this way, it has been suggested that psychotic symptoms may be distributed along a continuum that extends from schizophrenia to psychotic mood disorders with increasing level of severity. An explicative theory has to explain the evolution and the similarities between those affections including genetic and environmental liability. Some individuals, who are at high risk for psychosis, can even develop bipolar disorder or schizophrenia. Likewise, common factors can explain cognitive and social disorders in psychosis. So, there are various arguments for the dimensional approach of psychosis. These data are not completely in contradiction with Kraepelin: schizophrenia is a chronic affection and bipolar disorder is a cyclic pathology. However, common symptoms are not in favour of a strict categorization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Demily</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service hospitalo-universitaire de psychiatrie 69G12, Centre Hospitalier le Vinatier, 69500 Bron, France. caroline.demily@isc.cnrs.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacquet</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Marie-Cardine</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>L'évaluation cognitive permet-elle de distinguer la schizophrénie du trouble bipolaire ?</VernacularTitle><ArticleDate DateType="Electronic"><Year>2008</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012569" MajorTopicYN="N">Schizotypal Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>40</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>08</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>03</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19393382</ArticleId><ArticleId IdType="pii">S0013-7006(08)00159-0</ArticleId><ArticleId IdType="doi">10.1016/j.encep.2008.03.011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15727488</PMID><DateCompleted><Year>2005</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1175-2203</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>1</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>American journal of pharmacogenomics : genomics-related research in drug development and clinical practice</Title><ISOAbbreviation>Am J Pharmacogenomics</ISOAbbreviation></Journal><ArticleTitle>Monoamine oxidase a and tryptophan hydroxylase gene polymorphisms: are they associated with bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>45-52</MedlinePgn></Pagination><Abstract><AbstractText>Most of the candidate gene studies in bipolar disorder have focused on the major neurotransmitter systems that are influenced by drugs used in the treatment of this disorder. The monoamine oxidase A (MAOA) and the tryptophan hydroxylase (TPH1, TPH2) genes are two of the candidates that have been tested in a series of association studies using unrelated or family-based controls. This review summarizes the existing association studies regarding these genes. Most of these studies were based on the unrelated case-control design with samples of 50 to 600 subjects. Regarding MAOA, three meta-analyses with partially overlapping samples supported a modest effect of this gene in bipolar disorder in female Caucasians. However, as several studies could not replicate these findings, more work is necessary to demonstrate unequivocally the involvement of MAOA in bipolar disorder and establish the biological mechanism underlying the genetic association. With respect to TPH1 and TPH2, the majority of studies did not provide evidence for an association between these genes and bipolar disorder. The genes are more likely to be related to suicidal behavior than to bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Preisig</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Department of Adult Psychiatry, Site de Cery, CH-1008 Prilly-Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrero</LastName><ForeName>François</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Malafosse</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Am J Pharmacogenomics</MedlineTA><NlmUniqueID>100967746</NlmUniqueID><ISSNLinking>1175-2203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.16.4</RegistryNumber><NameOfSubstance UI="D014365">Tryptophan Hydroxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014365" MajorTopicYN="N">Tryptophan Hydroxylase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>63</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15727488</ArticleId><ArticleId IdType="pii">514</ArticleId><ArticleId IdType="doi">10.2165/00129785-200505010-00004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12397883</PMID><DateCompleted><Year>2002</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Psychopharmacology bulletin</Title><ISOAbbreviation>Psychopharmacol Bull</ISOAbbreviation></Journal><ArticleTitle>Premenstrual exacerbations of mood disorders.</ArticleTitle><Pagination><MedlinePgn>135-49</MedlinePgn></Pagination><Abstract><AbstractText>Premenstrual exacerbation of mood disorders has received little attention, despite the recent interest in premenstrual dysphoric disorder (PMDD) and premenstrual syndrome (PMS). Differentiating between PMDD/PMS and other disorders, which worsen premenstrually, is a poorly understood diagnostic challenge. Controversy also focuses on a possible coexistence of PMDD and other mood disorders. This review discusses the differences between mood-disorder exacerbations and premenstrual disorders, evidence for premenstrual magnification of mood disorders, and possible mechanisms for these variations as well as clinical implications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>M N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, East Tennessee State University, Quillen College of Medicine, Box 70567, Johnson City, TN 37614, USA. millerm@etsu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>B E</ForeName><Initials>BE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychopharmacol Bull</MedlineTA><NlmUniqueID>0101123</NlmUniqueID><ISSNLinking>0048-5764</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011293" MajorTopicYN="N">Premenstrual Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>69</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>10</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>10</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12397883</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23820830</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>170</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Behavioral treatment of insomnia in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>716-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2013.12050708</ELocationID><Abstract><AbstractText>Sleep disturbance is common in bipolar disorder. Stimulus control and sleep restriction are powerful, clinically useful behavioral interventions for insomnia, typically delivered as part of cognitive-behavioral therapy for insomnia (CBT-I). Both involve short-term sleep deprivation. The potential for manic or hypomanic symptoms to emerge after sleep deprivation in bipolar disorder raises questions about the appropriateness of these methods for treating insomnia. In a series of patients with bipolar disorder who underwent behavioral treatment for insomnia, the authors found that regularizing bedtimes and rise times was often sufficient to bring about improvements in sleep. Two patients in a total group of 15 patients reported mild increases in hypomanic symptoms the week following instruction on stimulus control. Total sleep time did not change for these individuals. Two of five patients who underwent sleep restriction reported mild hypomania that was unrelated to weekly sleep duration. Sleep restriction and stimulus control appear to be safe and efficacious procedures for treating insomnia in patients with bipolar disorder. Practitioners should encourage regularity in bedtimes and rise times as a first step in treatment, and carefully monitor changes in mood and daytime sleepiness throughout the intervention. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of California, Berkeley, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>Allison G</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R34 MH080958</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001521" MajorTopicYN="Y">Behavior Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007319" MajorTopicYN="N">Sleep Initiation and Maintenance Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23820830</ArticleId><ArticleId IdType="pii">1700614</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2013.12050708</ArticleId><ArticleId IdType="pmc">PMC4185309</ArticleId><ArticleId IdType="mid">NIHMS628333</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sleep. 2006 Sep;29(9):1155-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17040003</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 May 20;301(19):2005-15</Citation><ArticleIdList><ArticleId IdType="pubmed">19454639</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Sep 1;54(5):573-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12946886</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1996 May;26(3):477-86</Citation><ArticleIdList><ArticleId IdType="pubmed">8733206</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jul;165(7):820-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18519522</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Oct;62(10):1089-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16203954</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2008 Feb;117(1):164-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18266494</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Jun;163(6):981-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16741196</ArticleId></ArticleIdList></Reference><Reference><Citation>J Behav Ther Exp Psychiatry. 2010 Jun;41(2):145-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20004888</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2009 Aug;118(3):448-58</Citation><ArticleIdList><ArticleId IdType="pubmed">19685943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 1992 Aug;15(4):302-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1519003</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1996 Nov 15;65(2):121-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9122286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Apr;8(2):160-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16542186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2000 Mar 15;23(2):237-41</Citation><ArticleIdList><ArticleId IdType="pubmed">10737341</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 May;74(3):209-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12738039</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Apr;114(1-3):41-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18707765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Mar;10(2):256-65</Citation><ArticleIdList><ArticleId IdType="pubmed">18271904</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Jun 30;86(3):267-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10482346</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2006 Nov;29(11):1398-414</Citation><ArticleIdList><ArticleId IdType="pubmed">17162986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Aug;116(3):170-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):593-604</Citation><ArticleIdList><ArticleId IdType="pubmed">11018230</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2010 Sep;33(9):1159-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20857861</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Jun;80(2-3):145-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15207927</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2005 Feb;25(2):241-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15642648</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jan;162(1):50-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15625201</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2006 Jun 28;295(24):2851-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16804151</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep Med. 2001 Jul;2(4):297-307</Citation><ArticleIdList><ArticleId IdType="pubmed">11438246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2012 Feb 01;35(2):287-302</Citation><ArticleIdList><ArticleId IdType="pubmed">22294820</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 1995 Jan;18(1):55-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7761744</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 2004 Dec 15;27(8):1567-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15683149</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleep. 1987 Feb;10(1):45-56</Citation><ArticleIdList><ArticleId IdType="pubmed">3563247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17612849</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2009</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1040-1237</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>2</Issue><PubDate><MedlineDate>2007 Apr-Jun</MedlineDate></PubDate></JournalIssue><Title>Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists</Title><ISOAbbreviation>Ann Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Testing new diagnostic criteria for hypomania.</ArticleTitle><Pagination><MedlinePgn>99-104</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A recent series of studies has questioned DSM-IV diagnostic criteria for hypomania, suggesting that overactivity (increased goal-directed activity) should have priority over mood change as stem criterion. Angst has suggested new criteria for hypomania, giving priority to overactivity. Study aim was to test the validity of Angst's diagnostic criteria for hypomania.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A consecutive sample of remitted 213 DSM-IV bipolar-II disorder (BP-II) and major depressive disorder (MDD) outpatients were re-diagnosed, during a follow-up visit, by the Structured Clinical Interview for DSM-IV (yes/no structured questions on hypomanic symptoms, skip-out instruction of stem question on mood change not followed, in order to assess all past hypomanic symptoms), by a mood disorder specialist psychiatrist in a private practice. Angst's stem diagnostic criteria for hypomania were tested versus DSM-IV hypomania: 1) overactivity plus at least 3 of the 7 DSM-IV hypomanic symptoms 2) overactivity plus at least 2 of the 7 DSM-IV hypomanic symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DSM-IV criteria for hypomania were met by 137 patients, overactivity plus 2/7 was met by 146 patients, and overactivity plus 3/7 was met by 135 patients. Of the patients with overactivity plus 2/7, 83.5% also met DSM-IV criteria for hypomania, and of the patients with overactivity plus 3/7 86.6% also met DSM-IV criteria for hypomania. Logistic regression of DSM-IV hypomania versus overactivity plus 2/7 found odds ratio (OR) = 17.6, and versus overactivity plus 3/7 found OR = 18.8. Comparisons between DSM-IV hypomania and Angst's criteria for hypomania showed that there were no significant differences on age, gender, symptom structure of hypomania, number of episodes, episodes duration, and episodes level of functioning. Associations (ORs) between the stem criterion of each definition of hypomania and hypomanic symptoms were often strong. DSM-IV hypomania stem criterion was closely associated with overactivity (OR = 15.4), and Angst's hypomania stem criteria were closely associated with mood change (OR = 7.6 for overactivity plus 2/7, OR = 14.3 for overactivity plus 3/7).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Results support Angst's criteria for hypomania based on overactivity (overactivity plus 3/7 seems more supported). These criteria do not seem to lead to overdiagnosing hypomania. Previous studies supported the upgrading of overactivity among DSM-IV hypomanic symptoms. Angst's diagnostic criteria may positively impact the treatment of depression. It has been shown that focusing the probing for history of hypomania more on overactivity than on mood change reduces the false-negative BP-II. By using Angst' criteria for hypomania, clinicians may reduce the current high misdiagnosis of BP-II as MDD and the related mistreatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hecker Psychiatry Research Center, Forli, Italy. FrancoBenazzi@FBenazzi.it</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Psychiatry</MedlineTA><NlmUniqueID>8911021</NlmUniqueID><ISSNLinking>1040-1237</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Clin Psychiatry. 2008 Oct-Dec;20(4):234; author reply 235</RefSource><PMID Version="1">19034759</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17612849</ArticleId><ArticleId IdType="pii">779875429</ArticleId><ArticleId IdType="doi">10.1080/10401230701338219</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9771823</PMID><DateCompleted><Year>1998</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>9</Issue><PubDate><Year>1998</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Update on the management of bipolar illness.</ArticleTitle><Pagination><MedlinePgn>484-95; quiz 496</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>R C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Kowatch</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="D019204">GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019204" MajorTopicYN="N">GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007508" MajorTopicYN="N">Irritable Mood</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9771823</ArticleId><ArticleId IdType="doi">10.4088/jcp.v59n0909</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3579495</PMID><DateCompleted><Year>1987</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>5</Issue><PubDate><Year>1987</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The familial transmission of bipolar illness.</ArticleTitle><Pagination><MedlinePgn>441-7</MedlinePgn></Pagination><Abstract><AbstractText>As part of the National Institute of Mental Health Collaborative Program on the Psychobiology of Depression study, data were collected on 2225 first-degree relatives of 612 probands. We analyzed 187 families of bipolar patients (149 probands with a diagnosis of bipolar I disorder and 38 with a diagnosis of schizoaffective, manic subtype). Using traditional genetic methods, the morbid risk of bipolar illness in relatives was found to be 5.7% in the relatives of bipolar probands as contrasted with 1.1% in the relatives of probands with major depression. These values compared closely with those obtained using survival analysis. Relatives of probands with early onset were found to have a greater risk than relatives of probands with late onset. The sex of the relative, the sex of the proband, or the subtype of the proband (bipolar I or schizoaffective bipolar) did not influence the risk in the relative. The age at onset was found to be accelerated with birth cohort, with individuals born in more recent cohorts having an earlier onset. Multifactorial analysis found significant heterogeneity for sex-specific sibling correlations (with the brother-sister correlation smaller than the same-sexed correlations), and path analysis estimated transmissibility of liability to be 71%. The mixed model, which allows for a single major locus with a multifactorial background, gave evidence for the presence of a major locus when controlling for the effects of birth cohort and age at onset. However, this evidence is tempered when comparing the mixed model with a more general transmission model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Andreasen</LastName><ForeName>N C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Endicott</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Van Eerdewegh</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fishman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hirschfeld</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Klerman</LastName><ForeName>G L</ForeName><Initials>GL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-25430</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-31302</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-37685</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3579495</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1987.01800170063009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8707155</PMID><DateCompleted><Year>1996</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4572</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>2</Issue><PubDate><MedlineDate>1996 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Geriatric nursing (New York, N.Y.)</Title><ISOAbbreviation>Geriatr Nurs</ISOAbbreviation></Journal><ArticleTitle>When lithium does not help: the use of anticonvulsants and calcium channel blockers in the treatment of bipolar disorder in the older person.</ArticleTitle><Pagination><MedlinePgn>75-8</MedlinePgn></Pagination><Abstract><AbstractText>Although anticonvulsant agents and calcium channel blockers do not have any clear advantages over lithium, they do offer patients who cannot (or will not) take lithium another treatment option. It is not yet clear from the literature who will respond best to which drug or combination of drugs. The nurse should be supportive to the patients and family, in what may be a drawn out process, to find the best treatment. Optimism is justified because a lack of response to one drug is not indicative of nonresponse to other drugs. It is important to actively treat bipolar disorder because each episode of mania increases the risk of progression of the illness, with increasingly severe episodes occurring closer together. Bipolar disorder has high social costs (legal, financial, and relationship problems) that make improvements in treatment important for the patient and society. Anticonvulsant agents and calcium channel blockers may also be useful in treating depression. The number of people whose depressive symptoms respond is far less (25% to 30%) than the number who respond to the anti-manic effects, but this is an option when antidepressants and electroconvulsive therapy are not effective.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Geriatr Nurs</MedlineTA><NlmUniqueID>8309633</NlmUniqueID><ISSNLinking>0197-4572</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8707155</ArticleId><ArticleId IdType="pii">S0197-4572(96)80173-X</ArticleId><ArticleId IdType="doi">10.1016/s0197-4572(96)80173-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22939529</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2013</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7862</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: a principal component analysis of lifetime pharmacological and biophysic treatment options.</ArticleTitle><Pagination><MedlinePgn>263-75</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2012.07.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0924-977X(12)00197-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The treatment of patients with bipolar disorder (BD) is complex and psychiatrists often have to change treatment strategies. However, available data do not provide information about the most frequent patterns of treatment strategies prescribed in clinical practice and clinical/socio-demographic factors of drugs prescription.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aims of this study were: (1) to identify specific patterns of life-time treatment strategies in a representative sample of bipolar patients; (2) to assess consistency with guidelines recommendations; and (3) to investigate clinical/socio-demographic of patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Six-hundred and four BD I and II out-patients were enrolled in a naturalistic cohort study at the Barcelona Bipolar Disorders Program, in a cross-sectional analysis. A principal component analysis was applied to group psychotropic drugs into fewer underlying clusters which represent patterns of treatment strategies more frequently adopted in the life-time naturalistic treatment of BD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three main factors corresponding to three main prescription patterns were identified, which explained about 60% of cases, namely, Factor 1 (21.1% of common variance), defined the "antimanic stabilisation package" including treatments with antimanic mechanism of action in predominantly manic-psychotic BD I patients; Factor 2 (20.4%), "antidepressive stabilisation package" that grouped predominantly depressed patients, and Factor 3 (16.4%) defined the "anti-bipolar II package", including antidepressant monotherapy in BD II patients with depressive predominant polarity, melancholic features and higher rates of suicide behaviours.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study identified three patterns of lifetime treatment strategies in three specific and different groups of naturalistically treated bipolar patients.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier B.V. and ECNP. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nivoli</LastName><ForeName>Alessandra M A</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Clinical Neuroscience, Hospital Clínic, Universitat de Barcelona, IDIBAPS, CIBERSAM, Villarroel 170, 08036, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Murru</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Valentí</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mazzarini</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Del Mar Bonnin</LastName><ForeName>Caterina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sánchez-Moreno</LastName><ForeName>José</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025341" MajorTopicYN="N">Principal Component Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>06</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>07</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22939529</ArticleId><ArticleId IdType="pii">S0924-977X(12)00197-6</ArticleId><ArticleId IdType="doi">10.1016/j.euroneuro.2012.07.015</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24548785</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2014</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7528</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Neuroscience and biobehavioral reviews</Title><ISOAbbreviation>Neurosci Biobehav Rev</ISOAbbreviation></Journal><ArticleTitle>The theory of bipolar disorder as an illness of accelerated aging: implications for clinical care and research.</ArticleTitle><Pagination><MedlinePgn>157-69</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neubiorev.2014.02.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0149-7634(14)00024-4</ELocationID><Abstract><AbstractText>Bipolar Disorder (BD) has been conceptualized as both a cyclic and a progressive disorder. Mechanisms involved in neuroprogression in BD remain largely unknown although several non-mutually exclusive models have been proposed as explanatory frameworks. In the present paper, we propose that the pathophysiological changes observed in BD (e.g. brain structural alterations, cognitive deficits, oxidative stress imbalance, amyloid metabolism, immunological deregulation, immunosenescence, neurotrophic deficiencies and telomere shortening) converge on a model of accelerated aging (AA). Aging can be understood as a multidimensional process involving physical, neuropsychological, and social changes, which can be highly variable between individuals. Determinants of successful aging (e.g environmental and genetic factors), may also confer differential vulnerability to components of BD pathophysiology and contribute to the clinical presentation of BD. Herein we discuss how the understanding of aging and senescence can contribute to the search for new and promising molecular targets to explain and ameliorate neuroprogression in BD. We also present the strengths and limitations of this concept. </AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Lucas Bortolotto</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Program for Recognition and Intervention in Individuals in At-Risk Mental States (PRISMA), Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil; Interdisciplinary Laboratory of Clinical Neuroscience (LINC), Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Leonardo Gazzi</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Program for Recognition and Intervention in Individuals in At-Risk Mental States (PRISMA), Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil; Interdisciplinary Laboratory of Clinical Neuroscience (LINC), Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansur</LastName><ForeName>Rodrigo B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Program for Recognition and Intervention in Individuals in At-Risk Mental States (PRISMA), Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil; Interdisciplinary Laboratory of Clinical Neuroscience (LINC), Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swardfager</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belangero</LastName><ForeName>Síntia Iole</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>Interdisciplinary Laboratory of Clinical Neuroscience (LINC), Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil; Department of Morphology and Genetics, Federal University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassi-Oliveira</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Research and Faculty of Biosciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Moisés E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Research and Faculty of Biosciences, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brietzke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Program for Recognition and Intervention in Individuals in At-Risk Mental States (PRISMA), Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil; Interdisciplinary Laboratory of Clinical Neuroscience (LINC), Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil. Electronic address: elisabrietzke@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosci Biobehav Rev</MedlineTA><NlmUniqueID>7806090</NlmUniqueID><ISSNLinking>0149-7634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019588" MajorTopicYN="N">Aging, Premature</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aging</Keyword><Keyword MajorTopicYN="N">Amyloid</Keyword><Keyword MajorTopicYN="N">BDNF</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Immunosenescence</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Molecular imaging</Keyword><Keyword MajorTopicYN="N">Neuroprogression</Keyword><Keyword MajorTopicYN="N">Oxidative stress</Keyword><Keyword MajorTopicYN="N">Telomeres</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>02</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24548785</ArticleId><ArticleId IdType="pii">S0149-7634(14)00024-4</ArticleId><ArticleId IdType="doi">10.1016/j.neubiorev.2014.02.004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12469687</PMID><DateCompleted><Year>2002</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>11</Issue><PubDate><Year>2002</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>High frequency of residual depressive symptoms in bipolar II disorder: the need for a better treatment.</ArticleTitle><Pagination><MedlinePgn>1045-6; author reply 1046</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benazzi</LastName><ForeName>Franco</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Clin Psychiatry. 2002 Feb;63(2):120-5</RefSource><PMID Version="1">11874212</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>12</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>12</Month><Day>27</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>12</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12469687</ArticleId><ArticleId IdType="doi">10.4088/jcp.v63n1116b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19296014</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0037-5675</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Singapore medical journal</Title><ISOAbbreviation>Singapore Med J</ISOAbbreviation></Journal><ArticleTitle>Mania as a presentation of primary hypothyroidism.</ArticleTitle><Pagination><MedlinePgn>e65-7</MedlinePgn></Pagination><Abstract><AbstractText>Hypothyroidism is a common problem in clinical practice, with diverse manifestations. Neuropsychiatric problems include affective disorders, disturbances in cognition and psychosis. Mania is commonly associated with hyperthyroidism. Only a few selected case reports mention mania as a presenting feature of hypothyroidism. We report a case of mania with psychotic symptoms in a 47-year-old woman who had no previous history of psychiatric disorder. She had signs of florid hypothyroidism. She required both antipsychotic drugs and thyroxine replacement for the amelioration of her symptoms. The report is followed by a brief review of the literature on mania as a clinical presentation of hypothyroidism and its probable pathogenesis. One has to have a high index of suspicion of underlying organic causes in patients presenting with depression, psychosis or cognitive disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sathya</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Associates in Clinical Endocrinology, Education and Research, Geo Towers, 3rd floor, Apollo Speciality Hospital Annexe, Chennai 35, India. anjalisathyab@yahoo.co.in</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radhika</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mahadevan</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sriram</LastName><ForeName>Un</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Singapore Med J</MedlineTA><NlmUniqueID>0404516</NlmUniqueID><ISSNLinking>0037-5675</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q51BO43MG4</RegistryNumber><NameOfSubstance UI="D013974">Thyroxine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013974" MajorTopicYN="N">Thyroxine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19296014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31185485</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1740-634X</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>11</Month></PubDate></JournalIssue><Title>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</Title><ISOAbbreviation>Neuropsychopharmacology</ISOAbbreviation></Journal><ArticleTitle>Brain function during stages of working memory in schizophrenia and psychotic bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>2136-2142</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41386-019-0434-4</ELocationID><Abstract><AbstractText>Working memory (WM) is impaired in psychotic disorders and linked to functional outcome. Most neurobiological models emphasize prefrontal cortex (PFC) dysfunction in the etiology of WM impairment. However, WM is composed of multiple processes, including encoding and maintenance, and the delineation of the neurobiology of these sub-processes has not been well characterized in schizophrenia and psychotic bipolar disorder. Functional MRI was obtained during an event-related spatial delayed match-to-sample task from 58 healthy individuals, 72 individuals with schizophrenia and 41 people with bipolar I disorder with psychotic features in order to: 1) characterize neural responses during encoding, maintenance and retrieval stages of WM using complementary region-of-interest and whole brain approaches; 2) determine whether schizophrenia and psychotic bipolar disorder exhibit similar abnormalities in WM-related brain function; and 3) elucidate the associations between WM-related brain function, task performance, and neuropsychological functioning. Both schizophrenia and psychotic bipolar disorder groups showed encoding- and maintenance-related impairments in the posterior parietal cortex (PPC) and frontal eye fields (FEF). BOLD response in the PPC and FEF, during encoding and maintenance respectively, was associated with task performance independent of group. Additionally, encoding-related activation in the PPC correlated with general neuropsychological functioning independent of group. Only encoding-related activation in the right ventral striatum differed between schizophrenia and psychotic bipolar disorder; individuals with schizophrenia showed significantly lower activation than both psychotic bipolar disorder and healthy groups. Our results are consistent with emerging evidence implicating PPC dysfunction in WM impairment and suggest interventions targeting neural activation in PPC may improve WM and neuropsychological functioning across psychotic disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Anna S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave. S., Nashville, TN, 37212, USA. anna.s.huang@vumc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Baxter P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Vanderbilt University Institute of Imaging Sciences, Nashville, TN, 37212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anticevic</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale University School of Medicine, New Haven, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackford</LastName><ForeName>Jennifer Urbano</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave. S., Nashville, TN, 37212, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Research Health Scientist, Research and Development, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckers</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave. S., Nashville, TN, 37212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Neil D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, 1601 23rd Ave. S., Nashville, TN, 37212, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD021771</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH102266</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychopharmacology</MedlineTA><NlmUniqueID>8904907</NlmUniqueID><ISSNLinking>0893-133X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neuropsychopharmacology. 2019 Sep 2;:</RefSource><PMID Version="1">31477819</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065852" MajorTopicYN="N">Spatial Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>04</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>05</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31185485</ArticleId><ArticleId IdType="doi">10.1038/s41386-019-0434-4</ArticleId><ArticleId IdType="pii">10.1038/s41386-019-0434-4</ArticleId><ArticleId IdType="pmc">PMC6898667</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rev Neurosci. 1998;9(4):225-41</Citation><ArticleIdList><ArticleId IdType="pubmed">9886139</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2011 Jan;37(1):73-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19443616</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2011 Jul;129(2-3):156-62</Citation><ArticleIdList><ArticleId IdType="pubmed">21497488</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1993 Oct 21;365(6448):753-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8413653</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Jul 15;48(2):99-109</Citation><ArticleIdList><ArticleId IdType="pubmed">10903406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2009 Dec;30(12):3958-69</Citation><ArticleIdList><ArticleId IdType="pubmed">19449330</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2015 Sep;25(9):2494-506</Citation><ArticleIdList><ArticleId IdType="pubmed">24675869</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Aug;66(8):811-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19652121</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 May 1;35(4):1551-61</Citation><ArticleIdList><ArticleId IdType="pubmed">17363277</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2011 Sep 30;193(3):138-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21782395</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2017 May 15;81(10):874-885</Citation><ArticleIdList><ArticleId IdType="pubmed">28434616</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2019 Apr;206:413-419</Citation><ArticleIdList><ArticleId IdType="pubmed">31104720</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2000 Aug;67(2):369-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10880296</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2008 Jan 15;46(1):336-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17707869</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2014 Jan;165B(1):84-95</Citation><ArticleIdList><ArticleId IdType="pubmed">24243780</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2002 Jul 8;114(5):483-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12116181</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2019 Jun 18;45(4):804-812</Citation><ArticleIdList><ArticleId IdType="pubmed">30260448</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1997;23(3):437-58</Citation><ArticleIdList><ArticleId IdType="pubmed">9327508</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2005 Nov;114(4):599-611</Citation><ArticleIdList><ArticleId IdType="pubmed">16351383</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2019 May;22(5):820-827</Citation><ArticleIdList><ArticleId IdType="pubmed">30962628</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Psychol. 2015 Jan 3;66:115-42</Citation><ArticleIdList><ArticleId IdType="pubmed">25251486</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2010 Mar 11;65(5):585-96</Citation><ArticleIdList><ArticleId IdType="pubmed">20223196</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2010 Mar;48(4):1063-70</Citation><ArticleIdList><ArticleId IdType="pubmed">20005882</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21320248</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1987;13(2):261-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Oct;162(10):1849-58</Citation><ArticleIdList><ArticleId IdType="pubmed">16199831</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cogn Neurosci. 2002 May 15;14(4):659-71</Citation><ArticleIdList><ArticleId IdType="pubmed">12126506</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Oct;52(10):821-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7575101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2010 Aug;20(8):936-48</Citation><ArticleIdList><ArticleId IdType="pubmed">19693783</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2004 Apr 15;428(6984):751-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15085133</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2013 Jan;39(1):168-78</Citation><ArticleIdList><ArticleId IdType="pubmed">21914644</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1994 Fall;6(4):348-57</Citation><ArticleIdList><ArticleId IdType="pubmed">7841806</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Apr 1;53(7):624-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12679242</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Dec 15;64(12):1026-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18823880</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010 Aug 11;5(8):e12068</Citation><ArticleIdList><ArticleId IdType="pubmed">20725639</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Res. 1994 Nov;21(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">7708289</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Jan;35(1):47-57</Citation><ArticleIdList><ArticleId IdType="pubmed">18990710</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(11):e48586</Citation><ArticleIdList><ArticleId IdType="pubmed">23152783</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2000 Jul 15;52(5):309-17</Citation><ArticleIdList><ArticleId IdType="pubmed">10922508</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2014;204:290-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24434074</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008 Mar 12;3(3):e1760</Citation><ArticleIdList><ArticleId IdType="pubmed">18335036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2005 May;25(1):46-59</Citation><ArticleIdList><ArticleId IdType="pubmed">15846822</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2005 May;25(1):60-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15846819</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Mar;60(1):830-46</Citation><ArticleIdList><ArticleId IdType="pubmed">22178808</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2018 Sep 26;38(39):8378-8387</Citation><ArticleIdList><ArticleId IdType="pubmed">30104335</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1997 Mar 14;275(5306):1593-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9054347</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14672801</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>78</Volume><Issue>1</Issue><PubDate><Year>2004</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Earlier onset of bipolar disorder in children by antidepressants or stimulants? An hypothesis.</ArticleTitle><Pagination><MedlinePgn>81-4</MedlinePgn></Pagination><Abstract><AbstractText>Among adults and adolescents, bipolar disorder (BD) has a similar prevalence in the US and in the Netherlands. However, among pre-pubertal children, BD is frequently diagnosed in the US and seldomly in the Netherlands. This suggests that, among children, the prevalence of BD is lower in the Netherlands than in the US, indicating an earlier onset of BD in the US than in the Netherlands. It is hypothesized that this may be related to the greater use of antidepressants and stimulants for depression or attention deficit disorder with hyperactivity by US children. In those children who are genetically at risk to develop BD, these drugs may lead to a switch into mania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reichart</LastName><ForeName>Catrien G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Sophia Children's Hospital/Erasmus University of Rotterdam, Dr. Molewaterplein 40, Rotterdam 3015 GD, The Netherlands. reichart@psyd.azr.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>16</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14672801</ArticleId><ArticleId IdType="pii">S0165032702001805</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(02)00180-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9590667</PMID><DateCompleted><Year>1998</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>1998</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Medication compliance among patients with bipolar disorder and substance use disorder.</ArticleTitle><Pagination><MedlinePgn>172-4</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study examined patterns of medication compliance and reasons for noncompliance among patients with bipolar disorder and substance use disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Forty-four patients with current bipolar disorder and substance use disorder were administered a structured interview regarding lifetime compliance with prescribed psychotropic medications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients who were prescribed both lithium and valproate were significantly (p = .03) more likely to report full compliance with valproate than with lithium. Side effects were the most common reason for lithium noncompliance, but were not cited as a reason for valproate noncompliance. Also, a common pattern of noncompliance among patients prescribed benzodiazepines, neuroleptics, and tricyclic antidepressants was the use of more medication than prescribed.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Valproate may have greater acceptability than lithium among patients with bipolar disorder and substance use disorder. Clinicians should also be aware that these patients may take higher doses of medication than prescribed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>R D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Alcohol and Drug Abuse Program, McLean Hospital, Belmont, Mass 02178, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenfield</LastName><ForeName>S F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Najavits</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Wyner</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>DA00326</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA08631</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA09400</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="Y">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>5</Month><Day>20</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>5</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9590667</ArticleId><ArticleId IdType="doi">10.4088/jcp.v59n0405</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22446567</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-1701</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Fragile early visual percepts mark genetic liability specific to schizophrenia.</ArticleTitle><Pagination><MedlinePgn>839-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbs041</ELocationID><Abstract><AbstractText>Disruption of visual percepts by a subsequent stimulus (ie, backward masking) has been consistently noted in schizophrenia, with some evidence that this fragility in early perception is present in people with genetic liability for the disorder. Given the potential of backward masking paradigms to mark neural processes that confer risk for schizophrenia, it is important to test the diagnostic specificity of abnormalities in visual perception. To more fully assess whether masking visual stimuli reveals a marker of genetic liability (ie, endophenotype) specific to schizophrenia, we tested 44 people with the disorder, 29 people with bipolar disorder, 56 first-degree biological relatives of people with schizophrenia, 26 first-degree biological relatives of people with bipolar disorder, and 43 nonpsychiatric control participants using a magnocellular-biased visual backward masking procedure that included target-to-mask onset asynchronies ranging from 0 to 80 ms. Relatives of people with schizophrenia who were without schizophrenia spectrum disorders exhibited impaired performance compared with nonpsychiatric control participants and relatives of people with bipolar disorder when a visual mask interrupted early perception (eg, 27 ms). A similar vulnerability of early processes was noted in people with schizophrenia, yet they also had impaired performance when masks occurred at later time points (ie, 80 ms). Performance deficits were not attributable to intellectual function, measures of attention and memory, symptomatology, or medication dosage. Bipolar patients and their relatives failed to exhibit deficits on the backward masking task. Fragility of early visual percepts appears to mark genetic liability specific to schizophrenia and may serve as an endophenotype for the disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sponheim</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Minneapolis Veterans Affairs Health Care System, Minneapolis, MN 55417, USA. sponh001@umn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sass</LastName><ForeName>Sarah M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Noukki</LastName><ForeName>Althea L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Hegeman</LastName><ForeName>Bridget M</ForeName><Initials>BM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 CX000227</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058068" MajorTopicYN="N">Endophenotypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009039" MajorTopicYN="N">Motion Perception</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010468" MajorTopicYN="N">Perceptual Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010470" MajorTopicYN="N">Perceptual Masking</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">backward masking</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">endophenotype</Keyword><Keyword MajorTopicYN="N">magno-cellular</Keyword><Keyword MajorTopicYN="N">unaffected relatives</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22446567</ArticleId><ArticleId IdType="pii">sbs041</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbs041</ArticleId><ArticleId IdType="pmc">PMC3686444</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Nerv Ment Dis. 1998 Oct;186(10):597-603</Citation><ArticleIdList><ArticleId IdType="pubmed">9788635</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1985 Jan;173(1):26-31</Citation><ArticleIdList><ArticleId IdType="pubmed">3965608</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Dec;162(12):2330-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16330598</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2008 Nov;117(4):788-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19025226</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2001 Jul;31(5):915-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11459389</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2003 Oct 1;63(3):273-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12957706</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Jul 1;68(1):78-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20494338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Oct;6(5):374-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15383129</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1986;12(3):447-59</Citation><ArticleIdList><ArticleId IdType="pubmed">3764361</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Sep;156(9):1367-73</Citation><ArticleIdList><ArticleId IdType="pubmed">10484946</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1982 Sep;139(9):1127-30</Citation><ArticleIdList><ArticleId IdType="pubmed">6126128</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1984;10(2):160-203</Citation><ArticleIdList><ArticleId IdType="pubmed">6729409</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1993 Apr;181(4):233-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8473875</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 Apr 1;55(3):1219-26</Citation><ArticleIdList><ArticleId IdType="pubmed">21194569</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychophysiology. 1998 Nov;35(6):621-37</Citation><ArticleIdList><ArticleId IdType="pubmed">9844425</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 1;62(7):793-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17207777</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1997 May;54(5):465-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9152100</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1995 Feb;104(1):63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7897054</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 Dec;124(1-3):152-60</Citation><ArticleIdList><ArticleId IdType="pubmed">20674278</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Aug 15;40(4):295-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8871777</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1985 Feb;142(2):170-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3970241</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2008 Mar 5;147B(2):223-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17948281</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Sep;152(9):1286-90</Citation><ArticleIdList><ArticleId IdType="pubmed">7653682</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2009 Aug;259(5):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19390766</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Mar;168(3):253-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21285144</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Methods Psychiatr Res. 2002;11(2):83-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12459798</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Dec;51(12):945-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7979882</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Jul;35(4):826-39</Citation><ArticleIdList><ArticleId IdType="pubmed">18381357</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Aug;103(1-3):266-74</Citation><ArticleIdList><ArticleId IdType="pubmed">18450427</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Dec;51(12):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">7979881</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Mar 1;59(5):446-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16139818</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Dec;66(12):1295-303</Citation><ArticleIdList><ArticleId IdType="pubmed">19996034</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Oct 15;78(2-3):261-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16154058</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1996 Sep 18;21(3):171-82</Citation><ArticleIdList><ArticleId IdType="pubmed">8885045</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychophysiol. 2004 Mar;52(1):37-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15003371</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2010 May;34(6):897-921</Citation><ArticleIdList><ArticleId IdType="pubmed">19954751</ArticleId></ArticleIdList></Reference><Reference><Citation>Percept Psychophys. 2000 Nov;62(8):1572-95</Citation><ArticleIdList><ArticleId IdType="pubmed">11140180</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1986 Apr;174(4):208-13</Citation><ArticleIdList><ArticleId IdType="pubmed">3958701</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1981 Feb;38(2):175-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7212944</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Aug;162(8):1533-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16055778</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2011 Jul;37(4):700-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21606322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19500633</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4216</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Aug</Month><Day>31</Day></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Corpus callosum size and shape alterations in individuals with bipolar disorder and their first-degree relatives.</ArticleTitle><Pagination><MedlinePgn>1050-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pnpbp.2009.05.019</ELocationID><Abstract><AbstractText>Reductions in the size of the corpus callosum (CC) have been described in patients with bipolar disorder (BD), although the contribution of genetic factors to these changes is unclear. We previously showed a global thinning of the CC in BD patients, and found those with a family history of affective disorders had a larger CC than those without. In this study, we compared callosal size and shape in 180 individuals: 70 with BD, 45 of their first-degree relatives, and 75 healthy controls. The callosum was extracted from a mid-sagittal slice from T1-weighted magnetic resonance images, and its total area, length and curvature were compared across groups. A non-parametric permutation method was used to examine for alterations in width of the callosum along 39 points. Validating our previous findings, a significant global reduction in callosal thickness was seen in BD patients, with a disproportionate thinning in the anterior body. First-degree relatives did not differ in callosal size or shape from controls. In BD patients, duration of illness and age were associated with thinning in the anterior body; BD patients on lithium treatment showed a thicker anterior mid-body than those on other psychotropics. Global and regional thinning of the callosum is seen in BD but not in their first-degree relatives. This suggests that CC abnormalities are linked to disease expression in BD and may not represent a marker of familial predisposition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walterfang</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Australia. mark.walterfang@mh.org.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Amanda G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Barton</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Velakoulis</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Reutens</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Kempton</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Haldane</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pantelis</LastName><ForeName>Christos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Frangou</LastName><ForeName>Sophia</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003337" MajorTopicYN="N">Corpus Callosum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19500633</ArticleId><ArticleId IdType="pii">S0278-5846(09)00171-7</ArticleId><ArticleId IdType="doi">10.1016/j.pnpbp.2009.05.019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29933949</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0814</ISSN><JournalIssue CitedMedium="Internet"><Volume>157</Volume><PubDate><Year>2018</Year></PubDate></JournalIssue><Title>Progress in molecular biology and translational science</Title><ISOAbbreviation>Prog Mol Biol Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Epigenetic Drugs for Mood Disorders.</ArticleTitle><Pagination><MedlinePgn>151-174</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1877-1173(18)30018-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/bs.pmbts.2018.01.005</ELocationID><Abstract><AbstractText>There is increasing evidence that changes in epigenetic mechanisms of gene expression are involved in the pathogenesis of mood disorders. Such evidence stems from studies conducted on postmortem brain tissues and peripheral cells or tissues of patients with mood disorders. This article describes and discusses the epigenetic changes in the mood disorders (major depressive disorder and bipolar disorder) found to date. The article also describes and discusses preclinical drug trials of epigenetic drugs for treating mood disorders. In addition, nonrandomized and randomized controlled trials of nutritional drugs with effects on epigenetic mechanisms of gene expression in patients with major depressive disorder and bipolar disorder are discussed. Trials of epigenetic drugs and nutritional drugs with epigenetic effects are showing promising results for the treatment of mood disorders. Thus, epigenetic drugs and nutritional drugs with epigenetic effects could be useful in the treatment of patients with these disorders.</AbstractText><CopyrightInformation>Copyright © 2018. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peedicayil</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Christian Medical College, Vellore, India. Electronic address: jpeedi@cmcvellore.ac.in.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Aniket</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Christian Medical College, Vellore, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Prog Mol Biol Transl Sci</MedlineTA><NlmUniqueID>101498165</NlmUniqueID><ISSNLinking>1877-1173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="Y">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">epigenetic drugs</Keyword><Keyword MajorTopicYN="Y">gene expression</Keyword><Keyword MajorTopicYN="Y">major depressive disorder</Keyword><Keyword MajorTopicYN="Y">mood disorder</Keyword><Keyword MajorTopicYN="Y">postmortem</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29933949</ArticleId><ArticleId IdType="pii">S1877-1173(18)30018-8</ArticleId><ArticleId IdType="doi">10.1016/bs.pmbts.2018.01.005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23315174</PMID><DateCompleted><Year>2013</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of molecular neuroscience : MN</Title><ISOAbbreviation>J Mol Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene associated with treatment response to mood stabilizers in patients with bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>305-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12031-013-9956-0</ELocationID><Abstract><AbstractText>There is increasing evidence supporting the relationship between bipolar disorder (BP) and neurotrophin. The present study investigated the relationship between neurotrophic tyrosine kinase receptor type 2 (NTRK2) gene polymorphisms and bipolar I disorder (BP I) susceptibility and treatment response to mood stabilizers (lithium or valproate). Two-hundred eighty-four patients who met the DSM-IV criteria for BP I and 295 matched healthy controls were enrolled into this study. TaqMan® SNP genotyping assays were applied to genotype three NTRK2 gene polymorphisms (rs2769605, rs1565445, rs1387923). Our study showed a significant allelic association between NTRK2 gene polymorphism rs2769605 and treatment response to mood stabilizers in BP I patients (t = -2.53, P = 0.01). However, no significant association between NTRK2 gene polymorphisms and BP I susceptibility was observed after correcting for multiple comparisons. The results suggest that the NTRK2 gene polymorphism likely plays an essential role in treatment response to mood stabilizers in Han Chinese BP I patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zuowei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, People's Republic of China. wzwhk@163.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Jinbo</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Keming</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zezhi</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Zhenghui</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lingxiao</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Chengmei</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Wu</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Shunying</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yiru</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 RR024990</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Mol Neurosci</MedlineTA><NlmUniqueID>9002991</NlmUniqueID><ISSNLinking>0895-8696</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D020813">Receptor, trkB</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020813" MajorTopicYN="N">Receptor, trkB</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23315174</ArticleId><ArticleId IdType="doi">10.1007/s12031-013-9956-0</ArticleId><ArticleId IdType="pmc">PMC3658129</ArticleId><ArticleId IdType="mid">NIHMS448712</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurochem. 2010 May;113(4):952-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20193039</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2007 Jan;20(1):8-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17143075</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Sep;43(14):1175-84</Citation><ArticleIdList><ArticleId IdType="pubmed">19376528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Diagn Ther. 2007;11(3):161-70</Citation><ArticleIdList><ArticleId IdType="pubmed">17570738</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Sep;125(1-3):345-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20172611</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):48-58</Citation><ArticleIdList><ArticleId IdType="pubmed">14601036</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2012 Mar;26(3):368-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21890592</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Oct;63(10):942-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12416605</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2007 Feb;7(1):22-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17055337</ArticleId></ArticleIdList></Reference><Reference><Citation>Novartis Found Symp. 2008;289:60-72; discussion 72-3, 87-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18497095</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2009 Oct;34(9):1380-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19473771</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Dec;104(1-3):185-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17442400</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jun 15;59(12):1160-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16457783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Aug;14(8):755-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19488044</ArticleId></ArticleIdList></Reference><Reference><Citation>Genes Brain Behav. 2006 Feb;5(1):85-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16436192</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2006 Jul 5;141B(5):435-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16741941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Aug;15(8):810-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19255578</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jun 1;59(11):1006-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16487491</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):275-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19330778</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2010 Mar;33(1):181-224</Citation><ArticleIdList><ArticleId IdType="pubmed">20159346</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2004 May;45(2):104-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15145621</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2011 May;36(3):195-203</Citation><ArticleIdList><ArticleId IdType="pubmed">21223646</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005;7 Suppl 5:13-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16225556</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 Oct 15;72(8):663-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22609366</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacogenomics. 2008 Nov;9(11):1595-603</Citation><ArticleIdList><ArticleId IdType="pubmed">19018715</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15225147</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2007</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Community-based care for youths with early and very-early onset bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>299-304</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Phenomenological and treatment differences between children and adolescents with bipolar I disorder in a public mental health system were examined.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A systematic medical record review was performed on a sample of 83 patients, focusing on documented DSM IV symptoms of mania or depression, attention deficit hyperactivity disorder, conduct disorder, schizophrenia, and post-traumatic stress disorder. Cross-tabulation and logistic regression analyses were performed comparing the presence/absence of symptoms for each disorder and treatments provided for children and adolescents.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Prepubertal patients were significantly more likely to be male, easily distracted, inattentive, detached from others, hyper-vigilant, prescribed stimulant medication, and to meet the diagnostic criteria for attention-deficit/hyperactivity disorder or Conduct Disorder than adolescents.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Consistent with the published literature, phenomenological differences between children and adolescents are present and being recognized for differential diagnosis and treatment by community practitioners. More attention to documenting some cardinal symptoms of mania, the persistence of bipolar symptoms, and the nature of cycling for those with mixed states is needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jerrell</LastName><ForeName>Jeanette M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, Columbia, SC 29203, USA. jjerrell@gw.mp.sc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shugart</LastName><ForeName>Margaret A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003156" MajorTopicYN="N">Community Mental Health Services</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019955" MajorTopicYN="N">Conduct Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15225147</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00129.x</ArticleId><ArticleId IdType="pii">BDI129</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31911063</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7862</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><PubDate><Year>2020</Year><Month>03</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Obstetric complications in bipolar disorder: Psychiatric factors and the risk of caesarean section.</ArticleTitle><Pagination><MedlinePgn>47-55</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0924-977X(19)31889-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2019.12.115</ELocationID><Abstract><AbstractText>Bipolar Disorder (BD) is a chronic psychiatric condition with somatic morbidity that requires continuous mood stabilizing treatment to prevent relapses. Pregnant women with BD have shown an increased rate of caesarean section (C-Section) in comparison with women without BD. Because specific differentiated profiles between mothers with BD that require C-Section and those that do not require C-Section have not been largely discussed, we aim to explore the risk factors associated with the type of delivery in pregnant women with BD. A prospective cohort study was conducted at the Perinatal Mental Health Unit. 100 pregnant women with BD were followed throughout their pregnancy by obstetric and psychiatric services at the same hospital. The cohort was developed in order to compare psychiatric and obstetric outcomes between women with BD that required C-Section (N = 40) versus women that did not require C-Section (N = 60). Final regression models showed an increased risk for obstetric complications during labour (OR 4,52, 95% CI 1,66-12,29), higher rates of hypothyroidism (OR 3,73, 95% CI 1,04-13,73) and treatment with lithium + antidepressant (OR 4,24, 95% CI 1,34-13,40) amongst the C-Section group when compared to the non-C-Section group. In our sample, women with BD treated with lithium plus antidepressant, with hypothyroidism and without obstetric complications have a 70,5% probability of C-Section. In conclusion, psychopharmacology and thyroid function might help understanding which women with BD will have more probability of C-Section. The implementation of more targeted interventions in selected patients might be useful to avoid complications during delivery.</AbstractText><CopyrightInformation>Copyright © 2019. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Solé</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Perinatal Mental Health Unit, Department of Psychiatry and Clinical Psychology, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain; Bipolar and Depressives Disorder Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain. Electronic address: evsole@clinic.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roca</LastName><ForeName>Alba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Perinatal Mental Health Unit, Department of Psychiatry and Clinical Psychology, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain; Vulnerability, Psychopathology and Gender Research Group, Generalitat de Catalunya, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Perinatal Mental Health Unit, Department of Psychiatry and Clinical Psychology, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain; Vulnerability, Psychopathology and Gender Research Group, Generalitat de Catalunya, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernández</LastName><ForeName>Ana Sandra</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Maternal-Fetal Medicine, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández</LastName><ForeName>Noemí</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Perinatal Mental Health Unit, Department of Psychiatry and Clinical Psychology, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz</LastName><ForeName>Carmen Naranjo</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Perinatal Mental Health Unit, Department of Psychiatry and Clinical Psychology, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar and Depressives Disorder Unit, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Esteve</LastName><ForeName>Lluïsa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Perinatal Mental Health Unit, Department of Psychiatry and Clinical Psychology, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain; Vulnerability, Psychopathology and Gender Research Group, Generalitat de Catalunya, Catalonia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="N">Cesarean Section</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036861" MajorTopicYN="N">Delivery, Obstetric</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="N">Pregnancy Complications</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar Disorder</Keyword><Keyword MajorTopicYN="Y">Caesarean section</Keyword><Keyword MajorTopicYN="Y">Obstetric complications</Keyword></KeywordList><CoiStatement>Conflict of Interest ES, AR, AT, ASH, NF, CN and LGE have no conflicts of interest to declare. EV has received grants, CME-related honoraria or consulting fees from Alexza, Almirall, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Ferrer, Forest Research Institute, Gedeon Richter, GlaxoSmith-Kline, Janssen, Janssen-Cilag, Jazz, Johnson &amp; Johnson, Lundbeck, Merck, Novartis, Organon, Otsuka, Pfizer, Pierre-Fabre, Qualigen, Roche, Sanofi-Aventis, Schering- Plough, Servier, Shire, Solvay, Takeda, Teva, CIBERSAM, the Seventh European Framework Programme (ENBREC), the Stanley Medical Research Institute, United Biosource Corporation and Wyeth.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31911063</ArticleId><ArticleId IdType="pii">S0924-977X(19)31889-9</ArticleId><ArticleId IdType="doi">10.1016/j.euroneuro.2019.12.115</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22897029</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2658</ISSN><JournalIssue CitedMedium="Print"><Volume>114</Volume><Issue>7</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica</Title><ISOAbbreviation>Seishin Shinkeigaku Zasshi</ISOAbbreviation></Journal><ArticleTitle>[Cellular calcium signaling in bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>821-8</MedlinePgn></Pagination><Abstract><AbstractText>Many discussions have been made related to diagnosis of bipolar disorder in recent years. Especially, much attention has been devoted to the activation syndrome induced by antidepressants and the bipolar spectrum disorder proposed by Gahemi. Differential diagnosis between bipolar depression and monopolar depression is extremely important when planning treatment strategy, but it is difficult to differentiate between them using symptomatic information alone. Therefore, if an easily-accessible biological marker can differentiate between them, it is expected to be extremely useful in clinical practice. Several trait biological markers associated with the pathophysiology of bipolar disorder have been identified with a high evidence level. Abnormality of cellular calcium signaling is regarded as one such replicable trait marker. Especially because human platelets are easily accessible, increasingly numerous reports describe studies of intracellular calcium concentration increase induced by various agonists in patients with bipolar disorder. Summarizing previous reports, the agonist-stimulated calcium response is enhanced significantly in patients with bipolar disorder compared to normal subjects, although resting intraplatelet calcium concentration does not differ between them. Moreover, serotonin-induced calcium response in monopolar depression and the other psychiatric diseases is not significantly different from that in normal subjects, which suggests that the enhanced calcium response to serotonin is specific to bipolar disorder among various diseases. However, several problems arise in using this marker as a supplemental tool of clinical diagnosis. First, the calcium response has a fairly common distribution between bipolar depression and monopolar depression groups although the means of the responses are significantly different. Consequently, it is difficult to differentiate clearly between bipolar depression and monopolar depression merely by setting a discriminating value. Second, it is necessary to measure calcium response as soon as possible after blood collection. Third, drugs taken at the time of blood collection might affect the calcium response. Finally little evidence exists showing whether functions in peripheral tissue actually reflect brain function. Therefore, many obstacles remain to be solved before using this marker in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kusumi</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hokkaido University Graduate School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Katsuji</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Koyama</LastName><ForeName>Tsukasa</ForeName><Initials>T</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Seishin Shinkeigaku Zasshi</MedlineTA><NlmUniqueID>9801787</NlmUniqueID><ISSNLinking>0033-2658</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001792" MajorTopicYN="N">Blood Platelets</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="Y">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22897029</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15631544</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-6667</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>2</Issue><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Efficacy of atypical antipsychotics in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>257-69</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorder is a severe and recurrent disorder. Atypical antipsychotics have emerged as both an alternative and adjunct to conventional mood stabilisers. The manic phase of the illness is the best studied, and it appears that a class effect with regards to efficacy is present in both monotherapy and augmentation studies. Evidence for efficacy of atypical antipsychotics in depression is emerging. At this stage controlled data are available for both olanzapine and quetiapine. Maintenance data demonstrating efficacy are available for olanzapine. Atypical antipsychotics have utility in treating acute agitation and aggression in manic episodes of bipolar disorder. Subgroup analyses from trials treating manic phase bipolar disorder, and an open-label study of rapid cycling, have suggested that atypical antipsychotics may be useful for the treatment of mixed states and rapid cycling. Several studies have suggested that atypical antipsychotics may be useful in treatment-refractory episodes of bipolar disorder. The current available data suggest greater efficacy of the atypical antipsychotics in mania than in depression, although the data are fairly clear that induction of depression is not an issue with the atypical antipsychotics. A number of trials are underway that will hopefully address many of the questions still pending.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Biomedical Sciences, The University of Melbourne, Swanston Centre, PO Box 281, Geelong, VIC 3220, Australia. mikebe@barwonhealth.org.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dodd</LastName><ForeName>Seetal</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>79</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15631544</ArticleId><ArticleId IdType="pii">6526</ArticleId><ArticleId IdType="doi">10.2165/00003495-200565020-00006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2000 Sep;57(9):841-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10986547</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2004 Jan;19(1):41-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14716711</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Dec;63(12):1156-63</Citation><ArticleIdList><ArticleId IdType="pubmed">12523876</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1998 Apr;18(2):172-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9555604</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Jun;153(6):759-64</Citation><ArticleIdList><ArticleId IdType="pubmed">8633686</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Jul;62(7):509-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11488360</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Jul;159(7):1146-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12091192</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Oct;4(5):335-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12479667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 1999 Sep;11(3):137-40</Citation><ArticleIdList><ArticleId IdType="pubmed">10482123</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Apr;64(4):451-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12716249</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jan;59(1):62-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11779284</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Jun;159(6):1011-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12042191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):213-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15117400</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 May;156(5):702-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10327902</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2001 Fall;11(3):239-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11642474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2003 Aug;23 (4):370-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12920413</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 1999 Nov;14 (6):339-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10565800</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2003 Jul;18(4):227-35</Citation><ArticleIdList><ArticleId IdType="pubmed">12817157</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2003 Feb;182:141-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12562742</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Investig Drugs. 2003 Oct;12(10):1621-32</Citation><ArticleIdList><ArticleId IdType="pubmed">14519084</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2002 Oct;41(10):1216-23</Citation><ArticleIdList><ArticleId IdType="pubmed">12364843</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Dec;60(12 ):1218-26</Citation><ArticleIdList><ArticleId IdType="pubmed">14662554</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11869771</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Jun;157(6):982-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10831480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 1998;8(1):49-59</Citation><ArticleIdList><ArticleId IdType="pubmed">9639079</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1995 Sep;56(9):423-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7545159</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Sep;22(3):517-34, vii</Citation><ArticleIdList><ArticleId IdType="pubmed">10550853</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Oct;62(10):818-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11816872</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Sep;160(9):1651-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12944341</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2003 Aug;23 (4):342-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12920409</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1999 Sep;22(3):535-46, vii</Citation><ArticleIdList><ArticleId IdType="pubmed">10550854</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 1998 May-Jun;21(3):176-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9617509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003;64 Suppl 19:13-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14728085</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2002 Sep;17 (5):227-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12177585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003;5 Suppl 2:7-19</Citation><ArticleIdList><ArticleId IdType="pubmed">14700009</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):978-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12788243</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 May;61(5):329-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10847306</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Sep;64(9):1013-24</Citation><ArticleIdList><ArticleId IdType="pubmed">14628976</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Dec;47(12):1106-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2244795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):283</Citation><ArticleIdList><ArticleId IdType="pubmed">11001611</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):741-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12668364</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Dec;4(6):406-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12519101</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Jan;61(1):9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">10695639</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 1997 Mar;12(2):109-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9219046</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2004 Apr;184:337-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15056579</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jul;160(7):1263-71</Citation><ArticleIdList><ArticleId IdType="pubmed">12832240</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Nov;60(11):1079-88</Citation><ArticleIdList><ArticleId IdType="pubmed">14609883</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 May;49(2):119-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9609675</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Oct;72(1):15-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12204313</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2001 Oct;21(5):469-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11593070</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2001 Aug;21(4):389-97</Citation><ArticleIdList><ArticleId IdType="pubmed">11476123</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2003 Aug;27(5):863-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12921920</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Aug;156(8):1164-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10450255</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):155-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12507748</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28857347</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0879</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical psychology &amp; psychotherapy</Title><ISOAbbreviation>Clin Psychol Psychother</ISOAbbreviation></Journal><ArticleTitle>Improving functional outcome in bipolar disorder: A pilot study on metacognitive training.</ArticleTitle><Pagination><MedlinePgn>50-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpp.2124</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Effective group psychological interventions in bipolar disorder are rare. In this study, we present "metacognitive training (MCT) for bipolar disorder"-an adaption of a group intervention that has proven effective in other severe psychiatric disorders. MCT is a structured, interactive approach that addresses cognitive biases, social cognition, and self-esteem. In this pilot study, we investigated psychosocial functioning as primary outcome measure, as well as the feasibility of MCT and its acceptance among bipolar patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-four outpatients with bipolar disorder were recruited. Inclusion criteria were euthymia and psychosocial functioning with a score &gt;11 assessed by the Functional Assessment Short Test. The subjects received eight weekly MCT sessions. Before and after the intervention, psychosocial functioning, quality of life (QoL), and patient views were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients improved significantly in global psychosocial functioning, with a large effect size from baseline to post-treatment. Over the intervention period, patient QoL improved significantly in terms of their physical health, however not for other QoL subdomains. Treatment adherence was 80%, and patients' appraisal of the training was positive.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">As this study lacks a control group, it is not possible to ascertain whether the positive treatment effects are attributable to MCT. Additionally, it is unclear whether gains in psychosocial functioning would have been maintained long term.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This pilot trial conclusively shows that MCT is feasible and provides preliminary evidence for both the acceptance and efficacy of MCT. Further studies with larger samples and control condition will be necessary to build on these findings.</AbstractText><CopyrightInformation>Copyright © 2017 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haffner</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-4416-6438</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinlivan</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiebig</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sondergeld</LastName><ForeName>Lene-Marie</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strasser</LastName><ForeName>Elisa Sophie</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adli</LastName><ForeName>Mazda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fliedner Klinik, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moritz</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-8601-0143</Identifier><AffiliationInfo><Affiliation>Department for Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamm</LastName><ForeName>Thomas Josef</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Psychol Psychother</MedlineTA><NlmUniqueID>9416196</NlmUniqueID><ISSNLinking>1063-3995</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067489" MajorTopicYN="Y">Metacognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">metacognitive training</Keyword><Keyword MajorTopicYN="N">psychological intervention</Keyword><Keyword MajorTopicYN="N">psychosocial functioning</Keyword><Keyword MajorTopicYN="N">psychotherapy</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>07</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28857347</ArticleId><ArticleId IdType="doi">10.1002/cpp.2124</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1393337</PMID><DateCompleted><Year>1992</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>161</Volume><PubDate><Year>1992</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Seasonality of admissions in the psychoses: effect of diagnosis, sex, and age at onset.</ArticleTitle><Pagination><MedlinePgn>506-11</MedlinePgn></Pagination><Abstract><AbstractText>A summer peak was found in first admissions to hospitals in England and Wales between 1976 and 1986 for both affective psychoses and schizophrenia, but not for neurotic conditions or personality disorders. There was no significant relationship between age at first admission and season of admission. The summer peak was most prominent for mania, where it was present in both sexes; for schizophrenia, it was present only in females. These findings suggest that schizophrenia in females, and mania in both sexes, have some aetiological or precipitating factor in common.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takei</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Genetics Section, Institute of Psychiatry, London.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Callaghan</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sham</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Glover</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Tamura</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Br J Psychiatry. 1993 Feb;162:272-3</RefSource><PMID Version="1">8435709</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014852" MajorTopicYN="N" Type="Geographic">Wales</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1393337</ArticleId><ArticleId IdType="pii">S0007125000129757</ArticleId><ArticleId IdType="doi">10.1192/bjp.161.4.506</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16968146</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2011</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-8017</ISSN><JournalIssue CitedMedium="Print"><Volume>111</Volume><Issue>5</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>American journal of mental retardation : AJMR</Title><ISOAbbreviation>Am J Ment Retard</ISOAbbreviation></Journal><ArticleTitle>Mania and intellectual disability: the course of manic symptoms in persons with intellectual disability.</ArticleTitle><Pagination><MedlinePgn>378-83</MedlinePgn></Pagination><Abstract><AbstractText>Our aim was to extend the literature by examining the presence of manic symptoms in persons with intellectual deficits with and without bipolar disorder for 3 years. Three groups (bipolar, psychopathology other than bipolar disorder, and no Axis I diagnosis) were formed with 14 participants in each group. Initially, the presence of mania symptoms were examined across diagnostic groups. The bipolar group had significantly greater endorsements on the Parent Version of the Young Mania Rating Scale and the DASH-II Mania subscale item "decreased need for sleep" than did the other groups. A 3 (group) x 3 (year) ANOVA revealed that the item endorsements differed significantly over time for the bipolar group but not the other groups. Implications of these findings are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Louisiana State University, LA 70803, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matson</LastName><ForeName>Johnny L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Ment Retard</MedlineTA><NlmUniqueID>8800463</NlmUniqueID><ISSNLinking>0895-8017</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="N">Intellectual Disability</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012112" MajorTopicYN="N">Residential Facilities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16968146</ArticleId><ArticleId IdType="doi">10.1352/0895-8017(2006)111[378:MAIDTC]2.0.CO;2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12121208</PMID><DateCompleted><Year>2002</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>106</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>The boundary between mixed and manic episodes in the ICD-10 classification.</ArticleTitle><Pagination><MedlinePgn>109-16</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the boundary between ICD-10 mixed and manic episodes, which has apparently remained understudied.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In-patients with ICD-10 mixed (n=36) and manic episodes (n=145) were compared in terms of demographic, clinical, therapeutical and outcome variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of in-patients with manic episode, 26 (18%) had several depressive symptoms at admission. These patients (dysphoric manic patients) were very similar to patients with ICD-10 mixed episode in terms of current symptomatic presentations and several clinical and therapeutic variables, which were significantly different from those in patients with pure mania.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ICD-10 boundary between mixed and manic episodes is unlikely to be effective although experienced clinicians made the diagnoses. The system may have a high probability of diagnosing dysphoric manic patients as having manic episode, despite their great similarities to patients with mixed episode in terms of current psychopathological presentations as well as clinically important variables.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Psychiatrische Klinik und Poliklinik, LMU Munich, Germany. tetsuya.sato@t-online.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bottlender</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kleindienst</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Tanabe</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Möller</LastName><ForeName>H-J</ForeName><Initials>HJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>10</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>18</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12121208</ArticleId><ArticleId IdType="pii">2o242</ArticleId><ArticleId IdType="doi">10.1034/j.1600-0447.2002.02242.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11823276</PMID><DateCompleted><Year>2002</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>159</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Limbic hyperreactivity in bipolar II disorder.</ArticleTitle><Pagination><MedlinePgn>304-6</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors' goal was to determine whether patients with bipolar II disorder had altered regional brain responses to novel motor sequences.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Regional cerebral blood flow was measured with positron emission tomography in 13 patients with bipolar II disorder and 14 healthy comparison subjects. Participants performed a serial reaction time task in which they were visually cued to press one of four buttons at a time. The order of button presses was determined by a complex sequence that was changed in the latter half of the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the comparison subjects a spatial attention circuit in the superior parietal lobe and supplementary motor area was activated in response to the introduction of the new sequence. Patients did not display this activation pattern; instead, a widespread limbic network was activated in response to the new sequence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The attentional resources of patients with bipolar II disorder are not reallocated when they are confronted with a nonemotional motor task; rather, their performance is altered through activation of limbic circuitry.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berns</LastName><ForeName>Gregory S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>University of Pittsburgh, USA. gberns@emory.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Proper</LastName><ForeName>Shawnette M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DA-00367</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008032" MajorTopicYN="N">Limbic System</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012691" MajorTopicYN="N">Serial Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>2</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>3</Month><Day>7</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>2</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11823276</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.159.2.304</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8885575</PMID><DateCompleted><Year>1996</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-8567</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>10</Issue><PubDate><Year>1996</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title><ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Toward a rational prescribing practice.</ArticleTitle><Pagination><MedlinePgn>1258-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>8704565</NlmUniqueID><ISSNLinking>0890-8567</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011985">Receptors, Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044406">Receptors, Serotonin, 5-HT3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Am Acad Child Adolesc Psychiatry. 1996 Jan;35(1):4</RefSource><PMID Version="1">8567609</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001143" MajorTopicYN="N">Arousal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011985" MajorTopicYN="N">Receptors, Serotonin</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044406" MajorTopicYN="N">Receptors, Serotonin, 5-HT3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017557" MajorTopicYN="N">Ventral Tegmental Area</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8885575</ArticleId><ArticleId IdType="pii">S0890-8567(09)63619-4</ArticleId><ArticleId IdType="doi">10.1097/00004583-199610000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27394052</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>242</Volume><PubDate><Year>2016</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Maladaptive interpersonal schemas as sensitive and specific markers of borderline personality disorder among psychiatric inpatients.</ArticleTitle><Pagination><MedlinePgn>395-403</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(16)30470-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2016.06.007</ELocationID><Abstract><AbstractText>Diagnostic criteria for borderline personality disorder (BPD) and mood and psychotic disorders characterized by major mood episodes (i.e., major depressive, bipolar and schizoaffective disorder) share marked overlap in symptom presentation, complicating differential diagnosis. The current study tests the hypothesis that maladaptive interpersonal schemas (MIS) are characteristic of BPD, but not of the major mood disorders. One hundred psychiatric inpatients were assessed by SCID I, SCID II and the Young Schema Questionnaire (YSQ-S2). Logistic regression analyses tested the association between MIS (measured by the YSQ-S2) and BPD, bipolar, major depressive and schizoaffective disorder. Receiver operator characteristic (ROC) curve analyses assessed the sensitivity and specificity of MIS as a marker of BPD. After covariation for comorbidity with each of the 3 mood disorders, BPD was robustly associated with 4 out of 5 schema domains. In contrast, only one of fifteen regression analyses demonstrated a significant association between any mood disorder and schema domain after covariation for comorbid BPD. ROC analyses of the 5 schema domains suggested Disconnection/Rejection had the greatest power for identification of BPD cases. These data support the specific role of maladaptive interpersonal schemas in BPD and potentially contribute to greater conceptual clarity about the distinction between BPD and the major mood disorders.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Lisa J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai Beth Israel, 1st Avenue &amp; East 16th Street, New York, NY 10003, United States. Electronic address: lcohen@chpnet.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanis</LastName><ForeName>Thachell</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai Beth Israel, 1st Avenue &amp; East 16th Street, New York, NY 10003, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ardalan</LastName><ForeName>Firouz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai Beth Israel, 1st Avenue &amp; East 16th Street, New York, NY 10003, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaseen</LastName><ForeName>Zimri</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai Beth Israel, 1st Avenue &amp; East 16th Street, New York, NY 10003, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galynker</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Mount Sinai Beth Israel, 1st Avenue &amp; East 16th Street, New York, NY 10003, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="Y">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Borderline personality disorder</Keyword><Keyword MajorTopicYN="Y">Diagnosis</Keyword><Keyword MajorTopicYN="Y">Mood disorders</Keyword><Keyword MajorTopicYN="Y">Personality disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27394052</ArticleId><ArticleId IdType="pii">S0165-1781(16)30470-X</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2016.06.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21804628</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1213-8118</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia</Title><ISOAbbreviation>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</ISOAbbreviation></Journal><ArticleTitle>Bipolar affective disorder and dissociation--comparison with healthy controls.</ArticleTitle><Pagination><MedlinePgn>181-6</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">According to recent findings, certain clinical symptoms of patients suffering from affective and anxiety disorder can be related to dissociation. The aim of our study was to examine if the level of dissociation in bipolar affective disorder differed from the level of dissociation in healthy volunteers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">41 patients suffering from bipolar disorder (51.2% females), and 198 healthy controls ( 71.2% females) were included in the study. The patients with bipolar affective disorder in remission were recruited from the Outpatient department of the Department of Psychiatry of the University Hospital Olomouc. They were psychiatrically assessed and the state of the disorder was evaluated by an experienced psychiatrist. Only patients in remission, evaluated as 1 or 2 points of clinical global impression-severity scale, were included in the study. All participants were assessed with the Dissociative Experiences Scale (DES).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no differences in the two groups in demographic variables like age, gender and education. Patients had a significantly higher mean score on the DES and pathological DES than healthy controls.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results suggest that the level of psychological dissociation in bipolar affective patients is higher than in healthy controls.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Latalova</LastName><ForeName>Klara</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic. klaralat@centrum.cz.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasko</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pastucha</LastName><ForeName>Petr</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Grambal</LastName><ForeName>Ales</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kamaradova</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Diveky</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Jelenova</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Mainerova</LastName><ForeName>Barbora</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Vrbova</LastName><ForeName>Kristyna</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Czech Republic</Country><MedlineTA>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</MedlineTA><NlmUniqueID>101140142</NlmUniqueID><ISSNLinking>1213-8118</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004213" MajorTopicYN="N">Dissociative Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21804628</ArticleId><ArticleId IdType="doi">10.5507/bp.2011.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19407725</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>Lifetime subthreshold mania is related to suicidality in posttraumatic stress disorder.</ArticleTitle><Pagination><MedlinePgn>262-6</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Although the association between mood disorders, and particularly bipolar disorders, comorbidity and suicidality in posttraumatic (PTSD) patients is well established, less information is available on the impact of subsyndromal mood symptoms. The aim of the present study was, thus, to explore the frequency and relationship between subthreshold mood symptoms, assessed by a specific and validated questionnaire, and suicidality in PTSD patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Sixty-five PTSD outpatients without bipolar disorders and 65 healthy control subjects were asked to complete the Mood Spectrum-SR-Lifetime Version (MOODS-SR), a questionnaire exploring the presence of subthreshold affective symptoms. Logistic regression models were used to analyze the relationships between suicidality, explored by six items of the MOODS-SR combined and dichotomized to denote the presence or absence of suicidal ideations/plans and/or attempts, and the number of manic/hypomanic or depressive symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Statistically significant and positive associations were found between the presence of manic/hypomanic and depressive symptoms and the likelihood of suicidal ideation or attempts.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Besides depressive, even subthreshold manic/hypomanic features seem to be associated with higher suicidality in PTSD patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dell'osso</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmassi</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rucci</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ciapparelli</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Paggini</LastName><ForeName>Rosemma</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ramacciotti</LastName><ForeName>Carla E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Conversano</LastName><ForeName>Ciro</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Balestrieri</LastName><ForeName>Matteo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Marazziti</LastName><ForeName>Donatella</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013313" MajorTopicYN="N">Stress Disorders, Post-Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="Y">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19407725</ArticleId><ArticleId IdType="doi">10.1017/s1092852900025426</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14725603</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>109</Volume><Issue>2</Issue><PubDate><Year>2004</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Latency and outcome of prophylaxis in bipolar disorder: role of severity as a confounding variable?</ArticleTitle><Pagination><MedlinePgn>157; author reply 158</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Parveen</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Basu</LastName><ForeName>Debasish</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Thapar</LastName><ForeName>Satish</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>G4962QA067</RegistryNumber><NameOfSubstance UI="D018021">Lithium Chloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Acta Psychiatr Scand. 2003 Apr;107(4):260-7</RefSource><PMID Version="1">12662248</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015986" MajorTopicYN="N">Confounding Factors, Epidemiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018021" MajorTopicYN="N">Lithium Chloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>1</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>1</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14725603</ArticleId><ArticleId IdType="pii">257</ArticleId><ArticleId IdType="doi">10.1046/j.1600-0447.2003.00257.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20491717</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Clarithromycin-induced hypomania in a child - a case report.</ArticleTitle><Pagination><MedlinePgn>267-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1600-0447.2009.01522.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We report here a child developing hypomania while treated with clarithromycin.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Case report.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A 3-year-old boy was treated for pneumonia with oral clarithromycin in monotherapy. The boy became somewhat hyperactive and irritable after the second dose. After the third dose he presented with psychomotor agitation, pressured speech, irritability, aggressive behaviour and insomnia. The antibiotic was identified as the only possible cause of the described clinical picture and was discontinued immediately. The hypomanic symptoms subsided gradually over 36 h.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Commonly-used medications can produce uncommon adverse reactions. Clinicians, especially general practitioners, pediatricians, as well as child and adolescent psychiatrists ought to be aware of such a possibility when evaluating a child with suddenly changed behaviour.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baranowski</LastName><ForeName>Wojciech J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Higher Vocational School LKO, Lodz, Poland. kosmetologia@wp.pl</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>H1250JIK0A</RegistryNumber><NameOfSubstance UI="D017291">Clarithromycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017291" MajorTopicYN="N">Clarithromycin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017714" MajorTopicYN="N">Community-Acquired Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018410" MajorTopicYN="N">Pneumonia, Bacterial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20491717</ArticleId><ArticleId IdType="pii">ACP1522</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.2009.01522.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8419561</PMID><DateCompleted><Year>1993</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0884-8734</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>1993</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of general internal medicine</Title><ISOAbbreviation>J Gen Intern Med</ISOAbbreviation></Journal><ArticleTitle>Lithium intoxication: a coordinated treatment approach.</ArticleTitle><Pagination><MedlinePgn>33-40</MedlinePgn></Pagination><Abstract><AbstractText>This case illustrates the clinical features of lithium intoxication and the problems in treating it that may arise as a result of lithium's effects on the kidney. It also demonstrates the difficulties that can develop when a delicate physiologic balance is inadvertently disrupted by nonpharmacologic interventions such as seclusion and consequent restriction of access to food and water. Patients with lithium-induced urine-concentrating defects are especially at risk for dehydration, and care must be taken to ensure adequate fluid and salt intake. This case also shows how intense negative feelings evoked by chronically mentally ill patients can adversely affect their psychiatric and medical care. While such feelings are inevitable, their impact may be lessened by improved communication and coordination between the medical and psychiatric systems of care and by the presence of psychiatrists in the general medical hospital.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Minden</LastName><ForeName>S L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Division of Psychiatry, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassuk</LastName><ForeName>E L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Nadler</LastName><ForeName>S P</ForeName><Initials>SP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Gen Intern Med</MedlineTA><NlmUniqueID>8605834</NlmUniqueID><ISSNLinking>0884-8734</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004630" MajorTopicYN="N">Emergencies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000506" MajorTopicYN="Y">poisoning</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011041" MajorTopicYN="N">Poisoning</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>66</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8419561</ArticleId><ArticleId IdType="doi">10.1007/BF02600293</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Acta Psychiatr Scand. 1983 Nov;68(5):303-24</Citation><ArticleIdList><ArticleId IdType="pubmed">6139936</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1974 Jun;131(6):623-30</Citation><ArticleIdList><ArticleId IdType="pubmed">4597302</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Nerv Syst. 1977 Feb;38(2):107-11</Citation><ArticleIdList><ArticleId IdType="pubmed">837809</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1983 Nov;5(4):353-62</Citation><ArticleIdList><ArticleId IdType="pubmed">6229567</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Med. 1975;6(3):337-48</Citation><ArticleIdList><ArticleId IdType="pubmed">1230444</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1979 Mar 9;241(10):1011-2</Citation><ArticleIdList><ArticleId IdType="pubmed">216818</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1987 May;144(5):670-2</Citation><ArticleIdList><ArticleId IdType="pubmed">3555125</ArticleId></ArticleIdList></Reference><Reference><Citation>Pflugers Arch. 1979 Jun 12;380(2):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">573443</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1978 Apr 20;298(16):883-7</Citation><ArticleIdList><ArticleId IdType="pubmed">634331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Am. 1978 Feb;238(2):46-53</Citation><ArticleIdList><ArticleId IdType="pubmed">625656</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 1990 Mar;12(2):83-97</Citation><ArticleIdList><ArticleId IdType="pubmed">2407615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1978 May;88(5):607-9</Citation><ArticleIdList><ArticleId IdType="pubmed">646242</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 1984 Jan;6(1):77-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6693030</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Toxicol Adverse Drug Exp. 1988 Jan-Dec;3(1):18-32</Citation><ArticleIdList><ArticleId IdType="pubmed">3285125</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 1980;6(5):280-3</Citation><ArticleIdList><ArticleId IdType="pubmed">7413057</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 May;146(5):573-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2653052</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcif Tissue Res. 1977 May;22 Suppl:341-3</Citation><ArticleIdList><ArticleId IdType="pubmed">912541</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1991 Aug;148(8):1060-3</Citation><ArticleIdList><ArticleId IdType="pubmed">1853956</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1979 Jul 20;36(8 Spec No):856-9</Citation><ArticleIdList><ArticleId IdType="pubmed">378163</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1971 Jun;8(2):91-105</Citation><ArticleIdList><ArticleId IdType="pubmed">5090127</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry. 1979 Aug;42(3):201-7</Citation><ArticleIdList><ArticleId IdType="pubmed">111271</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1974 May;30(5):625-33</Citation><ArticleIdList><ArticleId IdType="pubmed">4824197</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephron. 1984;37(4):217-23</Citation><ArticleIdList><ArticleId IdType="pubmed">6379482</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lab Clin Med. 1987 Aug;110(2):130-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3298507</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1973 Dec;29(6):823-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4751821</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 1988;49(2):103-19</Citation><ArticleIdList><ArticleId IdType="pubmed">3064119</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1982 Feb;43(2):47-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7056703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1985 Feb;36(2):180-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3972345</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1975 May;132(5):529-31</Citation><ArticleIdList><ArticleId IdType="pubmed">1119612</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 1988 Summer;29(3):315-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3406348</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 1990 Jul;12(4):221-31</Citation><ArticleIdList><ArticleId IdType="pubmed">2165460</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1974 Apr;53(4):1115-23</Citation><ArticleIdList><ArticleId IdType="pubmed">4360856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int. 1981 Feb;19(2):374-87</Citation><ArticleIdList><ArticleId IdType="pubmed">6785515</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1991 Feb;148(2):189-92</Citation><ArticleIdList><ArticleId IdType="pubmed">1987816</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 1990 Jul;12(4):213-20</Citation><ArticleIdList><ArticleId IdType="pubmed">2198196</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1986 Jul;143(7):892-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3717431</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Mar;35(3):438-31</Citation><ArticleIdList><ArticleId IdType="pubmed">727892</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 1984 Sep;7(3):587-99</Citation><ArticleIdList><ArticleId IdType="pubmed">6384961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int. 1977 Sep;12(3):205-13</Citation><ArticleIdList><ArticleId IdType="pubmed">926612</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1982 Oct;141:387-400</Citation><ArticleIdList><ArticleId IdType="pubmed">6129016</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 1987 Jul;2(3):181-90</Citation><ArticleIdList><ArticleId IdType="pubmed">3320183</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1988;345:85-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3147581</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1984 Dec;70(6):594-602</Citation><ArticleIdList><ArticleId IdType="pubmed">6524425</ArticleId></ArticleIdList></Reference><Reference><Citation>Q J Med. 1978 Apr;47(186):123-44</Citation><ArticleIdList><ArticleId IdType="pubmed">356084</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Kidney Dis. 1987 Nov;10(5):329-45</Citation><ArticleIdList><ArticleId IdType="pubmed">3314489</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1981 Oct;64(4):281-94</Citation><ArticleIdList><ArticleId IdType="pubmed">6801926</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Int Suppl. 1982 May;11:S13-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6956771</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1979 Jul 20;36(8 Spec No):849-51</Citation><ArticleIdList><ArticleId IdType="pubmed">378161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathology. 1983 Oct;15(4):403-11</Citation><ArticleIdList><ArticleId IdType="pubmed">6371681</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1984 Oct;41(10):949-58</Citation><ArticleIdList><ArticleId IdType="pubmed">6332590</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1978 Jan;29(1):44-6</Citation><ArticleIdList><ArticleId IdType="pubmed">618795</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1980 Dec;137(12):1513-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7435706</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1988 Aug;18(3):535-43</Citation><ArticleIdList><ArticleId IdType="pubmed">3054986</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1982 Apr;139(4):443-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7065290</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1982 Nov;43(11):447-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7174620</ArticleId></ArticleIdList></Reference><Reference><Citation>New Dir Ment Health Serv. 1985 Dec;(28):3-10</Citation><ArticleIdList><ArticleId IdType="pubmed">4094612</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Med Scand. 1980;207(4):309-14</Citation><ArticleIdList><ArticleId IdType="pubmed">6104415</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1984 Sep 27;311(13):832-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6472385</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1988;22(4):287-96</Citation><ArticleIdList><ArticleId IdType="pubmed">3063813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1981 Mar;32(3):181-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7203415</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 1980 Dec;107(6):1693-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6253274</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs. 1982 Aug;24(2):133-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6126349</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23790555</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The Mood Disorder Questionnaire (MDQ) for detecting (hypo)manic episodes: its validity and impact of recall bias.</ArticleTitle><Pagination><MedlinePgn>203-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.05.078</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00457-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorders often remain unrecognized in clinical practice, which may be a consequence of imprecise recall of manic symptoms earlier in life. This study will therefore examine the validity of the widely-used Mood Disorder Questionnaire (MDQ) in detecting a (hypo)manic episode and explore the impact of recall bias.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">As an indication of impairments in recalling manic symptoms, we examined the long-term reliability of the MDQ after two years of follow-up in a sample of 2087 persons. Then, the validity of the MDQ was tested against the gold standard of a CIDI-based DSM-IV (hypo)manic episode. Its performance was compared for detecting a lifetime episode (at T1) versus a recent episode in the past two years (at T2).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The long-term reliability of the MDQ was limited as the correct recall of individual items ranged from 44.6% to 68.8% after two years. The overall validity of the MDQ in detecting a lifetime (hypo)manic episode was limited and no adequate cut-off point with acceptable sensitivity and specificity could be identified. However, the MDQ accurately detected a recent episode with a sensitivity of 0.83 and a specificity of 0.82 for the standard and optimal cut-off point of ≥ 7. Taking into account two additional MDQ questions on clustering in time and severity of problems decreased its validity.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Patients with a primary, clinical diagnosis of bipolar disorder were excluded.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The MDQ accurately detected recent (hypo)manic episodes, but imprecise recall may result in a limited performance for episodes earlier in life.</AbstractText><CopyrightInformation>© 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boschloo</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Interdisciplinary Center Psychopathology and Emotion Regulation (ICPE)/University Center Psychiatry (UCP), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. l.boschloo@umcg.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolen</LastName><ForeName>Willem A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Spijker</LastName><ForeName>Annet T</ForeName><Initials>AT</Initials></Author><Author ValidYN="Y"><LastName>Hoencamp</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Penninx</LastName><ForeName>Brenda W J H</ForeName><Initials>BW</Initials></Author><Author ValidYN="Y"><LastName>Schoevers</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Mood Disorder Questionnaire</Keyword><Keyword MajorTopicYN="N">Reliability</Keyword><Keyword MajorTopicYN="N">Validity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>02</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23790555</ArticleId><ArticleId IdType="pii">S0165-0327(13)00457-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.05.078</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27016660</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>198</Volume><PubDate><Year>2016</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Borderline personality disorder, but not euthymic bipolar I disorder, is associated with prolonged post-error slowing in sensorimotor performance.</ArticleTitle><Pagination><MedlinePgn>163-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2016.03.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)31164-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Borderline personality disorder (BPD) and bipolar disorder (BD) are common psychiatric diagnoses. Impulsivity and affective instability are prominent features of both illnesses, complicate treatment and are associated with poor clinical outcomes. Yet, little is known about sensorimotor control in these populations, whether they differ in their speed and accuracy of performance, and their ability to restore efficient performance following errors.</AbstractText><AbstractText Label="METHODS">Twenty females with DSM-IV BPD, 20 females with DSM-IV BD and 20 age- and cognitive-ability matched healthy control participants completed a simple, brief reaction time task in which two single-attribute stimuli were mapped to distinct motor responses.</AbstractText><AbstractText Label="RESULTS">Inspection of response latencies and errors showed that both the BPD and BD participants were able to respond as quickly and accurately as controls, reducing reaction times gently prior to errors, but that BPD participants showed prolonged post-error slowing (PES) before resuming normative levels of speed and accuracy.</AbstractText><AbstractText Label="LIMITATIONS">BD and BPD participants were taking psychotropic medication.</AbstractText><AbstractText Label="CONCLUSIONS">These findings suggest that BPD and BD individuals can achieve normative speed-accuracy trade-offs; but that only BPD individuals exhibit differentially slowed recovery following errors, indicating a specific impartment in basic sensorimotor control.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>Kate E A</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, United Kingdom. Electronic address: kate.saunders@psych.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, United Kingdom. Electronic address: guy.goodwin@psych.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>School of Psychology, Bangor University, Adeilad Brigantia, Penrallt Road, Gwynedd, North Wales LL57 2AS, United Kingdom. Electronic address: r.rogers@bangor.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0700410</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>PB-PG-0909-19070</GrantID><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013647" MajorTopicYN="N">Task Performance and Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Action-monitoring</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Borderline personality disorder</Keyword><Keyword MajorTopicYN="Y">Post-error slowing</Keyword><Keyword MajorTopicYN="Y">Reaction times</Keyword><Keyword MajorTopicYN="Y">Speed accuracy trade-off</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>02</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27016660</ArticleId><ArticleId IdType="pii">S0165-0327(15)31164-2</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2016.03.027</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14675740</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>121</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Executive dysfunctions as potential markers of familial vulnerability to bipolar disorder and schizophrenia.</ArticleTitle><Pagination><MedlinePgn>207-17</MedlinePgn></Pagination><Abstract><AbstractText>Attentional and executive impairments have been found both in patients with schizophrenia and in their unaffected first-degree relatives, suggesting that they might be considered as familial vulnerability markers. Several studies have shown that the performance of bipolar patients does not significantly differ from that of schizophrenic patients, so that executive and attentional deficits might not be specific to schizophrenia. In the present study, we aimed to identify executive dysfunctions in schizophrenia and bipolar disorder that might be vulnerability trait markers specific to one or common to both of these diseases. We assessed cognitive performance of euthymic bipolar and schizophrenic patients, their unaffected first-degree relatives and a healthy control group, using neuropsychological tasks to test different components of executive function: the Verbal Fluency Test, the Stroop Word Colour Test, the Wisconsin Card Sorting Test and the Trail Making Test. The two groups of patients and their unaffected relatives demonstrated disproportionately increased slowness on the Stroop test in comparison to the normal healthy group. Patients with schizophrenia performed poorly on all the tests in comparison to the normal healthy subjects, while no other impairment was observed in the bipolar patients and in the relatives of schizophrenic and bipolar patients. Enhanced susceptibility to interference and reduced inhibition could be transnosographical markers for a shared familial vulnerability common to schizophrenia and bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zalla</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institut de Sciences Cognitives, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joyce</LastName><ForeName>Cécile</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Szöke</LastName><ForeName>Andrei</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schürhoff</LastName><ForeName>Franck</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pillon</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Komano</LastName><ForeName>Odile</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Perez-Diaz</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Alter</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rouillon</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Houde</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>Marion</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="Y">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>7</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14675740</ArticleId><ArticleId IdType="pii">S016517810300252X</ArticleId><ArticleId IdType="doi">10.1016/s0165-1781(03)00252-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8071302</PMID><DateCompleted><Year>1994</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>8</Issue><PubDate><Year>1994</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Manic depressive disorder and lithium over the decades: the very educational case of Mrs. L.</ArticleTitle><Pagination><MedlinePgn>340-3</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Manic depressive disorder is a recurrent illness with a variable clinical course. Before the advent of modern pharmacotherapy, ECT was a common treatment; more recently, lithium has become the long-term treatment of choice, but it is a treatment that is not without complications.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The psychiatric and medical history of an 80-year-old patient was reviewed and analyzed based on clinical interview and medical records. The findings were integrated with literature review to illustrate a number of important clinical points about manic depressive disorder and its treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">(1) ECT is an effective treatment for mania, (2) a sustained remission may occur spontaneously, (3) a mania-depression-euthymia episode sequence predicts favorable response to lithium, (4) lithium discontinuation is not without risk, (5) lithium continuation is not without risk (thyroid, kidneys, eyes).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The case of Mrs. L illustrates the longitudinal course of manic depressive disorder and how it can be influenced by treatment and withdrawal of treatment. It also illustrates the potential of lithium for causing adverse effects on several organ systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jefferson</LastName><ForeName>J W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Dean Foundation for Health, Research and Education, Madison, WI 53717-1914.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sen</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009395" MajorTopicYN="N">Nephritis, Interstitial</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009759" MajorTopicYN="N">Nystagmus, Pathologic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011141" MajorTopicYN="N">Polyuria</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8071302</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12650958</PMID><DateCompleted><Year>2003</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-977X</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder.</ArticleTitle><Pagination><MedlinePgn>129-34</MedlinePgn></Pagination><Abstract><AbstractText>The value of a long-term treatment with clonazepam in the prophylaxis of affective disorder is discussed controversially in the scientific literature. Altogether there are only a few reports on the use of this compound as a mood stabilizer, most of them describing patients suffering from bipolar affective disorder. The aim of this investigation was to evaluate clonazepam as a phase prophylactic medication in affective disorder. We conducted a retrospective chart review in 34 out-patients of our lithium clinic (15 suffering from unipolar depression, 15 from bipolar disorder, four from schizoaffective disorder), who had been treated with clonazepam as a long-term medication. Clonazepam was either given as monotherapy, or as in the case of lithium non-responders, as adjunctive therapy. Patients with unipolar depression had significantly (P=0.026) less depressive episodes after initiation of treatment with clonazepam. Patients with bipolar disorder did not benefit from this therapy. Neither manic/hypomanic phases nor depressive episodes were reduced in this group of patients. Interestingly, clonazepam also reduced affective phases in our four schizoaffective patients on a trend level. Our results indicate that patients with unipolar depression may benefit from a maintenance treatment with clonazepam. Due to methodological limitations our results need to be replicated in controlled double-blind randomized clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winkler</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of General Psychiatry, University Hospital for Psychiatry, Währinger Gürtel 18-20, A-1090, Vienna, Austria. dietmar.winkler@akh-wien.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willeit</LastName><ForeName>Matthäus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Stamenkovic</LastName><ForeName>Mara</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tauscher</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pjrek</LastName><ForeName>Edda</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Konstantinidis</LastName><ForeName>Anastasios</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Shird</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Barnas</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kasper</LastName><ForeName>Siegfried</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5PE9FDE8GB</RegistryNumber><NameOfSubstance UI="D002998">Clonazepam</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002998" MajorTopicYN="N">Clonazepam</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013995" MajorTopicYN="N">Time</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>3</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>5</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>3</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12650958</ArticleId><ArticleId IdType="pii">S0924977X02001748</ArticleId><ArticleId IdType="doi">10.1016/s0924-977x(02)00174-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>